RESULT_COUNT: 695,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
BMRN,BMRN:UW,BBG000CZX7N1,See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.,2017-10-20 12:02:30 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120230579.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $927 million."
BMRN,BMRN:UW,BBG000CZX7N1,Implied FXH Analyst Target Price: $74,2017-10-19 13:48:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x3STbBL1Cxo/implied-fxh-analyst-target-price-74-cm861822,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BMRN,BMRN:UW,BBG000CZX7N1,"Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi",2017-10-19 13:00:01 +0000,https://finance.yahoo.com/news/zacks-industry-outlook-highlights-acorda-130001205.html?.tsrc=rss,"Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi"
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : October 19, 2017",2017-10-19 12:16:18 +0000,http://finance.yahoo.com/r/8efdf405-ec81-3f92-9fc7-23e70da7c953/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-bmrn-us-october-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioMarin Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical: Cramer's Top Takeaways,2017-10-19 10:39:00 +0000,http://finance.yahoo.com/r/2811d018-d708-3d7a-85c7-d7397ea4649d/biomarin-pharmaceutical-cramer-s-top-takeaways.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"JJ Bienaime, CEO of orphan drugmaker BioMarin Pharmaceutical, gives Jim Cramer an update on the company's drug portfolio."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin is 'close as can get' to a hemophilia cure, CEO ...",2017-10-18 23:00:00 +0000,https://finance.yahoo.com/video/biomarin-close-hemophilia-cure-ceo-230000818.html?.tsrc=rss,"Jim Cramer caught up with JJ Bienaime, the chairman and CEO of BioMarin, who spoke to his company's promising pipeline of drugs."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical (BMRN) Shares Cross Below 200 DMA,2017-10-18 21:49:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LCzdjCO18C0/biomarin-pharmaceutical-bmrn-shares-cross-below-200-dma-cm861596,In trading on Wednesday shares of BioMarin Pharmaceutical Inc Symbol BMRN crossed below their 200 day moving average of 89 73 changing hands as low as 86 90 per share BioMarin Pharmaceutical Inc shares are currently trading down about 5 3 on the day The chart below shows the one
BMRN,BMRN:UW,BBG000CZX7N1,"Market Close Report: Historical high reached as NASDAQ Composite Index closes at 6,624.22.",2017-10-18 20:49:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9d-UwX_xXas/market-close-report-historical-high-reached-as-nasdaq-composite-index-closes-at-662422-cm861595,Wednesday s session closes with the NASDAQ Composite Index reaching a historical high The index closed at 6 624 22 up 56 for the day The index had a previous high 6624 00464 on 10 16 2017 The total shares traded for the NASDAQ was over 1 77 billion Wednesday s session closes with the
BMRN,BMRN:UW,BBG000CZX7N1,"Noteworthy Wednesday Option Activity: BMRN, SALT, ABT",2017-10-18 20:49:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VKx7HiruQKY/noteworthy-wednesday-option-activity-bmrn-salt-abt-cm861566,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in BioMarin Pharmaceutical Inc Symbol BMRN where a total of 7 906 contracts have traded so far representing approximately 790 600 underlying shares That amounts to about 72 9
BMRN,BMRN:UW,BBG000CZX7N1,Have Investors Already Priced In BioMarin Pharmaceutical Inc’s (BMRN) Growth?,2017-10-18 18:11:45 +0000,https://finance.yahoo.com/news/investors-already-priced-biomarin-pharmaceutical-181145729.html?.tsrc=rss,Let’s talk about the popular BioMarin Pharmaceutical Inc (NASDAQ:BMRN). The company’s shares saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqGS.Read More...
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York,2017-10-18 16:24:00 +0000,https://finance.yahoo.com/news/biomarin-highlights-breadth-innovative-development-162400406.html?.tsrc=rss,"SAN RAFAEL, Calif., Oct. 18, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) updated the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases."
BMRN,BMRN:UW,BBG000CZX7N1,See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.,2017-10-18 12:05:55 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120555628.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing Bell",2017-10-16 17:07:58 +0000,https://finance.yahoo.com/news/biomarin-pharmaceutical-inc-nasdaq-bmrn-170758893.html?.tsrc=rss,"What: BioMarin Pharmaceutical, Inc., a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes, will visit the Nasdaq MarketSite in Times ..."
BMRN,BMRN:UW,BBG000CZX7N1,How Spark's Gene Therapy Win Could Also Be A Boon For These Biotechs,2017-10-13 22:16:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Es_cHrfg1D8/how-sparks-gene-therapy-win-could-also-be-a-boon-for-these-biotechs-cm859500,Spark Therapeutics ONCE positive vote by a Food and Drug Administration committee could be a boon for other drugmakers working on gene therapies including Audentes Therapeutics BOLD BioMarin Pharmaceutical BMRN and Ultragenyx
BMRN,BMRN:UW,BBG000CZX7N1,How Spark&apos;s Gene Therapy Win Could Also Be A Boon For These Biotechs,2017-10-13 16:09:05 +0000,http://finance.yahoo.com/r/597ea164-2154-37fe-b395-0610fa76a9f5/how-sparks-gene-therapy-win-could-also-be-a-boon-for-these-biotechs?src=A00220&yptr=yahoo&.tsrc=rss,"Spark&apos;s positive vote by an FDA committee could be a boon for other drugmakers working on gene therapies including Audentes, BioMarin and Ultragenyx."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York,2017-10-11 12:30:00 +0000,https://finance.yahoo.com/news/biomarin-highlight-breadth-innovative-development-123000392.html?.tsrc=rss,"SAN RAFAEL, Calif. , Oct. 11, 2017 /PRNewswire/ --  Key program updates will include the following: BMN 270 gene therapy for hemophilia A:  4e13 dose and Phase 3 Study Design Vosoritide for achondroplasia:  ..."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, October 26 at 4:30 p.m. ET",2017-10-10 12:30:00 +0000,https://finance.yahoo.com/news/biomarin-host-third-quarter-2017-123000133.html?.tsrc=rss,"SAN RAFAEL, Calif. , Oct. 10, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ..."
BMRN,BMRN:UW,BBG000CZX7N1,See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.,2017-10-09 12:02:29 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120229211.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $508 million."
BMRN,BMRN:UW,BBG000CZX7N1,Analysts’ Recommendations for Biogen in October 2017,2017-10-09 11:43:47 +0000,http://finance.yahoo.com/r/a07d0540-f7e6-3773-884c-51f3cbded280/analysts-recommendations-for-biogen-in-october-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Of the 29 analysts covering Biogen (BIIB) in October 2017, six analysts recommended a “strong buy,” 12 analysts recommended a “buy,” and 11 analysts recommended a “hold.” Biogen didn't receive any “sell” ..."
BMRN,BMRN:UW,BBG000CZX7N1,Alexion on the Street: Analyst Recommendations in October,2017-10-04 11:44:26 +0000,http://finance.yahoo.com/r/c49592e2-16f8-37d0-b1b5-43caa49a7a02/alexion-on-the-street-analyst-recommendations-in-october?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In August 2017, the EC (European Commission) approved the label expansion of Alexion Pharmaceuticals' (ALXN) Soliris."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors",2017-10-03 12:30:00 +0000,https://finance.yahoo.com/news/biomarin-appoints-robert-j-hombach-123000017.html?.tsrc=rss,"SAN RAFAEL, Calif. , Oct. 3, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former ..."
BMRN,BMRN:UW,BBG000CZX7N1,Interesting BMRN Put And Call Options For December 15th,2017-10-02 15:47:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5cb7lQooCn4/interesting-bmrn-put-and-call-options-for-december-15th-cm853880,Investors in BioMarin Pharmaceutical Inc Symbol BMRN saw new options become available today for the December 15th expiration One of the key inputs that goes into the price an option buyer is willing to pay is the time value so with 74 days until expiration the newly available
BMRN,BMRN:UW,BBG000CZX7N1,See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.,2017-10-02 12:04:04 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120404952.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $15 million."
BMRN,BMRN:UW,BBG000CZX7N1,See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.,2017-09-29 12:02:07 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120207752.html?.tsrc=rss,Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN
BMRN,BMRN:UW,BBG000CZX7N1,See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.,2017-09-28 12:02:05 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120205433.html?.tsrc=rss,Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN
BMRN,BMRN:UW,BBG000CZX7N1,"ETFs with exposure to BioMarin Pharmaceutical, Inc. : September 27, 2017",2017-09-27 14:24:49 +0000,http://finance.yahoo.com/r/e5efbb88-0b0c-3dbf-8b3c-b32e47c5c155/etfs-with-exposure-to-biomarin-pharmaceutical-inc-september-27-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioMarin Pharmaceutical, Inc. Here are 5 ETFs with the largest exposure to BMRN-US. Comparing the performance and risk of BioMarin Pharmaceutical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,Here's Why Sarepta Stock is Up More Than 60% So Far in 2017,2017-09-25 15:53:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oAvlAfpG6Eo/heres-why-sarepta-stock-is-up-more-than-60-so-far-in-2017-cm850383,Shares of Sarepta Therapeutics Inc SRPT have been rising since the beginning of this year This biotech company is up 64 7 so far this year outperforming the 15 6 increase registered by the industry during this period Let s analyze the factors that have driven the rally so far
BMRN,BMRN:UW,BBG000CZX7N1,Here&apos;s Why Sarepta Stock is Up More Than 60% So Far in 2017,2017-09-25 13:40:01 +0000,https://finance.yahoo.com/news/apos-why-sarepta-stock-more-134001241.html?.tsrc=rss,"Sarepta (SRPT) shares have been on an uptrend so far this year, fueled by its DMD drug, Exondys 51&apos;s strong performance. The settlement of a patent litigation also boosted the stock."
BMRN,BMRN:UW,BBG000CZX7N1,"Nasdaq 100 Movers: JD, BMRN",2017-09-21 17:38:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bdUgySeU1pc/nasdaq-100-movers-jd-bmrn-cm849131,In early trading on Thursday shares of BioMarin Pharmaceutical BMRN topped the list of the day s best performing components of the Nasdaq 100 index trading up 0 9 Year to date BioMarin Pharmaceutical registers a 12 7 gain And the worst performing Nasdaq 100 component thus far
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook",2017-09-20 14:40:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WunUELYk5dA/biotech-stock-roundup-fda-nod-for-first-cancer-biosimilar-halo-up-on-deals-raised-outlook-cm848300,A key development this week was the FDA approval of the first cancer biosimilar Amgen AMGN and Allergan s Mvasi a biosimilar version of Roche s blockbuster cancer drug Avastin Other updates include important data presentations from companies like Nabriva Therapeutics NBRV and AbbVie
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook",2017-09-20 12:45:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-fda-nod-124512730.html?.tsrc=rss,"Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen&apos;s (AMGN) Mvasi."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA,2017-09-18 23:35:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/arkUsemfgQ0/biomarin-says-fda-not-planning-an-adcom-for-pegvaliase-bla-cm847452,BioMarin Pharmaceutical Inc BMRN announced that the FDA is currently not planning to hold an advisory committee meeting AdCom to discuss the Biologics License Application BLA for pipeline candidate pegvaliase The company is looking to get pegvaliase approved for lowering
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA,2017-09-18 21:37:09 +0000,https://finance.yahoo.com/news/biomarin-says-fda-not-planning-213709484.html?.tsrc=rss,"The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin&apos;s (BMRN) pipeline candidate, pegvaliase."
BMRN,BMRN:UW,BBG000CZX7N1,Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You?,2017-09-18 14:39:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_bwsKgVau78/billionaire-george-soros-fund-bought-these-3-pharma-stocks-should-you-cm847017,Billionaire George Soros is an iconic figure in the world of investing because of his unique ability to consistently beat the broader markets As such the quarterly 13F filings of his namesake fund Soros Fund Management are must read material for any serious investor The latest
BMRN,BMRN:UW,BBG000CZX7N1,Billionaire George Soros&apos; Fund Bought These 3 Pharma Stocks: Should You?,2017-09-18 13:00:00 +0000,http://finance.yahoo.com/r/bf6570c6-54bf-3f7b-aae6-6af1c170e2b0/billionaire-george-soros-fund-bought-these-3-stock.aspx?yptr=yahoo&.tsrc=rss,These three orphan drugmakers were on Soros&apos; radar last quarter.
BMRN,BMRN:UW,BBG000CZX7N1,The Math Shows FBT Can Go To $140,2017-09-15 13:36:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NgWaY5HNkIk/the-math-shows-fbt-can-go-to-140-cm846165,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BMRN,BMRN:UW,BBG000CZX7N1,FDA Not Currently Planning to Hold Advisory Committee Meeting for BioMarin's Pegvaliase Biologics License Application (BLA),2017-09-14 20:05:00 +0000,https://finance.yahoo.com/news/fda-not-currently-planning-hold-200500081.html?.tsrc=rss,"Regulatory Review Process Proceeding In-line with Company's Expectations SAN RAFAEL, Calif. , Sept. 14, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:  BMRN) today announced that the U.S. Food ..."
BMRN,BMRN:UW,BBG000CZX7N1,"ETFs with exposure to BioMarin Pharmaceutical, Inc. : September 13, 2017",2017-09-13 21:33:01 +0000,http://finance.yahoo.com/r/c5f2ebcd-6dff-3abf-a960-86addbd2f67c/etfs-with-exposure-to-biomarin-pharmaceutical-inc-september-13-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioMarin Pharmaceutical, Inc. Here are 5 ETFs with the largest exposure to BMRN-US. Comparing the performance and risk of BioMarin Pharmaceutical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.,2017-09-12 12:06:09 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120609378.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $2.82 billion."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin’s Strong Pipeline Could Be a Long-Term Growth Driver,2017-09-12 11:37:57 +0000,http://finance.yahoo.com/r/46b4251e-1290-33f2-b1cc-79c293328462/biomarins-strong-pipeline-could-be-a-long-term-growth-driver?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"After success in the company's phase 1/2 trial with BMN 270, an investigational gene therapy for hemophilia A, BioMarin Pharmaceuticals (BMRN) is expected to start phase 3 trials."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017",2017-09-11 18:16:20 +0000,http://finance.yahoo.com/r/1b8a11d9-304e-3b73-9c14-99a555e7c36c/biomarin-pharmaceutical-inc-bmrn-us-earnings-analysis-q2-2017-by-the-numbers-september-11-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis BioMarin Pharmaceutical, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of BioMarin Pharmaceutical, Inc. – Ultragenyx Pharmaceutical, Inc., Shire PLC Sponsored ADR, Esperion Therapeutics, Inc., Sanofi Sponsored ADR, Sangamo Therapeutics, Inc., Alexion Pharmaceuticals, Inc., Catalyst Pharmaceuticals, Inc. and Amicus ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,How Did BioMarin Pharmaceuticals’ Drugs Perform in 1H17?,2017-09-11 14:37:42 +0000,http://finance.yahoo.com/r/cf93a6db-47d5-3545-a9c2-5ec354e7385f/how-did-biomarin-pharmaceuticals-drugs-perform-in-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, BioMarin Pharmaceuticals’ (BMRN) Aldurazyme generated revenues of around $20 million, which was a ~6% increase on a year-over-year (or YoY) basis."
BMRN,BMRN:UW,BBG000CZX7N1,How Did BioMarin Pharmaceuticals Perform in 2Q17?,2017-09-11 13:07:58 +0000,http://finance.yahoo.com/r/5f3119dd-8e47-326c-a391-bfbf70357e39/how-did-biomarin-pharmaceuticals-perform-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, BioMarin Pharmaceuticals (BMRN) generated revenues of around $317 million, which reflected ~6% growth on a year-over-year (or YoY) basis and ~5% growth on a quarter-over-quarter basis."
BMRN,BMRN:UW,BBG000CZX7N1,What Analysts Recommend for BioMarin Pharmaceuticals in September,2017-09-11 11:38:17 +0000,http://finance.yahoo.com/r/acfe4f97-5dd2-31ee-95b0-606c7b6e2104/what-analysts-recommend-for-biomarin-pharmaceuticals-in-september?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,About 77.2% of analysts tracking BioMarin Pharmaceuticals in September 2017 suggested some form of a “buy” rating.
BMRN,BMRN:UW,BBG000CZX7N1,"Sarepta's Golodirsen Positive in DMD Study, Shares Soar",2017-09-07 19:49:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-xjVg7LaJFM/sareptas-golodirsen-positive-in-dmd-study-shares-soar-cm842520,Sarepta Therapeutics Inc 160 SRPT announced positive results from a phase I II study 4053 101 evaluating its Exon 53 skipping candidate golodirsen for the treatment of Duchenne Muscular Dystrophy DMD patients DMD is a genetic disorder in which the absence of a protein
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Presents Interim Data on BMN 250 from Phase I/II,2017-09-07 19:48:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_NUAgn4ozDo/biomarin-presents-interim-data-on-bmn-250-from-phase-iii-cm842516,BioMarin Pharmaceutical Inc BMRN announced interim data from part 2 portion of an ongoing dose escalation phase I II study on investigational enzyme replacement therapy BMN 250 currently developed for treatment of patients with Sanfilippo B syndrome or mucopolysaccharidosis IIIB MPS
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Presents Interim Data on BMN 250 from Phase I/II,2017-09-07 17:24:05 +0000,https://finance.yahoo.com/news/biomarin-presents-interim-data-bmn-172405988.html?.tsrc=rss,BioMarin&apos;s (BMRN) interim data from a current dose escalation phase I/II study on BMN 250 shows improvement signs in cognitive Development Quotient.
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Up 2.5% Since Earnings Report: Can It Continue?,2017-09-07 10:51:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G27Z4WCYgY0/biomarin-bmrn-up-25-since-earnings-report-can-it-continue-cm842049,It has been about a month since the last earnings report for BioMarin Pharmaceutical Inc BMRN Shares have added about 2 5 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a pullback
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Up 2.5% Since Earnings Report: Can It Continue?,2017-09-07 08:32:08 +0000,https://finance.yahoo.com/news/biomarin-bmrn-2-5-since-083208139.html?.tsrc=rss,BioMarin (BMRN) reported earnings about a month ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
BMRN,BMRN:UW,BBG000CZX7N1,Nasdaq 100 Biotechnology: Beyond Pure Tech; Still Pure Innovation,2017-09-06 15:12:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7XYkrK6D_uI/nasdaq-100-biotechnology-beyond-pure-tech-still-pure-innovation-cm841662,"Shutterstock photo    While the pure technology sector is the engine of innovation for much of what we consider the highest technology advancements of our age, there is a host of other industries represented in the Nasdaq-100 that are trailblazing. These companies that lie outside the pure tech sphere are some of"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017,2017-09-06 15:00:00 +0000,https://finance.yahoo.com/news/biomarin-presents-interim-data-phase-150000489.html?.tsrc=rss,"SAN RAFAEL, Calif., Sept. 6, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that it presented interim data from the dose escalation arm of a Phase 1/2 trial for BMN 250, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha-N-acetylglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2 (IGF2), for the treatment of Sanfilippo B syndrome or mucopolysaccharidosis IIIB (MPS IIIB) at the 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017.  Discovered by BioMarin, BMN 250 is being studied in a multicenter, international clinical trial evaluating safety and tolerability, as well as cognitive function of patients with Sanfilippo B receiving BMN 250."
BMRN,BMRN:UW,BBG000CZX7N1,Behind Bioverativ’s Analyst Recommendations This September,2017-09-06 11:37:49 +0000,http://finance.yahoo.com/r/06c943b4-ba2f-31ed-8397-34d58f7e0de5/behind-bioverativs-analyst-recommendations-this-september?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a ""hold."""
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. – Value Analysis (NASDAQ:BMRN) : September 6, 2017",2017-09-06 02:53:27 +0000,http://finance.yahoo.com/r/89468624-4960-333f-bdc4-2d609935e00e/biomarin-pharmaceutical-inc-value-analysis-nasdaqbmrn-september-6-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives BioMarin Pharmaceutical, Inc. a score of 50. Our analysis is based on comparing BioMarin Pharmaceutical, Inc. with the following peers – Ultragenyx Pharmaceutical, Inc., Amicus Therapeutics, Inc., Sanofi Sponsored ADR, Alexion Pharmaceuticals, Inc., Shire PLC Sponsored ADR, Sangamo Therapeutics, Inc., Catalyst Pharmaceuticals, Inc. and Esperion Therapeutics, Inc. ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta: Time to Buy?,2017-09-05 16:31:00 +0000,http://finance.yahoo.com/r/8b68ff46-cd26-37a4-b0b6-8361070015a7/sarepta-time-to-buy-1504629099?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"What could drive shares of Sarepta Therapeutics (SRPT) higher?  Back in July, my colleague Andrew Bary noted thatExondys 51, the company’s controversial drug for Duchenne muscular dystrophy (DMD), is gaining traction, which could push the stock price higher.  Credit Suisse analyst Alethia Young and her team say the company could release top-line data from an early stage study of its experimental drug SRP-4053 before releasing the full data later this year."
BMRN,BMRN:UW,BBG000CZX7N1,Alexion: Quite a Comeback,2017-09-05 15:50:00 +0000,http://finance.yahoo.com/r/76e782ab-6a7d-3e0d-abae-bfafcc337361/alexion-quite-a-comeback-1504626651?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"J.P. Morgan analyst Anupam Rama and his team are rethinking their stance on Alexion Pharmaceuticals (ALXN).  Today, Rama has reversed course, resuming a bullish stance on Alexion, restoring his previous Overweight rating and lifting his price target from $163 a share to $175 a share.  On the 2Q earnings call, Alexion prudently set low expectations for the 2H17 earnings and we believe Street focus is shifting to 2H17 / 1H18 clinical catalysts as key drivers over the next 6-12 months."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces 3 Platform and 15 Poster Presentations at 13th International Congress of Inborn Errors of Metabolism 2017,2017-09-05 12:30:00 +0000,https://finance.yahoo.com/news/biomarin-announces-3-platform-15-123000559.html?.tsrc=rss,"SAN RAFAEL, Calif. , Sept. 5, 2017 /PRNewswire/ -- BioMarin (Nasdaq:BMRN) announced that the company will present data in three platform presentations and fifteen poster presentations at the 13th International ..."
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech ETF on track for fourth straight daily rise, hits highest level since 2015",2017-08-31 17:50:59 +0000,http://finance.yahoo.com/r/7b3c31bd-0b64-3742-88c5-83106e0ab1b0/Story.aspx?guid=4AC56AB3-F8D6-4227-9B02-D372941B38D6&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"The largest exchange-traded fund to track the biotechnology sector rallied on Thursday, moving in its biggest one-day percentage pop since June as it hit levels not seen since early 2016. The iShares Nasdaq ..."
BMRN,BMRN:UW,BBG000CZX7N1,"Stock Market News For August 31, 2017",2017-08-31 15:55:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bUnUZCpGO8U/stock-market-news-for-august-31-2017-cm839700,Stock market closed higher on Wednesday following a couple of bullish economic reports even as the S amp P 500 notched up a four day winning streak Markets digested the ongoing geopolitical tussle between North Korea and U S and also the fallout of Hurricane Harvey Moreover President Trump
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update",2017-08-31 14:55:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fr6yNe5WHj0/biotech-stock-roundup-car-t-in-focus-on-gilead-kite-deal-incyte-up-on-baricitinib-update-cm839673,CAR T stocks were in the news this week with key biotech player Gilead Sciences GILD announcing its intention to acquire Kite Pharma KITE one of the most advanced players in the CAR T therapy market Moreover the FDA approved Novartis Kymriah yesterday making it the first CAR T therapy
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) in Focus: Stock Moves 5.6% Higher,2017-08-31 14:53:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/epNCL38XL-w/biomarin-bmrn-in-focus-stock-moves-56-higher-cm839624,BioMarin Pharmaceutical Inc BMRN was a big mover last session as the company saw its shares rise nearly 6 on the day The move came on solid volume too with far more shares changing hands than in a normal session This stock which remained volatile and traded within the range of 80
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) in Focus: Stock Moves 5.6% Higher,2017-08-31 13:00:01 +0000,https://finance.yahoo.com/news/biomarin-bmrn-focus-stock-moves-130001904.html?.tsrc=rss,"BioMarin (BMRN) shares rose nearly 6% in the last trading session, amid huge volumes."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : August 31, 2017",2017-08-31 12:54:08 +0000,http://finance.yahoo.com/r/3506ae87-4f65-3bf5-9df1-c17e1567d015/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bullish-manner-bmrn-us-august-31-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioMarin Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update",2017-08-31 12:42:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-car-t-124212645.html?.tsrc=rss,It&apos;s all about CAR-T stocks this week with Gilead (GILD) announcing its intention to acquire Kite Pharma for $11.9 billion and Novartis gaining FDA approval for the first CAR-T cell therapy.
BMRN,BMRN:UW,BBG000CZX7N1,How Much Can This Biotech Pop After The FDA OKs Its Drug Bid?,2017-08-30 20:23:14 +0000,http://finance.yahoo.com/r/edacaa62-e7f0-300c-8894-7cfacad74b73/how-much-can-this-biotech-pop-after-the-fda-oks-its-drug-bid?src=A00220&yptr=yahoo&.tsrc=rss,BioMarin hit a three-week high Wednesday as investor sentiment thawed after the FDA accepted BioMarin&apos;s application for a rare-disease drug.
BMRN,BMRN:UW,BBG000CZX7N1,Why BioMarin is Jumping,2017-08-30 19:01:00 +0000,http://finance.yahoo.com/r/0747c276-2f79-38a3-af3c-45c9c7bacd59/why-biomarin-is-jumping-1504119685?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of BioMarin Pharmaceutical (BMRN) are soaring today after the FDA accepted the companies Biologics License Application, or BLA, for a rare-disease treatment. The treatment for a condition known ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin's Pegvaliase BLA Granted Priority Review by the FDA,2017-08-30 16:52:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5joWee5MWTw/biomarins-pegvaliase-bla-granted-priority-review-by-the-fda-cm839195,BioMarin Pharmaceutical Inc BMRN announced that the Biologics License Application BLA for pegvaliase has been accepted by the FDA for priority review A decision is expected on Feb 28 2018 BioMarin is looking to get pegvaliase approved for lowering blood phenylalanine Phe levels in
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin&apos;s Pegvaliase BLA Granted Priority Review by the FDA,2017-08-30 15:10:03 +0000,https://finance.yahoo.com/news/biomarin-apos-pegvaliase-bla-granted-151003007.html?.tsrc=rss,"BioMarin Pharmaceutical (BMRN) announced that the FDA has accepted and granted priority review to the BLA for phenylketonuria candidate, Pegvaliase with a decision expected in February 2018."
BMRN,BMRN:UW,BBG000CZX7N1,"APRI Makes 2nd Try, PRQR To Reveal Data On Sep.25, PFE Awaits FDA Decision",2017-08-30 02:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tYljtDA0jSY/apri-makes-2nd-try-prqr-to-reveal-data-on-sep25-pfe-awaits-fda-decision-20170830-00061,"APRI Makes 2nd Try, PRQR To Reveal Data On Sep.25, PFE Awaits FDA Decision"
BMRN,BMRN:UW,BBG000CZX7N1,FDA Accepts BioMarin's Pegvaliase BLA And Grants Priority Review Designation,2017-08-29 22:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ksHS5w7-ixI/fda-accepts-biomarins-pegvaliase-bla-and-grants-priority-review-designation-20170829-01254,FDA Accepts BioMarin's Pegvaliase BLA And Grants Priority Review Designation
BMRN,BMRN:UW,BBG000CZX7N1,FDA Accepts BioMarin's Pegvaliase Biologics License Application (BLA) and Grants Priority Review Designation,2017-08-29 20:05:00 +0000,https://finance.yahoo.com/news/fda-accepts-biomarins-pegvaliase-biologics-200500029.html?.tsrc=rss,"SAN RAFAEL, Calif., Aug. 29, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for pegvaliase, a PEGylated recombinant phenylalanine ammonia lyase enzyme product, to reduce blood phenylalanine (Phe) levels in adult patients with phenylketonuria (PKU) who have uncontrolled blood Phe levels on existing management.  The FDA has granted priority review designation to pegvaliase, which is granted to drugs that treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition."
BMRN,BMRN:UW,BBG000CZX7N1,These 3 Stocks Look Expensive but Are Actually Cheap,2017-08-29 15:50:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aRMiADJyPrk/these-3-stocks-look-expensive-but-are-actually-cheap-cm838586,A stock s price or even its current valuation rarely tell the whole story regarding its ability to produce respectable returns on capital over the long term In fact deep value can be tremendously difficult to quantify in many cases leading to some stocks being incorrectly
BMRN,BMRN:UW,BBG000CZX7N1,These 3 Stocks Look Expensive but Are Actually Cheap,2017-08-29 14:00:00 +0000,http://finance.yahoo.com/r/2d017379-3782-366e-957e-927671d63eae/these-3-stocks-look-expensive-but-are-actually-che.aspx?yptr=yahoo&.tsrc=rss,"This orphan drugmaker, video-game publisher, and investment management giant might all be under-appreciated bargain buys."
BMRN,BMRN:UW,BBG000CZX7N1,"3 Big Stock Charts for Wednesday: Twilio Inc (TWLO), BioMarin Pharmaceutical Inc. (BMRN) and Mondelez International Inc (MDLZ)",2017-08-23 20:39:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/75IjwRjcDHY/3-big-stock-charts-for-wednesday-twilio-inc-twlo-biomarin-pharmaceutical-inc-bmrn-and-mondelez-international-inc-mdlz-cm836228,InvestorPlace Stock Market News Stock Advice amp Trading Tips The market starts on another down day as the Dog Days of August persist in whittling away the positive backdrop of the earnings season According to a number of our technical indicators and models the S amp P
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces Exercise in Full of Underwriters' Option to Purchase Additional 0.599% Senior Subordinated Convertible Notes Due 2024,2017-08-23 20:05:00 +0000,https://finance.yahoo.com/news/biomarin-announces-exercise-full-underwriters-200500344.html?.tsrc=rss,"SAN RAFAEL, Calif. , Aug. 23, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the underwriters of its recently announced public offering of 0.599% senior subordinated ..."
BMRN,BMRN:UW,BBG000CZX7N1,"3 Big Stock Charts for Wednesday: Twilio Inc (TWLO), BioMarin Pharmaceutical Inc. (BMRN) and Mondelez International Inc (MDLZ)",2017-08-23 15:38:36 +0000,https://finance.yahoo.com/news/3-big-stock-charts-wednesday-153836618.html?.tsrc=rss,"According to a number of our technical indicators and models, the S&P 500 Index is falling into a deeper chance of seeing a more corrective phase continue through the equally seasonally weak September, which means that traders should be on the lookout for additional opportunities to benefit from falling stocks.  Today’s three big stock charts look at the technical pictures of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Mondelez International Inc (NASDAQ:MDLZ) and Twilio Inc (NYSE:TWLO) as each of these companies are flashing their own signs that more selling is in their near-term future.  BioMarin stock is pressing hard against the round-numbered support that should be making itself available at $80."
BMRN,BMRN:UW,BBG000CZX7N1,Relative Strength Alert For BioMarin Pharmaceutical,2017-08-21 21:37:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TXuqI4-cUGo/relative-strength-alert-for-biomarin-pharmaceutical-cm834970,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
BMRN,BMRN:UW,BBG000CZX7N1,Forbes Ranks BioMarin 12th Most Innovative Company in the World,2017-08-21 12:30:00 +0000,https://finance.yahoo.com/news/forbes-ranks-biomarin-12th-most-123000297.html?.tsrc=rss,"SAN RAFAEL, Calif., Aug. 21, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that it has been ranked 12th on Forbes magazine's 2017 list of the ""World's Most Innovative Companies."" BioMarin, a pharmaceutical company focused on rapidly developing and delivering first-in-class or best-in-class therapies for those with severe rare diseases, is dedicated to providing therapies for unmet medical needs.  This is the fourth consecutive year that BioMarin has received the recognition, acknowledging the company's commitment to making an impact in the lives of small patient populations.  The two previous years the company was ranked 10th and in 2014, the company ranked 7th."
BMRN,BMRN:UW,BBG000CZX7N1,"Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst",2017-08-17 14:05:00 +0000,https://finance.yahoo.com/news/video-regeneron-biomarin-abbvie-could-140500425.html?.tsrc=rss,Evercore ISI analyst Josh Schimmer is bullish on biotech.
BMRN,BMRN:UW,BBG000CZX7N1,Why Gilead Sciences Might Not Make an Oncology Acquisition,2017-08-15 21:37:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OrEq6-IqO44/why-gilead-sciences-might-not-make-an-oncology-acquisition-cm832462,Is Gilead Sciences NASDAQ GILD backing away from its plans to acquire a smaller biotech focusing on oncology That could be the case Gilead CEO John Milligan reportedly told 160 Leerink analyst Geoffrey Porges that the company 160 might end up doing nothing in oncology
BMRN,BMRN:UW,BBG000CZX7N1,Why Gilead Sciences Might Not Make an Oncology Acquisition,2017-08-15 20:22:00 +0000,http://finance.yahoo.com/r/7073c7dc-fc6b-3075-8dbd-f9d84ffe0986/why-gilead-sciences-might-not-make-an-oncology-acq.aspx?yptr=yahoo&.tsrc=rss,Gilead Sciences&apos; CEO hints that buying a biotech with an oncology focus might not happen. Here&apos;s what this could mean for the big biotech.
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin to Attend Upcoming Investor Conferences,2017-08-15 12:30:00 +0000,https://finance.yahoo.com/news/biomarin-attend-upcoming-investor-conferences-123000548.html?.tsrc=rss,- Citi's 12th Annual Biotech Conference on September 6 in Boston - Baird's 2017 Global Healthcare Conference on September 7 in New York - Morgan Stanley 15th Annual Global Healthcare Conference on September ...
BMRN,BMRN:UW,BBG000CZX7N1,Analysts Forecast 10% Gains Ahead For VXF,2017-08-14 14:37:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4aRkhHiYUKg/analysts-forecast-10-gains-ahead-for-vxf-cm831571,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BMRN,BMRN:UW,BBG000CZX7N1,See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.,2017-08-12 12:02:36 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120236010.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $4.72 billion."
BMRN,BMRN:UW,BBG000CZX7N1,Edited Transcript of BMRN earnings conference call or presentation 2-Aug-17 8:30pm GMT,2017-08-12 01:26:06 +0000,https://finance.yahoo.com/news/edited-transcript-bmrn-earnings-conference-063052440.html?.tsrc=rss,Q2 2017 Biomarin Pharmaceutical Inc Earnings Call
BMRN,BMRN:UW,BBG000CZX7N1,See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.,2017-08-11 12:02:35 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120235533.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $4.72 billion."
BMRN,BMRN:UW,BBG000CZX7N1,See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.,2017-08-10 12:02:52 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120252929.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $3.10 billion."
BMRN,BMRN:UW,BBG000CZX7N1,See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.,2017-08-09 12:02:52 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120252857.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $2.91 billion."
BMRN,BMRN:UW,BBG000CZX7N1,"20 Undervalued, Sustainable Stocks",2017-08-09 10:00:00 +0000,http://finance.yahoo.com/r/00e2798d-9061-36f2-abcb-d4ee5c2558c1/article.aspx?id=820331&SR=Yahoo&yptr=yahoo&.tsrc=rss,"These stocks are positioned to outperform their peers, and they also score well on environmental, social, and governance metrics."
BMRN,BMRN:UW,BBG000CZX7N1,What Weighed On Biotechs Last Week?,2017-08-08 14:17:00 +0000,http://finance.yahoo.com/r/01118dc4-4b17-3894-8038-12c8aa6fb481/what-weighed-on-biotechs-last-week-1502201887?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Nomura Instinet's Christopher Marai and his team take a look at biotech news, as the The Nasdaq Biotechnology Index (NBI) has trailed both the Nasdaq and S&P 500 the past week, down about 1% compared to the index's 0.05% and .26% gains.  From his note:  The Senate passed a key FDA re-funding bill and the right-to-try bill on Thursday, allowing patients with life-threatening diseases to request access to unapproved treatments in the clinic, as long as the FDA is continuing to oversee its development."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024,2017-08-07 23:24:00 +0000,https://finance.yahoo.com/news/biomarin-announces-offering-450-million-232400714.html?.tsrc=rss,"SAN RAFAEL, Calif. , Aug. 7, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), announced today an underwritten offering of $450 million aggregate principal amount of 0.599% senior subordinated ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces Offering of $450 Million of Senior Subordinated Convertible Notes Due 2024,2017-08-07 20:01:00 +0000,https://finance.yahoo.com/news/biomarin-announces-offering-450-million-200100813.html?.tsrc=rss,"SAN RAFAEL, Calif., Aug. 7, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN), announced today an underwritten offering of $450 million aggregate principal amount of senior subordinated convertible notes due 2024 (the Notes).  BioMarin has also granted the underwriters a 13-day option to purchase up to an additional $50 million aggregate principal amount of Notes.  BioMarin intends to use a majority of the net proceeds from the offering to repay, repurchase or settle in cash some or all of BioMarin's 0.75% senior subordinated convertible notes due in October 2018, although it does not intend to effect any such repayment or repurchase concurrently with the offering.  BioMarin intends to use the remaining net proceeds from this offering for general corporate purposes, including clinical trials of its product candidates and the expansion of its manufacturing capacity, particularly with respect to the manufacturing capability for its gene therapy program."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical Inc. Got It Done in the Second Quarter,2017-08-04 19:01:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bpwi8J4vrs4/biomarin-pharmaceutical-inc-got-it-done-in-the-second-quarter-cm827439,BioMarin Pharmaceutical NASDAQ BMRN turned in a 160 second quarter report on Wednesday that showed it continuing to grow sales of its current drugs getting new drugs approved and producing promising clinical trial data on its pipeline candidates There isn t much else investors
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical Inc. Got It Done in the Second Quarter,2017-08-04 17:43:00 +0000,http://finance.yahoo.com/r/dd652c98-8345-331b-8558-f44711d73023/biomarin-pharmaceutical-inc-got-it-done-in-Q2.aspx?yptr=yahoo&.tsrc=rss,"The biotech produced growing drug sales, won an FDA and EMA approval, filed a marketing application for another drug, and released promising on data on pipeline candidates."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates",2017-08-03 16:06:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mV3zY2Fgu1g/biomarin-bmrn-q2-loss-narrows-sales-surpass-estimates-cm826565,BioMarin Pharmaceutical Inc BMRN reported a narrower than expected loss in the second quarter of 2017 and also beat estimates for sales The biotech also raised its previously issued full year sales outlook The company also announced that it will take both evaluated doses of its hemophilia
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates",2017-08-03 13:38:01 +0000,https://finance.yahoo.com/news/biomarin-bmrn-q2-loss-narrows-133801599.html?.tsrc=rss,BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected loss in Q2 and also beat estimates for sales. The biotech also raised its previously issued full year sales outlook.
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin reports 2Q loss,2017-08-03 02:02:38 +0000,https://finance.yahoo.com/news/biomarin-reports-2q-loss-210156161.html?.tsrc=rss,"The San Rafael, California-based company said it had a loss of 21 cents per share. Earnings, adjusted for one-time gains and costs, came to 15 cents per share. The results exceeded Wall Street expectations. ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces Second Quarter 2017 Financial Results,2017-08-02 20:05:00 +0000,https://finance.yahoo.com/news/biomarin-announces-second-quarter-2017-200500139.html?.tsrc=rss,- Company Announces Record Total BioMarin Revenues of $317.4 million in the Second Quarter of 2017 - GAAP Net Loss Reduced to $36.8 million ; Non-GAAP Income of $26.6 million Reported in the Second Quarter ...
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies",2017-08-02 20:01:00 +0000,https://finance.yahoo.com/news/biomarin-announces-plans-progress-both-200100158.html?.tsrc=rss,"SAN RAFAEL, Calif., Aug. 2, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that it will expand its development plan for BMN 270, its investigational gene therapy for hemophilia A, to include an additional Phase 3 study of the 4e13 vg/kg dose based on updated data as of July 28, 2017 from its ongoing open-label Phase 1/2 study of BMN 270.  Since the last data update presented at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress, the Factor VIII activity levels in the 4e13 vg/kg cohort have continued to trend upwards and now support an additional Phase 3 study to the development program.  Based on these updated results, BioMarin plans to initiate two separate Phase 3 studies as soon as possible, one with the 4e13 vg/kg dose and one with the 6e13 vg/kg dose.  In addition, the Company has commissioned its commercial gene therapy manufacturing facility and expects to start the Phase 3 program in the fourth quarter of 2017."
BMRN,BMRN:UW,BBG000CZX7N1,Investor Network: BioMarin Pharmaceutical Inc. to Host Earnings Call,2017-08-02 14:20:00 +0000,https://finance.yahoo.com/news/investor-network-biomarin-pharmaceutical-inc-142000941.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 2, 2017 / BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) will be discussing their earnings results in their Q2 Earnings Call to be held on Wednesday, August 2, 2017 at ..."
BMRN,BMRN:UW,BBG000CZX7N1,Is Zoetis (ZTS) Poised for a Beat This Earnings Season?,2017-08-01 22:55:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eXLf8XXNC0E/is-zoetis-zts-poised-for-a-beat-this-earnings-season-cm825326,Zoetis Inc ZTS is scheduled to report second quarter 2017 results on Aug 8 before the market opens Zoetis has consistently surpassed earnings estimates in each of the last four quarters with an average positive surprise of 9 8 In the last quarter the company beat expectations with
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET",2017-07-31 20:01:00 +0000,https://finance.yahoo.com/news/biomarin-host-second-quarter-2017-200100888.html?.tsrc=rss,"- Company to Also Provide Data and Development Plan Update on 4e13 vg/kg Dose of Investigational Gene Therapy Product BMN 270 for Hemophilia A SAN RAFAEL, Calif. , July 31, 2017 /PRNewswire/ -- BioMarin ..."
BMRN,BMRN:UW,BBG000CZX7N1,Can Horizon Pharma (HZNP) Spring a Surprise in Q2 Earnings?,2017-07-31 16:55:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2aBJAElhYig/can-horizon-pharma-hznp-spring-a-surprise-in-q2-earnings-cm824287,Horizon Pharma plc HZNP is scheduled to report second quarter 2017 results before the opening bell on Aug 7 Last quarter the company missed expectations by 16 Let s see how things are shaping up for this quarter Horizon s shares have declined 24 9 in the year so far
BMRN,BMRN:UW,BBG000CZX7N1,Will Teladoc (TDOC) Pull Off a Surprise in Q2 Earnings?,2017-07-31 14:59:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ddJ0oq7TFkw/will-teladoc-tdoc-pull-off-a-surprise-in-q2-earnings-cm824265,Teladoc Inc TDOC is scheduled to report second quarter 2017 results on Aug 2 after market close Riding on higher revenues Teladoc delivered a positive earnings surprise of nearly 11 43 in the first quarter Results reflected healthy growth in subscription access fees and visit fees that
BMRN,BMRN:UW,BBG000CZX7N1,Why Earnings Season Could Be Great for BioMarin (BMRN),2017-07-31 13:56:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UdARN7P9B6k/why-earnings-season-could-be-great-for-biomarin-bmrn-cm824141,Investors are always looking for stocks that are poised to beat at earnings season and BioMarin Pharmaceutical Inc BMRN may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because BioMarin is seeing
BMRN,BMRN:UW,BBG000CZX7N1,Why Earnings Season Could Be Great for BioMarin (BMRN),2017-07-31 12:41:12 +0000,https://finance.yahoo.com/news/why-earnings-season-could-great-124112505.html?.tsrc=rss,BioMarin (BMRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BMRN,BMRN:UW,BBG000CZX7N1,Can BioMarin (BMRN) Keep the Earnings Streak Alive in Q2?,2017-07-27 15:04:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hPxLMZHV4EQ/can-biomarin-bmrn-keep-the-earnings-streak-alive-in-q2-cm822387,We expect BioMarin Pharmaceutical Inc BMRN to beat expectations when it reports second quarter 2017 results on Aug 2 after the market closes BioMarin delivered a positive earnings surprise of 110 in the last quarter BioMarin s shares are up 7 7 so far this year This
BMRN,BMRN:UW,BBG000CZX7N1,Can BioMarin (BMRN) Keep the Earnings Streak Alive in Q2?,2017-07-27 13:03:01 +0000,https://finance.yahoo.com/news/biomarin-bmrn-keep-earnings-streak-130301674.html?.tsrc=rss,BioMarin Pharmaceutical Inc. (BMRN) is likely to see continued momentum in Vimizim and Kuvan sales backed by robust patient growth in Q2.
BMRN,BMRN:UW,BBG000CZX7N1,"ETFs with exposure to BioMarin Pharmaceutical, Inc. : July 24, 2017",2017-07-24 18:27:45 +0000,http://finance.yahoo.com/r/f486278e-2073-3e50-8236-700d69c52428/etfs-with-exposure-to-biomarin-pharmaceutical-inc-july-24-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioMarin Pharmaceutical, Inc. Here are 5 ETFs with the largest exposure to BMRN-US. Comparing the performance and risk of BioMarin Pharmaceutical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta Therapeutics (SRPT) Stock Surged 24% Today: Here's Why,2017-07-20 19:02:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5JodzM9eF0A/sarepta-therapeutics-srpt-stock-surged-24-today-heres-why-cm818866,On Thursday shares of Sarepta Therapeutics SRPT are surging up almost 24 to 42 14 per share in morning trading after the biotech company reported second quarter revenues that blew past expectations in its earnings report yesterday after the bell Sarepta reported quarterly revenue of
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta Therapeutics (SRPT) Stock Surged 24% Today: Here&apos;s Why,2017-07-20 17:09:05 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-srpt-stock-surged-170905691.html?.tsrc=rss,"On Thursday, shares of Sarepta Therapeutics (SRPT) are surging, up almost 24% to $42.14 per share in morning trading after the biotech company reported second-quarter revenues that blew past expectations in its earnings report yesterday after the bell."
BMRN,BMRN:UW,BBG000CZX7N1,"Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View",2017-07-20 17:06:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Levo9K_I7JY/sarepta-srpt-q2-loss-narrows-ups-exondys-51-sales-view-cm818801,Sarepta Therapeutics Inc SRPT reported narrower than expected loss in the second quarter of 2017 The biotech also increased its 2017 sales outlook for Exondys 51 a treatment for Duchenne muscular dystrophy DMD and its only marketed drug Shares were up almost 15 in after hours trading
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta & BioMarin Settle Patent Litigation on Exon Skipping,2017-07-19 23:03:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7ePfPMTgsXU/sarepta-biomarin-settle-patent-litigation-on-exon-skipping-cm818405,Sarepta Therapeutics Inc SRPT and BioMarin Pharmaceutical Inc BMRN have settled their ongoing global patent litigation regarding the exclusive license on a patent pertaining to exon skipping technology used in Duchenne muscular dystrophy DMD therapies BioMarin has licensed the
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta & BioMarin Settle Patent Litigation on Exon Skipping,2017-07-19 20:56:08 +0000,https://finance.yahoo.com/news/sarepta-biomarin-settle-patent-litigation-205608020.html?.tsrc=rss,"Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies."
BMRN,BMRN:UW,BBG000CZX7N1,"Sarepta Rockets On Consensus-Crushing Sales, Narrowing Losses",2017-07-19 20:22:14 +0000,http://finance.yahoo.com/r/91fc105a-2d85-3351-b2cc-7cc221d23a01/sarepta-rockets-on-consensus-crushing-sales-narrowing-losses?src=A00220&yptr=yahoo&.tsrc=rss,Sarepta stock bolted after the biotech smashed views for second-quarter sales and it reported narrower losses
BMRN,BMRN:UW,BBG000CZX7N1,​Sarepta skips over a Duchenne patent battle with $35M settlement,2017-07-19 17:45:10 +0000,http://finance.yahoo.com/r/7a303899-d504-39b9-b8f2-cc86b885841b/sarepta-skips-over-a-duchenne-patent-battle-with.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Cambridge-based Sarepta Therapeutics has agreed to pay $35 million plus royalties and potential milestones to a California biotech to resolve a dispute over patents on its Duchenne muscular dystrophy drug.  Sarepta (SRPT) said Tuesday that it had reached an agreement to license the intellectual property of San Rafael-based BioMarin Pharmaceutical (BMRN).  BioMarin had previously challenged key patents covering Sarepta’s approved Duchenne drug, Exondys 51, as well as other so-called “exon-skipping” treatments."
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs",2017-07-19 12:39:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-vertex-boosted-123912004.html?.tsrc=rss,Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET",2017-07-18 20:30:00 +0000,https://finance.yahoo.com/news/biomarin-host-second-quarter-2017-203000443.html?.tsrc=rss,"SAN RAFAEL, Calif. , July 18, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ..."
BMRN,BMRN:UW,BBG000CZX7N1,​BioMarin snags cash as Sarepta skips Duchenne patent battle,2017-07-18 17:45:11 +0000,http://finance.yahoo.com/r/8768d65e-54cb-34c3-9e30-3244f178f836/biomarin-sarepta-bmrn-srpt-duchenne-exondys-51.html?ana=yahoo&yptr=yahoo&.tsrc=rss,Sarepta Therapeutics Inc. agreed to pay $35 million plus royalties and potential milestones to BioMarin Pharmaceutical Inc. to resolve a dispute over patents on its Duchenne muscular dystrophy drug. Sarepta ...
BMRN,BMRN:UW,BBG000CZX7N1,"Sarepta, BioMarin Fall After Settling Patent Fight",2017-07-18 17:32:00 +0000,http://finance.yahoo.com/r/d00245f4-55ac-3311-be0a-22fd81c2bc7e/sarepta-biomarin-fall-after-settling-patent-fight-1500399152?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics (SRPT) and BioMarin Pharmaceutical (BMRN) are falling Tuesday, after announced they had reached a settlement regarding the exclusive license on a patent pertaining to exon skipping technology used in Duchenne muscular dystrophy (DMD) therapies.  The settlement is a long-awaited one, and the agreement means that Sarepta will pay BioMarin an upfront fee of $15 million, and owe a 5% royalty on US sales of drugs using the technology, as well as an 8% royalty on European sales through 2023 and 2024, respectively.  Leerink's Joseph Schwartz and Dae Gon Ha reiterated Outperform ratings on both Sarepta and BioMarin, but write that the news is better for the latter than the former."
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta Therapeutics and BioMarin Pharmaceutical Inc. Announce Execution of a Global Settlement and a License Agreement Resolving Exon Skipping Patent Litigation,2017-07-18 12:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-biomarin-pharmaceutical-inc-123000612.html?.tsrc=rss,"CAMBRIDGE, Mass. and SAN RAFAEL, Calif., July 18, 2017-- Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics ..."
BMRN,BMRN:UW,BBG000CZX7N1,Wall Street’s 5 Hottest Biotech Stocks Right Now,2017-07-17 23:45:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Pr9S-b3dxaE/wall-streets-5-hottest-biotech-stocks-right-now-cm817217,InvestorPlace Stock Market News Stock Advice amp Trading Tips Biotech stocks recently experienced their best week since the start of 2017 The biotechnology sector spiked following news that President Donald Trump plans to address drug prices with an executive order rather than
BMRN,BMRN:UW,BBG000CZX7N1,"Market Close Report: NASDAQ Composite index closes at 6,314.43 up 1.96 points",2017-07-17 20:48:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/quvt46iWJmk/market-close-report-nasdaq-composite-index-closes-at-631443-up-196-points-cm817161,Monday s session closes with the NASDAQ Composite Index at 6 314 43 The total shares traded for the NASDAQ was over 1 58 billion Monday s session closes with the NASDAQ Composite Index at 6 314 43 The total shares traded for the NASDAQ was over 1 58 billion Advancers stocks led declining by 1
BMRN,BMRN:UW,BBG000CZX7N1,"ETFs with exposure to BioMarin Pharmaceutical, Inc. : July 14, 2017",2017-07-14 17:09:23 +0000,http://finance.yahoo.com/r/905f7f5f-4e2a-3fd3-babf-d49311a38986/etfs-with-exposure-to-biomarin-pharmaceutical-inc-july-14-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioMarin Pharmaceutical, Inc. Here are 5 ETFs with the largest exposure to BMRN-US. Comparing the performance and risk of BioMarin Pharmaceutical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,Biotech 2Q17: It's Mostly all Gravy,2017-07-13 13:46:00 +0000,http://finance.yahoo.com/r/fc9f4171-9d0c-316f-9b64-af53d2daab53/biotech-2q17-its-mostly-all-gravy-1499953599?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"There's still a big question mark around healthcare policy, but drug pricing concerns have abated and investor sentiment appears to be improving. Exchange-traded funds tracking biotechnology stocks are ..."
BMRN,BMRN:UW,BBG000CZX7N1,The Math Shows BBH Can Go To $140,2017-07-12 14:44:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j6F-eEB6c8c/the-math-shows-bbh-can-go-to-140-cm814932,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : July 12, 2017",2017-07-12 12:34:47 +0000,http://finance.yahoo.com/r/9a82dac2-9171-36df-8491-43582547da14/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bullish-manner-bmrn-us-july-12-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioMarin Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,Could This Biotech Win In Hemophilia With &apos;One And Done&apos; Drug?,2017-07-11 20:43:27 +0000,http://finance.yahoo.com/r/725b0580-60d6-30bc-ad5f-3ba5a771395a/could-this-biotech-win-in-hemophilia-with-one-and-done-drug?src=A00220&yptr=yahoo&.tsrc=rss,BioMarin Pharmaceutical stock popped Tuesday on strong data from a hemophilia study for its drug BMN 270.
BMRN,BMRN:UW,BBG000CZX7N1,InPlay from Briefing.com,2017-07-11 09:53:47 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels within Normal Range for over One Year,2017-07-11 07:30:00 +0000,https://finance.yahoo.com/news/biomarins-investigational-gene-therapy-hemophilia-073000091.html?.tsrc=rss,"SAN RAFAEL, Calif. , July 11, 2017 /PRNewswire/ --  BioMarin Provides BMN 270 Data at International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress Initiation of Phase 3 Registrational Study ..."
BMRN,BMRN:UW,BBG000CZX7N1,What Analysts Recommend for BioMarin Pharmaceuticals,2017-07-10 13:07:54 +0000,http://finance.yahoo.com/r/cf02b496-4085-3899-b066-ca212cbdc160/what-analysts-recommend-for-biomarin-pharmaceuticals?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"A total of 20 analysts were analyzing BioMarin Pharmaceuticals in July 2017. Six analysts recommended a “strong buy,” while nine analysts suggested a “buy.”"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Expects These Drugs to Generate Steady Revenues,2017-07-10 11:38:19 +0000,http://finance.yahoo.com/r/a268b41e-cc5a-3b7b-9809-26193662f19d/biomarin-expects-these-drugs-to-generate-steady-revenues?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, BioMarin Pharmaceuticals’ (BMRN) Naglazyme generated revenues of around $297 million, a ~2% year-over-year (or YoY) decline."
BMRN,BMRN:UW,BBG000CZX7N1,A Barrage Of Biotech Updates Expected At ISTH Meeting,2017-07-07 21:08:01 +0000,https://finance.yahoo.com/news/barrage-biotech-updates-expected-isth-210801883.html?.tsrc=rss,"Biotech stocks are highly volatile investments, which look toward catalytic events such as FDA decisions, clinical trial results and data presentation at various conferences. Benzinga has compiled a list ..."
BMRN,BMRN:UW,BBG000CZX7N1,Vimizim Could Significantly Drive BioMarin’s Revenue Growth,2017-07-07 20:37:10 +0000,http://finance.yahoo.com/r/26ecb679-0048-322a-a732-be79276fbbec/vimizim-could-significantly-drive-biomarins-revenue-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, BioMarin Pharmaceuticals’ (BMRN) Vimizim reported revenues of around $354 million, a ~55% year-over-year (or YoY) increase."
BMRN,BMRN:UW,BBG000CZX7N1,Kuvan Could Boost BioMarin’s Revenue Growth in 2017,2017-07-07 19:05:54 +0000,http://finance.yahoo.com/r/2c125ff4-5076-3852-82b2-745e974b6e00/kuvan-could-boost-biomarins-revenue-growth-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, BioMarin Pharmaceuticals’ (BMRN) Kuvan reported revenues of around $348 million, a ~45% year-over-year (or YoY) increase."
BMRN,BMRN:UW,BBG000CZX7N1,What to Expect from BioMarin Pharmaceuticals in 2017,2017-07-07 17:30:25 +0000,http://finance.yahoo.com/r/30a53531-d915-3d50-a364-495227479d0d/what-to-expect-from-biomarin-pharmaceuticals-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY)."
BMRN,BMRN:UW,BBG000CZX7N1,Shire Completes NDA Filing for Hemophilia Drug with FDA,2017-07-07 15:50:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LmhXyvCPdZ0/shire-completes-nda-filing-for-hemophilia-drug-with-fda-cm813018,Shire plc SHPG recently announced that it has filed an investigational new drug IND application with the FDA seeking approval for its recombinant factor VIII FVIII gene therapy candidate SHP654 for the treatment of patients with Hemophilia A The bleeding disorder disease affects
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More",2017-07-05 13:48:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TlttQR7dBQo/biotech-stock-roundup-cara-plunges-on-study-data-regulatory-updates-more-cm811794,It s been a pretty slow week for the biotech sector with not too many major updates being provided Among key news Cara Therapeutics CARA saw its shares declining on mixed data on its experimental pain treatment Meanwhile companies like BioMarin BMRN and Acorda ACOR provided
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More",2017-07-05 12:12:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-cara-plunges-121212415.html?.tsrc=rss,Key highlights in the biotech sector include mixed data from Cara (CARA) and regulatory updates from companies like BioMarin.
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase,2017-07-03 16:48:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h-OWLtkE5Ls/biomarin-files-bla-for-phenylketonuria-candidate-pegvaliase-cm811322,BioMarin Pharmaceutical Inc BMRN announced that it has filed a biologics license application BLA with the FDA for its pipeline candidate pegvaliase for phenylketonuria PKU The company had earlier stated that it will file the application in the second quarter of 2017 BioMarin is
BMRN,BMRN:UW,BBG000CZX7N1,3 Reasons Why Gilead Sciences Shouldn't Buy Vertex Pharmaceuticals,2017-07-03 15:45:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pXLFFlUxL1E/3-reasons-why-gilead-sciences-shouldnt-buy-vertex-pharmaceuticals-cm811188,The idea of a 160 marriage between Gilead Sciences NASDAQ GILD and Vertex Pharmaceuticals NASDAQ VRTX has been repeatedly floated by analysts for the better part of the last two years After all a deal to buy Vertex would easily fall within Gilead s price range and
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase,2017-07-03 14:11:02 +0000,https://finance.yahoo.com/news/biomarin-files-bla-phenylketonuria-candidate-141102201.html?.tsrc=rss,"BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU)."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Submits Pegvaliase Biologics License Application (BLA) to the U.S. FDA for Treatment of Phenylketonuria (PKU),2017-06-30 13:10:00 +0000,https://finance.yahoo.com/news/biomarin-submits-pegvaliase-biologics-license-131000370.html?.tsrc=rss,"SAN RAFAEL, Calif., June 30, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced that the company submitted a Biologics License Application (BLA) on Friday, June 30, 2017 to the U.S. Food and Drug Administration (FDA) for pegvaliase, a PEGylated recombinant phenylalanine ammonia lyase enzyme product, to reduce blood phenylalanine (Phe) levels in adult patients with PKU who have uncontrolled blood Phe levels on existing management.  Following receipt of the BLA, the FDA conducts an initial assessment of the application to determine its fileability.  The FDA typically notifies the applicant of their filing decision and planned Prescription Drug User Fee Act (PDUFA) action date within 60 to 74 days after receipt of the application.  The company also intends to submit an application for registration in the European Union (EU) by year end 2017."
BMRN,BMRN:UW,BBG000CZX7N1,3 Pivotal Drug Trials to Watch for Explosive Potential,2017-06-30 07:03:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uuxEsWGSVlY/3-pivotal-drug-trials-to-watch-for-explosive-potential-cm810308,InvestorPlace Stock Market News Stock Advice amp Trading Tips We re midway through the year and the U S Food and Drug Administration FDA has already approved just shy of 50 new drugs The second half of the year however promises to be just as interesting as the first
BMRN,BMRN:UW,BBG000CZX7N1,Why is Catalyst Pharmaceuticals' Stock Up 160% this Year?,2017-06-28 16:07:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_UITnbfgPlk/why-is-catalyst-pharmaceuticals-stock-up-160-this-year-cm809418,Shares of Catalyst Pharmaceuticals Inc CPRX have soared 161 this year so far massively outperforming the Zacks classified Medical Drugs industry s gain of 8 Here we analyze the factors that led to the rally Catalyst Pharma s key drug Firdapse is currently approved in the EU for
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : June 28, 2017",2017-06-28 13:08:56 +0000,http://finance.yahoo.com/r/596555ba-0ed9-3711-9612-bb223d35d0c0/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-bmrn-us-june-28-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioMarin Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,"Rare Diseases: Biotech's High Risk, Highest Reward Sub-Sector",2017-06-27 18:36:00 +0000,http://finance.yahoo.com/r/ddb65af1-a728-3161-9d19-5d6d55de609a/rare-diseases-biotechs-high-risk-highest-reward-sub-sector?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Companies developing drugs for rare diseases have attracted negative publicity for their often sky-high drug prices creating what Todd Hagopian believes is biotech’s high risk, highest reward sub-sector."
BMRN,BMRN:UW,BBG000CZX7N1,"ETFs with exposure to BioMarin Pharmaceutical, Inc. : June 26, 2017",2017-06-26 19:27:41 +0000,http://finance.yahoo.com/r/828d8804-4c47-36b3-8b7c-84cc3bc28fe2/etfs-with-exposure-to-biomarin-pharmaceutical-inc-june-26-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioMarin Pharmaceutical, Inc. Here are 5 ETFs with the largest exposure to BMRN-US. Comparing the performance and risk of BioMarin Pharmaceutical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,Quick Tips on Investing in the Pharmaceutical and Medical Device Industry,2017-06-25 20:49:06 +0000,https://finance.yahoo.com/news/quick-tips-investing-pharmaceutical-medical-204906094.html?.tsrc=rss,An introduction to myself as well as a concise resource for new investors looking at better understanding the pharmaceutical and medical device world
BMRN,BMRN:UW,BBG000CZX7N1,Interesting BMRN Put And Call Options For August 18th,2017-06-23 15:52:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jhktc-9cvMg/interesting-bmrn-put-and-call-options-for-august-18th-cm807422,Investors in BioMarin Pharmaceutical Inc Symbol BMRN saw new options become available this week for the August 18th expiration At Stock Options Channel our YieldBoost formula has looked up and down the BMRN options chain for the new August 18th contracts and identified one put and one
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) in Focus: Stock Moves 7% Higher,2017-06-22 14:25:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4H0RMT_woYw/biomarin-bmrn-in-focus-stock-moves-7-higher-cm806764,BioMarin Pharmaceutical Inc BMRN was a big mover last session as the company saw its shares rise 7 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend of the company as the stock is now trading above
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) in Focus: Stock Moves 7% Higher,2017-06-22 12:37:12 +0000,https://finance.yahoo.com/news/biomarin-bmrn-focus-stock-moves-123712065.html?.tsrc=rss,"BioMarin (BMRN) was a big mover last session, as the company saw its shares rise 7% on the day."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : June 16, 2017",2017-06-16 12:38:09 +0000,http://finance.yahoo.com/r/c5aa4530-66b9-36e5-a60d-06ecf6e90521/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-bmrn-us-june-16-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioMarin Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis 2017 Congress,2017-06-16 12:31:00 +0000,https://finance.yahoo.com/news/biomarin-announces-acceptance-breaking-abstract-123100594.html?.tsrc=rss,"Oral Presentation to Include Interim Results from its Ongoing Phase 1/2 BMN 270 Clinical Program, a Gene Therapy for Hemophilia A Conference call and web-cast to be held July 11th at 2:30pm CEST/8:30am ..."
BMRN,BMRN:UW,BBG000CZX7N1,"ETFs with exposure to BioMarin Pharmaceutical, Inc. : June 15, 2017",2017-06-15 17:18:50 +0000,http://finance.yahoo.com/r/00ce6701-2ef3-3423-85d3-f6adfacd7a2e/etfs-with-exposure-to-biomarin-pharmaceutical-inc-june-15-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioMarin Pharmaceutical, Inc. Here are 5 ETFs with the largest exposure to BMRN-US. Comparing the performance and risk of BioMarin Pharmaceutical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017",2017-06-14 13:45:24 +0000,http://finance.yahoo.com/r/b78698ae-bc5c-34e8-bb5b-de120c96ad19/biomarin-pharmaceutical-inc-bmrn-us-earnings-analysis-q1-2017-by-the-numbers-june-14-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis BioMarin Pharmaceutical, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of BioMarin Pharmaceutical, Inc. – Ultragenyx Pharmaceutical, Inc., Shire PLC Sponsored ADR, Esperion Therapeutics, Inc., Sangamo Therapeutics, Inc., Alexion Pharmaceuticals, Inc., Catalyst Pharmaceuticals, Inc. and Amicus Therapeutics, Inc. (RARE-US, ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,7 Reasons Why Prescription Drug Prices Are Extremely Expensive,2017-06-09 11:28:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D3tBCPPcZXw/7-reasons-why-prescription-drug-prices-are-extremely-expensive-cm800997,Image source Getty Images Spending on prescription drugs increased by 3 8 in 2016 according 160 to pharmacy benefit manager Express Scripts While that s slower growth than the 5 2 year over year increase experienced in 2015 spending is still headed in the wrong
BMRN,BMRN:UW,BBG000CZX7N1,7 Reasons Why Prescription Drug Prices Are Extremely Expensive,2017-06-09 10:00:00 +0000,http://finance.yahoo.com/r/c69ec843-fa9b-31a8-b497-2f6fdeaf309a/7-reasons-why-prescription-drug-prices-are-extreme.aspx?yptr=yahoo&.tsrc=rss,There are myriad reasons going to the drugstore hurts the wallet.
BMRN,BMRN:UW,BBG000CZX7N1,It takes billions of dollars to bring a new drug to the market; here are some of the reasons why,2017-06-09 00:20:08 +0000,http://finance.yahoo.com/r/b4ea2d68-0a5d-345d-ae1a-957b56f8c364/biotech-2017-price-of-a-new-drug-biomarin.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"In late April, rare disease drug maker BioMarin Pharmaceutical Inc. unveiled its newest biologic offering: a first-in-class drug for a one-in-a-million form of a genetic disorder Batten disease, which attacks the nervous system and kills those affected at ages as young as 8-12 years old.  Also notable: Brineura’s $702,000 list price, which falls to an estimated annual net price of $486,000 after government discounts, rebates and projected usage.  “Pricing is one part art, one part science,” said Jeff Ajer, executive vice president and chief commercial officer for BioMarin."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Down 8% Since Earnings Report: Can It Rebound?,2017-06-08 15:31:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4uvmSH65LQc/biomarin-bmrn-down-8-since-earnings-report-can-it-rebound-cm800518,A month has gone by since the last earnings report for BioMarin Pharmaceutical Inc BMRN Shares have lost nearly 8 in that time frame underperforming the market Will the recent negative trend continue leading up to the stock s next earnings release or is it due for a breakout Before
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Down 8% Since Earnings Report: Can It Rebound?,2017-06-08 13:47:01 +0000,https://finance.yahoo.com/news/biomarin-bmrn-down-8-since-134701706.html?.tsrc=rss,BioMarin (BMRN) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
BMRN,BMRN:UW,BBG000CZX7N1,Sum Up The Pieces: BBH Could Be Worth $138,2017-06-06 15:04:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eYDDLOKk1zs/sum-up-the-pieces-bbh-could-be-worth-138-cm799307,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : June 5, 2017",2017-06-05 12:44:01 +0000,http://finance.yahoo.com/r/09aa9b60-c48b-3086-b240-fb51998e9e89/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bullish-manner-bmrn-us-june-5-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioMarin Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin's (BMRN) Brineura Approved by European Commission,2017-06-02 17:33:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_36tAOoEN_Q/biomarins-bmrn-brineura-approved-by-european-commission-cm798110,BioMarin Pharmaceutical Inc BMRN announced that the European Commission has approved Brineura cerliponase alfa for the treatment of neuronal ceroid lipofuscinosis type 2 CLN2 CLN2 is also known as tripeptidyl peptidase 1 TPP1 deficiency a form of Batten disease and ultra rare
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin&apos;s (BMRN) Brineura Approved by European Commission,2017-06-02 15:14:03 +0000,https://finance.yahoo.com/news/biomarin-apos-bmrn-brineura-approved-151403877.html?.tsrc=rss,BioMarin Pharmaceutical Inc. (BMRN) announced that the European Commission has approved Brineura (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2).
BMRN,BMRN:UW,BBG000CZX7N1,Health Care Sector Update for 06/01/2017: BMRN,2017-06-01 13:51:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wxlB71vbSlo/health-care-sector-update-for-06012017-bmrn-cm797301,Top Health care stocks Top Health care stocks JNJ flatJNJ flat PFE 0 6 PFE 0 6 ABT 0 5 ABT 0 5 MRK flatMRK flat AMGN 0 2 AMGN 0 2 Health care shares were mixed in pre market trade on Thursday Health care shares were mixed in pre market trade on Thursday In health care
BMRN,BMRN:UW,BBG000CZX7N1,"European Commission Approves Brineura™ (cerliponase alfa), the First Treatment for CLN2 Disease, a Form of Batten Disease and Ultra-Rare Brain Disorder in Children",2017-06-01 12:31:00 +0000,https://finance.yahoo.com/news/european-commission-approves-brineura-cerliponase-123100767.html?.tsrc=rss,"On April 21, 2017, the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), adopted a positive opinion for the company's Marketing Authorization Application (MAA) for BrineuraTM (cerliponase alfa) following an accelerated review procedure, reserved for medicinal products expected to be of major public health interest.  The EMA revised process for accelerated assessment came into effect June 1, 2016."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Reports Marketing Authorization For Brineura In European Union,2017-06-01 08:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/su2fXXFYhF0/biomarin-reports-marketing-authorization-for-brineura-in-european-union-20170601-00690,BioMarin Reports Marketing Authorization For Brineura In European Union
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin to Attend Upcoming Investor Conference,2017-05-31 10:00:00 +0000,https://finance.yahoo.com/news/biomarin-attend-upcoming-investor-conference-100000976.html?.tsrc=rss,"SAN RAFAEL, Calif., May 31, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will participate ..."
BMRN,BMRN:UW,BBG000CZX7N1,Ultragenyx Receives Priority Review for rhGUS from FDA,2017-05-24 14:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kF8pl1tlk8M/ultragenyx-receives-priority-review-for-rhgus-from-fda-cm793872,Ultragenyx Pharmaceutical Inc RARE recently announced that it has submitted regulatory applications in both the U S and the EU for recombinant human beta glucuronidase rhGUS This is an investigational candidate that is being developed for the treatment of mucopolysaccharidosis VII MPS
BMRN,BMRN:UW,BBG000CZX7N1,Ultragenyx Receives Priority Review for rhGUS from FDA,2017-05-24 13:17:01 +0000,https://finance.yahoo.com/news/ultragenyx-receives-priority-review-rhgus-131701283.html?.tsrc=rss,"The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)&apos;s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017."
BMRN,BMRN:UW,BBG000CZX7N1,Why Sangamo Therapeutics Inc. Jumped Higher Today,2017-05-12 20:31:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UotegqtYj68/why-sangamo-therapeutics-inc-jumped-higher-today-cm788774,What happened Sangamo Therapeutics NASDAQ SGMO ended the day up 16 after catapulting over 60 higher yesterday following the announcement that Pfizer NYSE PFE licensed Sangamo s hemophilia A gene therapy SB 525 So what The partnership came with a 70
BMRN,BMRN:UW,BBG000CZX7N1,Why Sangamo Therapeutics Inc. Jumped Higher Today,2017-05-12 20:20:00 +0000,http://finance.yahoo.com/r/28138258-1510-36e0-8686-d918f720fc0d/why-sangamo-therapeutics-inc-jumped-higher-today.aspx?yptr=yahoo&.tsrc=rss,"A deal with Pfizer, coupled with some likely short-seller covering, has shares headed higher for the second day in a row."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical Breaks Below 200-Day Moving Average - Notable for BMRN,2017-05-10 17:02:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IhnnDryv3os/biomarin-pharmaceutical-breaks-below-200-day-moving-average-notable-for-bmrn-cm787304,In trading on Wednesday shares of BioMarin Pharmaceutical Inc Symbol BMRN crossed below their 200 day moving average of 90 04 changing hands as low as 89 74 per share BioMarin Pharmaceutical Inc shares are currently trading off about 1 4 on the day The chart below shows the one
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death",2017-05-10 14:05:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ENZtDOEpGpw/biotech-stock-roundup-regeneron-biomarin-report-q1-kite-down-on-patient-death-cm787163,Kite Pharma s KITE announcement regarding a patient death related to its lead pipeline candidate was the big news in the biotech sector with the company s shares taking a hit Meanwhile major players like Regeneron REGN and BioMarin BMRN reported 1Q results while Regeneron posted a
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death",2017-05-10 12:30:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-regeneron-biomarin-123012933.html?.tsrc=rss,Kite&apos;s (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical Inc. Moves Toward Profitability,2017-05-09 19:03:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/thAUdrhEmZI/biomarin-pharmaceutical-inc-moves-toward-profitability-cm786702,BioMarin Pharmaceutical NASDAQ BMRN released earnings last week with solid revenue growth moving the company toward profitability Biomarin Pharmaceutical results The raw numbers Metric Q1
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical Inc. Moves Toward Profitability,2017-05-09 17:40:00 +0000,http://finance.yahoo.com/r/ec3519a8-cbdd-3a56-8421-bdae9b63b156/biomarin-pharmaceutical-inc-moves-towards-profitab.aspx?yptr=yahoo&.tsrc=rss,It was a solid first quarter from the orphan-drug expert.
BMRN,BMRN:UW,BBG000CZX7N1,Edited Transcript of BMRN earnings conference call or presentation 4-May-17 8:30pm GMT,2017-05-09 13:10:52 +0000,http://finance.yahoo.com/news/edited-transcript-bmrn-earnings-conference-050933375.html?.tsrc=rss,Q1 2017 Biomarin Pharmaceutical Inc Earnings Call
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : May 9, 2017",2017-05-09 13:00:11 +0000,http://finance.yahoo.com/r/30ac61e5-b6bd-3304-9f61-614d57d6b72b/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-bmrn-us-may-9-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioMarin Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin: Is Profitability On The Horizon?,2017-05-08 18:57:00 +0000,http://finance.yahoo.com/r/cc0a47e1-94b4-33a2-b154-c473e610724a/biomarin-is-profitability-on-the-horizon-1494269871?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"When will BioMarin Pharmaceuticals (BMRN) turn a profit? The drug maker specializes in therapies for rare diseases, and already markets a handful of medications that generated revenue of $1.12 billion ..."
BMRN,BMRN:UW,BBG000CZX7N1,"Market Close Report: Historical high reached as NASDAQ Composite Index closes at 6,100.76.",2017-05-05 20:48:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2n1zJsEXAg8/market-close-report-historical-high-reached-as-nasdaq-composite-index-closes-at-610076-cm785296,Friday s session closes with the NASDAQ Composite Index reaching a historical high The index closed at 6 100 76 up 25 42 for the day The index had a previous high 6095 36645 on 05 02 2017 The total shares traded for the NASDAQ was over 2 04 billion Friday s session closes with the
BMRN,BMRN:UW,BBG000CZX7N1,These Biotechs Are Grabbing Bullish Views In Wake Of Earnings,2017-05-05 20:27:13 +0000,http://finance.yahoo.com/r/356aa738-2142-37f4-a2ce-5f0beba0a586/which-biotechs-are-grabbing-bullish-post-q1-views-heres-some-incyte?src=A00220&yptr=yahoo&.tsrc=rss,"Incyte stock toppled to a 10-week low Friday on a fourth consecutive quarter of losses, but it was among a slew of biotechs to grab bullish reports."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up",2017-05-05 15:25:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4E0_JPbrJP8/biomarin-bmrn-posts-earnings-in-q1-sales-top-stock-up-cm784989,BioMarin Pharmaceutical Inc BMRN reported earnings of 3 cents per share in the first quarter of 2017 including stock based compensation expense significantly better than the year ago loss of 36 cents and the Zacks Consensus Estimate of a loss of 30 cents per share Higher gross margins
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up",2017-05-05 14:30:02 +0000,http://finance.yahoo.com/news/biomarin-bmrn-posts-earnings-q1-143002320.html?.tsrc=rss,BioMarin Pharmaceutical Inc. (BMRN) reported earnings of 3 cents per share in the first quarter of 2017.
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin reports 1Q loss,2017-05-04 20:46:37 +0000,http://finance.yahoo.com/news/biomarin-reports-1q-loss-204637674.html?.tsrc=rss,"The San Rafael, California-based company said it had a loss of 9 cents per share. Earnings, adjusted for stock option expense and non-recurring costs, came to 21 cents per share. The results beat Wall ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces First Quarter 2017 Financial Results,2017-05-04 20:02:00 +0000,http://finance.yahoo.com/news/biomarin-announces-first-quarter-2017-200200275.html?.tsrc=rss,"SAN RAFAEL, Calif., May 4, 2017 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2017 2016 % Change Total BioMarin Revenues ..."
BMRN,BMRN:UW,BBG000CZX7N1,"After-Hours Earnings Report for May 4, 2017 :  ATVI, MNST, ED, CBS, BMRN, MSI, MTD, MRO, PBA, MELI, ANET, Y",2017-05-04 19:19:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NN7M6ty9NzU/after-hours-earnings-report-for-may-4-2017-atvi-mnst-ed-cbs-bmrn-msi-mtd-mro-pba-meli-anet-y-cm784449,The following companies are expected to report earnings after hours on 05 04 2017 Visit our Earnings Calendar for a full list of expected earnings releases Activision Blizzard Inc ATVI is reporting for the quarter ending March 31 2017 The toy game
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharmaceutical Q1 17 Earnings Conference Call At 4:30 PM ET,2017-05-04 15:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z0QdKxcQ8nY/biomarin-pharmaceutical-q1-17-earnings-conference-call-at-430-pm-et-20170504-01676,Biomarin Pharmaceutical Q1 17 Earnings Conference Call At 4:30 PM ET
BMRN,BMRN:UW,BBG000CZX7N1,Investor Network: BioMarin Pharmaceutical Inc. to Host Earnings Call,2017-05-04 14:55:00 +0000,http://finance.yahoo.com/news/investor-network-biomarin-pharmaceutical-inc-145500414.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 4, 2017 / BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) will be discussing their earnings results in their Q1 Earnings Call to be held May 4, 2017 at 4:30 PM Eastern Time. ..."
BMRN,BMRN:UW,BBG000CZX7N1,[$$] Did Gilead Cut Buybacks for Acquisition?,2017-05-04 14:38:00 +0000,http://finance.yahoo.com/r/a32cbbba-8ee9-39e9-bc85-b4887f022975/did-gilead-cut-buybacks-for-acquisition-1493908695?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Gilead Sciences (GILD) repurchased $565 million of shares in the first quarter, even less than the $1 billion of buybacks in the fourth quarter, indicating that Gilead is holding cash for acquisition that is potentially a midsize biotech.  -- Jing He  To be considered for the Soapbox feature, please submit an original article of less than 1,000 words to research@barrons.com with “Soapbox Submission” in the headline."
BMRN,BMRN:UW,BBG000CZX7N1,Analysts Forecast 12% Upside For BBH,2017-05-04 14:13:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W6-sOyMFAsM/analysts-forecast-12-upside-for-bbh-cm784035,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update",2017-05-03 13:31:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6O0dk47b5ew/biotech-stock-roundup-amgen-gilead-celgene-q1-earnings-sunesis-down-on-vosaroxin-update-cm783260,It was all about earnings this week with companies like Amgen AMGN Celgene CELG Vertex AbbVie Alexion and Gilead GILD reporting results So far it looks like a mixed quarter for quite a few companies with earnings topping expectations while revenues fell short Recap of the Week
BMRN,BMRN:UW,BBG000CZX7N1,Why Earnings Season Could Be Great for BioMarin (BMRN),2017-05-03 12:48:12 +0000,http://finance.yahoo.com/news/why-earnings-season-could-great-124812941.html?.tsrc=rss,BioMarin (BMRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BMRN,BMRN:UW,BBG000CZX7N1,What Lies Ahead for Stericycle (SRCL) this Earnings Season?,2017-05-03 12:28:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yntV9y0I1VE/what-lies-ahead-for-stericycle-srcl-this-earnings-season-cm783227,Waste management firm Stericycle Inc SRCL is scheduled to report first quarter 2017 results after the closing bell on May 4 In the last reported quarter adjusted earnings exceeded the Zacks Consensus Estimate by 7 cents The company has a mixed earnings surprise history with two beats and
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin to Attend Two Upcoming Investor Conferences,2017-05-02 12:30:00 +0000,http://finance.yahoo.com/news/biomarin-attend-two-upcoming-investor-123000437.html?.tsrc=rss,"SAN RAFAEL, Calif., May 2, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will participate in Deutsche ..."
BMRN,BMRN:UW,BBG000CZX7N1,Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store?,2017-05-01 16:31:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UEE1oOnqS3o/agios-pharmaceuticals-agio-q1-earnings-whats-in-store-cm782059,Agios Pharmaceuticals Inc AGIO is scheduled to report first quarter results on May 4 before market open Shares gained 19 1 so far this year while the Zacks classified Medical Products industry witnessed an increase of 14 3 Agios performance has been mixed with the company
BMRN,BMRN:UW,BBG000CZX7N1,6 FDA Events to Watch Out for in May 2017,2017-05-01 14:33:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/veBBExn2k4I/6-fda-events-to-watch-out-for-in-may-2017-cm781882,The FDA which approved 22 treatments last year has given its approval to 16 drugs so far in 2017 including 4 in April Key approvals so far in 2017 include Roche s multiple sclerosis treatment Ocrevus Regeneron and Sanofi s eczema treatment Dupixent Tesaro s PARP inhibitor Zejula
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin CEO says 'the system will have to determine' the...,2017-04-28 23:13:00 +0000,http://finance.yahoo.com/video/biomarin-ceo-says-system-determine-231300696.html?.tsrc=rss,Jim Cramer spoke with JJ Bienaimé for more on the company's newest drug that treats a very rare disease.
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin CEO says 'the system will have to determine' the worth of its new $702,000 drug",2017-04-28 22:58:40 +0000,http://finance.yahoo.com/r/1ab27563-60da-318a-acc0-58c5b3426330/104435807?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104435807&yptr=yahoo&.tsrc=rss,Jim Cramer spoke with JJ Bienaimé for more on the company's newest drug that treats a very rare disease.
BMRN,BMRN:UW,BBG000CZX7N1,Today's Research Reports on Biotech Stocks to Watch: Pacific Biosciences of California and BioMarin Pharmaceutical,2017-04-28 11:30:00 +0000,http://finance.yahoo.com/news/todays-research-reports-biotech-stocks-113000321.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / April 28, 2017 / BioMarin shares trended higher this week after the FDA approved the pharma giant's Brineura drug that treats a type of Batten disease. Brinuera is the first ..."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin wins FDA approval for life-changing drug for kids — with a $700,000-per-year cost",2017-04-27 23:29:52 +0000,http://finance.yahoo.com/r/2cdcc2bd-5f06-3bae-b85e-50d9ade814aa/biomarin-bmrn-batten-disease-brineura-cln2.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Rare disease drug developer BioMarin Pharamceutical Inc. won regulatory approval Thursday of a drug that promises to change the course of a fatal childhood neurodegenerative disease.  San Rafael-based BioMarin's Brineura is the first drug approved by the Food and Drug Administration to treat children with CLN2, a form of Batten disease.  It took four years from BioMarin's first clinical trial of the drug to FDA approval, a relatively fast timeline in an industry that says drug development generally takes 10-plus years and more than $1 billion."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Prices Orphan Drug at $702,000, Promises Big Discounts",2017-04-27 22:17:13 +0000,http://finance.yahoo.com/r/5a7a4b5a-db36-3c3b-b2a0-38538439483e/biomarin-prices-orphan-drug-at-702-000-promises-big-discounts?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,BioMarin Pharmaceutical Inc. won approval from U.S. regulators for a treatment for an ultrarare pediatric brain disorder. The therapy will have an extraordinary price tag.
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin sets high price for rare pediatric brain disease drug,2017-04-27 22:03:17 +0000,http://finance.yahoo.com/news/u-fda-approves-biomarins-batten-181023972.html?.tsrc=rss,"Biomarin Pharmaceuticals Inc  said the annual price for its drug, which won U.S. approval on  Thursday, to treat a rare and fatal type of pediatric brain  disease is expected to be $486,000 after mandatory government  discounts and rebates.  The Food and Drug Administration approved Brineura, an  enzyme replacement therapy, for patients aged 3 and older to  slow the loss of walking ability, making it the first approved  medicine for the progressive type of Batten disease known as  late infantile neuronal ceroid lipofuscinosis type 2, or CLN2.  The approval was based on data from just 22 treated patients  between the ages of 3 and 8, who were compared with 42 untreated  patients."
BMRN,BMRN:UW,BBG000CZX7N1,FDA Oks BioMarin's Brineura As Treatment For Specific Form Of Batten Disease,2017-04-27 21:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qpWlBbaZcww/fda-oks-biomarins-brineura-as-treatment-for-specific-form-of-batten-disease-20170427-02450,FDA Oks BioMarin's Brineura As Treatment For Specific Form Of Batten Disease
BMRN,BMRN:UW,BBG000CZX7N1,"Biomarin Newly Approved Drug for Rare, Childhood Disease Will Cost $700K Per Year",2017-04-27 20:36:00 +0000,http://finance.yahoo.com/r/990a0f59-3b81-3072-bac6-c335ccbeccb3/biomarin-rare-disease-drug-picks-up-european-endorsement-ahead-of-fda-action.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Brineura is first and only treatment for CLN2 disease, a form of Batten disease."
BMRN,BMRN:UW,BBG000CZX7N1,InPlay from Briefing.com,2017-04-27 18:54:59 +0000,http://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?,2017-04-27 17:29:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PhMg_W_7qB4/biomarin-bmrn-q1-earnings-will-it-beat-estimates-again-cm780424,We expect BioMarin Pharmaceutical Inc BMRN to beat expectations when it reports first quarter 2017 results on May 4 after the market closes BioMarin had delivered a positive earnings surprise of 5 13 in the last quarter BioMarin s shares are up 16 so far this year This
BMRN,BMRN:UW,BBG000CZX7N1,"FDA Approves Brineura™ (cerliponase alfa) for the Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare Pediatric Brain Disorder in Children",2017-04-27 17:28:00 +0000,http://finance.yahoo.com/news/fda-approves-brineura-cerliponase-alfa-172800768.html?.tsrc=rss,"SAN RAFAEL, Calif., April 27, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) today announced that the U.S. Food and Drug Administration (FDA) approved Brineura™ (cerliponase alfa) to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.  Brineura is the first treatment approved to treat children with CLN2 disease, a form of Batten disease.  CLN2 disease is an ultra-rare, rapidly progressive fatal brain condition, which affects less than one in one million U.S. residents, many of whom are undiagnosed.  Every year approximately 20 children are born in the U.S. with CLN2 disease.  These affected children completely lose the ability to walk and talk around 6 years of age.  During the later stages of the disease, feeding and tending to everyday needs become very difficult with death often occurring between 8 and 12 years of age."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?,2017-04-27 15:34:03 +0000,http://finance.yahoo.com/news/biomarin-bmrn-q1-earnings-beat-153403289.html?.tsrc=rss,"We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes."
BMRN,BMRN:UW,BBG000CZX7N1,A Tax Cut in Progress,2017-04-27 13:25:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/648ECEaC-tw/a-tax-cut-in-progress-cm780027,From the market s reaction today you might think that it just hated the President s long awaited tax plan as the major indices made a beeline to the negative side after it was announced But that s not the case Certainly this market would LOVE a 15 corporate tax rate Instead several of
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug",2017-04-26 14:07:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z8kcvhvq52c/biotech-stock-roundup-biogen-gains-on-strong-q1-nash-data-on-gilead-drug-cm779308,Earnings season for the biotech sector is off to a promising start with Biogen BIIB reporting better than expected first quarter results While focus remained on Biogen s results companies like Gilead GILD were also in the news on the presentation of pipeline data Recap of the Week s
BMRN,BMRN:UW,BBG000CZX7N1,Blog Coverage Capricor Announces Positive Results from Trial for the Treatment of Duchenne Muscular Dystrophy,2017-04-26 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-capricor-announces-positive-121500485.html?.tsrc=rss,"Upcoming AWS Coverage on BioMarin Pharmaceutical Post-Earnings Results LONDON, UK / ACCESSWIRE / April 26, 2017 / Active Wall St. blog coverage looks at the headline from Capricor Therapeutics, Inc. (NASDAQ: ..."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. – Value Analysis (NASDAQ:BMRN) : April 25, 2017",2017-04-25 20:05:25 +0000,http://finance.yahoo.com/r/ec9389ec-7196-33d7-bf1c-87f987ef34b7/biomarin-pharmaceutical-inc-value-analysis-nasdaqbmrn-april-25-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives BioMarin Pharmaceutical, Inc. a score of 47. Our analysis is based on comparing BioMarin Pharmaceutical, Inc. with the following peers – Ultragenyx Pharmaceutical, Inc., Shire PLC Sponsored ADR, Esperion Therapeutics, Inc., Sanofi Sponsored ADR, Sangamo Therapeutics, Inc., Alexion Pharmaceuticals, Inc., Catalyst Pharmaceuticals, Inc. and Amicus Therapeutics, Inc. ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates,2017-04-25 17:44:54 +0000,http://finance.yahoo.com/news/mark-calendar-days-may-play-174454598.html?.tsrc=rss,"Investment in biotech stocks is fraught with risks. These stocks trade in anticipation of some ""make-or-break"" events called catalysts and therefore face the danger of seeing wild swings in the ..."
BMRN,BMRN:UW,BBG000CZX7N1,"Notable Monday Option Activity: AA, VLO, BMRN",2017-04-24 21:04:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w6Bllc17Vxg/notable-monday-option-activity-aa-vlo-bmrn-cm778245,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Alcoa Corporation Symbol AA where a total of 18 271 contracts have traded so far representing approximately 1 8 million underlying shares That amounts to about 42 5 of AA s
BMRN,BMRN:UW,BBG000CZX7N1,"Nasdaq 100 Movers: MU, BMRN",2017-04-24 16:05:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TqY2mr8tbW8/nasdaq-100-movers-mu-bmrn-cm777848,In early trading on Monday shares of BioMarin Pharmaceutical BMRN topped the list of the day s best performing components of the Nasdaq 100 index trading up 4 6 Year to date BioMarin Pharmaceutical registers a 11 7 gain And the worst performing Nasdaq 100 component thus far on
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : April 24, 2017",2017-04-24 12:43:45 +0000,http://finance.yahoo.com/r/0a46832f-ca06-3600-aa4e-769bab2211b9/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-bmrn-us-april-24-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioMarin Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Receives Positive CHMP Opinion in Europe for Brineura™ (cerliponase alfa) for First Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare and Fatal Brain Disorder in Children",2017-04-21 17:29:00 +0000,http://finance.yahoo.com/news/biomarin-receives-positive-chmp-opinion-172900506.html?.tsrc=rss,"SAN RAFAEL, Calif., April 21, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion for the company's Marketing Authorization Application (MAA) for Brineura™ (cerliponase alfa) to treat children with Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) disease, a form of Batten disease, which is also known as tripeptidyl peptidase 1 (TPP1) deficiency.  The CHMP's recommendation is now referred to the European Commission (EC), which is expected to render its final decision by the second quarter of 2017."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin to Host First Quarter 2017 Financial Results Conference Call and Webcast on Thursday, May 4 at 4:30pm ET",2017-04-20 20:53:00 +0000,http://finance.yahoo.com/news/biomarin-host-first-quarter-2017-205300016.html?.tsrc=rss,"SAN RAFAEL, Calif., April 20, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ..."
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed",2017-04-19 14:06:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ElHVpLVTn4U/biotech-stock-roundup-fda-crl-hits-incyte-pipeline-setbacks-weigh-on-oncomed-cm775728,The FDA s complete response letter CRL for Incyte INCY and Lilly s experimental rheumatoid arthritis RA treatment was the big news in the biotech sector while OncoMed OMED continued to be hit by more pipeline setbacks Recap of the Week s Most Important Stories CRL for Incyte s
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed",2017-04-19 11:57:11 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-fda-crl-115711490.html?.tsrc=rss,Incyte&apos;s (INCY) shares were hit by the FDA&apos;s complete response letter (CRL) for the company&apos;s rheumatoid arthritis drug.
BMRN,BMRN:UW,BBG000CZX7N1,5 Drug Stocks That Could Be Big Winners this Earnings Season,2017-04-17 14:58:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QPLo4QQxIuo/5-drug-stocks-that-could-be-big-winners-this-earnings-season-cm774522,The first quarter earnings season is off to a start with results expected to ramp up this week as 177 companies including 61 S amp P 500 members provide numbers While it is still early in the season total Q1 earnings are expected to be up 7 6 on revenue growth of 6 3 This compares
BMRN,BMRN:UW,BBG000CZX7N1,5 Drug Stocks That Could Be Big Winners this Earnings Season,2017-04-17 13:20:01 +0000,http://finance.yahoo.com/news/5-drug-stocks-could-big-132001722.html?.tsrc=rss,Here is a look at five companies including Pfizer (PFE) that sport a favorable Zacks Rank and have a positive earnings ESP.
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : April 14, 2017",2017-04-14 12:05:41 +0000,http://finance.yahoo.com/r/8402cd9e-ad83-3d56-a7d3-b4f28b174246/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bullish-manner-bmrn-us-april-14-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioMarin Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,The Hot Stock: Alexion Pharmaceuticals Climbs 3.3%,2017-04-13 20:18:00 +0000,http://finance.yahoo.com/r/881789be-222a-3d9f-964e-c66f05d98bf3/the-hot-stock-alexion-pharmaceuticals-climbs-3-3?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Alexion Pharmaceuticals (ALXN), a drug maker focused on rare diseases, ended Thursday at the top of the list of the best performing stocks in the S&P 500 index.  It’s been a rough two years for Alexion.  Since mid-2015, when the stock traded above $200, shares have tumbled on worries about the durability of its main drug Soliris, political furor over high drug prices, and the abrupt departure of two top executives amid an investigation into sales practices."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces Kuvan® (sapropterin dihydrochloride) Patent Challenge Settlement,2017-04-13 12:30:00 +0000,http://finance.yahoo.com/news/biomarin-announces-kuvan-sapropterin-dihydrochloride-123000218.html?.tsrc=rss,"SAN RAFAEL, Calif., April 13, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN), today announced that it has entered into a settlement agreement with Par Pharmaceutical that resolves patent litigation in the United States (U.S.) related to BioMarin's Kuvan® (sapropterin dihydrochloride) 100mg oral tablets and powder for oral solution in 100mg packets.  Under the terms of the settlement, BioMarin will grant Par a non-exclusive license to its patents related to Kuvan to allow Par to market a generic version of sapropterin dihydrochloride 100mg tablets and powder for oral solution in 100mg and 500 mg sachets in the U.S. for the indications approved for Kuvan beginning October 1, 2020 or earlier under certain circumstances."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Enters Into Settlement Agreement With Par Pharma Related To Kuvan,2017-04-13 08:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ccY-b8E5oj4/biomarin-enters-into-settlement-agreement-with-par-pharma-related-to-kuvan-20170413-00515,BioMarin Enters Into Settlement Agreement With Par Pharma Related To Kuvan
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta Therapeutics Stock History: A Biotech Roller-Coaster Ride,2017-04-12 21:55:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_2v0H1crjPk/sarepta-therapeutics-stock-history-a-biotech-roller-coaster-ride-cm773499,Stocks in the biotech and pharmaceuticals industries can give investors a ride more intense than the wildest roller coasters A quick analysis of the stock history of Sarepta Therapeutics NASDAQ SRPT provides a great example of this For two decades Sarepta stock has soared
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta Therapeutics Stock History: A Biotech Roller-Coaster Ride,2017-04-12 20:42:00 +0000,http://finance.yahoo.com/r/f7513c9b-c5f5-34fc-bf47-6f0f6a5646c6/sarepta-therapeutics-stock-history-a-biotech-rolle.aspx?yptr=yahoo&.tsrc=rss,Sarepta Therapeutics stock history through the years has given investors a wild ride.
BMRN,BMRN:UW,BBG000CZX7N1,3 Stocks We'd Buy and Hold for the Next 20 Years,2017-04-06 13:56:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GGPkTInMunI/3-stocks-wed-buy-and-hold-for-the-next-20-years-cm770614,Buying and holding quality stocks for long periods of time is the only strategy that s proven to produce life changing returns on capital on a consistent basis Even so it can be tricky to identify which stocks can truly stand the test of time With this question in mind we asked
BMRN,BMRN:UW,BBG000CZX7N1,3 Stocks We&apos;d Buy and Hold for the Next 20 Years,2017-04-06 12:24:00 +0000,http://finance.yahoo.com/r/85a41ffd-ca9e-3595-abce-272c24aab0ce/3-stocks-wed-buy-and-hold-for-the-next-20-years.aspx?yptr=yahoo&.tsrc=rss,These three stocks are worth holding on to for the duration.
BMRN,BMRN:UW,BBG000CZX7N1,Just How Much Is a Medical Miracle Worth?,2017-04-06 09:00:15 +0000,http://finance.yahoo.com/news/just-much-medical-miracle-worth-090015067.html?.tsrc=rss,Years of costly treatments could give way to pricier one-shot cures like Spark Therapeutics’ blindness drug. But insurers aren’t ready.
BMRN,BMRN:UW,BBG000CZX7N1,4 FDA Decisions to Watch Out for in Apr 2017,2017-04-03 13:38:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/72iKZWmPenc/4-fda-decisions-to-watch-out-for-in-apr-2017-cm768879,The FDA which approved 22 treatments last year has given its approval to 12 drugs so far in 2017 including 7 in March Key approvals this year include Roche s RHHBY multiple sclerosis treatment Ocrevus Regeneron REGN and Sanofi s eczema treatment Dupixent Tesaro s TSRO PARP
BMRN,BMRN:UW,BBG000CZX7N1,Implied IYH Analyst Target Price: $171,2017-04-03 13:35:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lxvlhQOAc8c/implied-iyh-analyst-target-price-171-cm768870,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BMRN,BMRN:UW,BBG000CZX7N1,4 FDA Decisions to Watch Out for in Apr 2017,2017-04-03 11:41:11 +0000,http://finance.yahoo.com/news/4-fda-decisions-watch-apr-114111333.html?.tsrc=rss,"Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month."
BMRN,BMRN:UW,BBG000CZX7N1,4 FDA Decisions to Watch Out for in Apr 2017,2017-04-03 11:41:11 +0000,http://finance.yahoo.com/news/4-fda-decisions-watch-apr-114111333.html,4 FDA Decisions to Watch Out for in Apr 2017
BMRN,BMRN:UW,BBG000CZX7N1,4 Drug Stocks With Big News Coming in April,2017-04-02 17:35:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2_bq9BTaeoA/4-drug-stocks-with-big-news-coming-in-april-cm768806,Fill in the blank April brings Some might say that April brings April showers Others eyeing the calendar with dread might say that April brings tax day But for four drugmakers April brings big news that could be catalysts for their stocks Here s what s coming up this month
BMRN,BMRN:UW,BBG000CZX7N1,4 Drug Stocks With Big News Coming in April,2017-04-02 15:41:00 +0000,https://www.fool.com/investing/2017/04/02/4-drug-stocks-with-big-news-coming-in-april.aspx,4 Drug Stocks With Big News Coming in April
BMRN,BMRN:UW,BBG000CZX7N1,4 Drug Stocks With Big News Coming in April,2017-04-02 15:41:00 +0000,http://finance.yahoo.com/r/706729f1-72a5-3e3c-a956-8d7dbde1451c/4-drug-stocks-with-big-news-coming-in-april.aspx?yptr=yahoo&.tsrc=rss,"Major FDA decisions are on the way this month for Neurocrine, Incyte, Lilly, and BioMarin."
BMRN,BMRN:UW,BBG000CZX7N1,Coverage initiated on BioMarin Pharm by UBS,2017-03-30 13:24:18 +0000,http://finance.yahoo.com/q/ud?s=BMRN,Coverage initiated on BioMarin Pharm by UBS
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : March 30, 2017",2017-03-30 12:13:12 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bullish-manner-bmrn-us-march-30-2017/,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : March 30, 2017"
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : March 30, 2017",2017-03-30 12:13:12 +0000,http://finance.yahoo.com/r/4a0b1f7d-d804-3add-9b6a-ca811bb192eb/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bullish-manner-bmrn-us-march-30-2017?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioMarin Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more    
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,Why Is BioMarin (BMRN) Down 2.2% Since the Last Earnings Report?,2017-03-28 12:59:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AXbR0iTEpYc/why-is-biomarin-bmrn-down-22-since-the-last-earnings-report-cm766323,A month has gone by since the last earnings report for BioMarin Pharmaceutical Inc BMRN Shares have lost about 2 2 in that time frame underperforming the market Will the recent negative trend continue leading up to the stock s next earnings release or is it due for a breakout Before
BMRN,BMRN:UW,BBG000CZX7N1,Why Is BioMarin (BMRN) Down 2.2% Since the Last Earnings Report?,2017-03-28 11:10:11 +0000,http://finance.yahoo.com/news/why-biomarin-bmrn-down-2-111011106.html?.tsrc=rss,BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BMRN,BMRN:UW,BBG000CZX7N1,Why Is BioMarin (BMRN) Down 2.2% Since the Last Earnings Report?,2017-03-28 11:10:11 +0000,http://finance.yahoo.com/news/why-biomarin-bmrn-down-2-111011106.html,Why Is BioMarin (BMRN) Down 2.2% Since the Last Earnings Report?
BMRN,BMRN:UW,BBG000CZX7N1,"Sanofi Could Acquire This Biotech, But Is $1 Billion Too Low?",2017-03-24 20:19:53 +0000,http://www.investors.com/news/technology/sanofi-could-acquire-this-biotech-but-is-1-billion-too-low/?src=A00220A,"Sanofi Could Acquire This Biotech, But Is $1 Billion Too Low?"
BMRN,BMRN:UW,BBG000CZX7N1,Biotech Stocks Facing FDA Decision In April,2017-03-24 06:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/70ZD2H6sCX8/biotech-stocks-facing-fda-decision-in-april-20170324-00160,Biotech Stocks Facing FDA Decision In April
BMRN,BMRN:UW,BBG000CZX7N1,Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse,2017-03-23 16:02:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gGAzA3iL3kk/catalyst-pharma-cprx-focused-on-us-approval-for-firdapse-cm764693,We issued an updated research report on Catalyst Pharmaceuticals Inc CPRX on Mar 22 Catalyst s share price has increased significantly by 60 year to date compared with the Zacks classified Medical Drugs industry s gain of 2 1 Catalyst has in licensed rights to Firdapse
BMRN,BMRN:UW,BBG000CZX7N1,Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse,2017-03-23 13:47:01 +0000,http://finance.yahoo.com/news/catalyst-pharma-cprx-focused-u-134701783.html?.tsrc=rss,"We issued an updated research report on Catalyst Pharmaceuticals, Inc. (CPRX) on Mar 22."
BMRN,BMRN:UW,BBG000CZX7N1,Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse,2017-03-23 13:47:01 +0000,http://finance.yahoo.com/news/catalyst-pharma-cprx-focused-u-134701783.html,Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical (BMRN) Shares Cross Below 200 DMA,2017-03-21 17:09:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3S5FAmhcTbc/biomarin-pharmaceutical-bmrn-shares-cross-below-200-dma-cm763559,In trading on Tuesday shares of BioMarin Pharmaceutical Inc Symbol BMRN crossed below their 200 day moving average of 89 05 changing hands as low as 88 51 per share BioMarin Pharmaceutical Inc shares are currently trading off about 1 4 on the day The chart below shows the one
BMRN,BMRN:UW,BBG000CZX7N1,Catalyst Pharmaceuticals Inc (CPRX): Here’s What’s Next,2017-03-16 16:03:41 +0000,http://finance.yahoo.com/r/0a87e401-402e-3ca1-9a18-168aced2aa30/catalyst-pharmaceuticals-inc-cprx-heres-whats-next-566863?yptr=yahoo&.tsrc=rss,"After struggling throughout the latter half of 2016 with various development and regulatory pressures, Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has finally found some reprieve. Said reprieve comes in the form of some data just put out relating to the company’s lead development candidate (although not related to said candidate’s lead indication directly) and Catalyst is running […]"
BMRN,BMRN:UW,BBG000CZX7N1,Catalyst Pharmaceuticals Inc (CPRX): Here’s What’s Next,2017-03-16 16:03:41 +0000,http://www.insidermonkey.com/blog/catalyst-pharmaceuticals-inc-cprx-heres-whats-next-566863/,Catalyst Pharmaceuticals Inc (CPRX): Here’s What’s Next
BMRN,BMRN:UW,BBG000CZX7N1,"Commit To Purchase BioMarin Pharmaceutical At $70, Earn 8.1% Using Options",2017-03-15 17:06:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/55kiVLyl6M4/commit-to-purchase-biomarin-pharmaceutical-at-70-earn-81-using-options-cm761187,Investors eyeing a purchase of BioMarin Pharmaceutical Inc Symbol BMRN stock but cautious about paying the going market price of 91 32 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharma. To Present At Barclays Healthcare Conference At 8:00 AM ET,2017-03-15 07:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7De_YHoD0lE/biomarin-pharma-to-present-at-barclays-healthcare-conference-at-800-am-et-20170315-00286,Biomarin Pharma. To Present At Barclays Healthcare Conference At 8:00 AM ET
BMRN,BMRN:UW,BBG000CZX7N1,Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?,2017-03-07 17:16:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DE_1MfwK0Vc/catalyst-pharma-cprx-whats-in-store-in-q4-earnings-cm757312,Catalyst Pharmaceuticals Inc CPRX is expected to report fourth quarter 2016 results this month Last quarter the company recorded a positive earnings surprise of 16 67 The company beat expectations in all of the last four quarters with average positive earnings surprise of 10
BMRN,BMRN:UW,BBG000CZX7N1,Repros (RPRX) Q4 Earnings: What's in Store for the Stock?,2017-03-07 17:15:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cDlpJrfqGJ8/repros-rprx-q4-earnings-whats-in-store-for-the-stock-cm757305,Repros Therapeutics Inc RPRX is expected to report fourth quarter 2016 results this month Let s see how things are shaping up for this quarter Repros Therapeutics share price decreased 8 3 year to date while the Zacks classified Medical Biomed Genetics industry gained 10
BMRN,BMRN:UW,BBG000CZX7N1,Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?,2017-03-07 14:32:02 +0000,http://finance.yahoo.com/news/catalyst-pharma-cprx-store-q4-143202785.html,Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharma. To Participate In Cowen Health Care Conference At 11:20 AM ET,2017-03-07 10:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8RE81izagxo/biomarin-pharma-to-participate-in-cowen-health-care-conference-at-1120-am-et-20170307-00897,Biomarin Pharma. To Participate In Cowen Health Care Conference At 11:20 AM ET
BMRN,BMRN:UW,BBG000CZX7N1,Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?,2017-03-06 16:18:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2lf1UbtqDS0/celldex-therapeutics-cldx-q4-earnings-whats-in-store-cm756607,Celldex Therapeutics Inc CLDX is expected to report fourth quarter 2016 results on Mar 4 after market close Celldex s performance has been encouraging with a three quarter average positive surprise of 5 12 In the last reported quarter the company recorded a positive surprise of 9
BMRN,BMRN:UW,BBG000CZX7N1,What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?,2017-03-06 16:17:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k5aEl1tkxCw/whats-in-store-for-merck-kgaa-mkgaf-in-q4-earnings-cm756581,Merck KGaA MKGAF is scheduled to report fourth quarter 2016 earnings results on Mar 9 The company reports results under three business sectors Healthcare Life Science and Performance Materials Strong performance at Life Science which was the catalyst behind sales growth in the last
BMRN,BMRN:UW,BBG000CZX7N1,BioDelivery (BDSI): What's in Store this Earnings Season?,2017-03-06 16:17:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fR0k5t-5pr8/biodelivery-bdsi-whats-in-store-this-earnings-season-cm756577,BioDelivery Sciences International Inc BDSI is expected to report fourth quarter 2016 results on Mar 17 before the opening bell Last quarter the company s loss was wider than expected Year to date BioDelivery s shares have outperformed the Zacks classified Medical Biomed
BMRN,BMRN:UW,BBG000CZX7N1,Inovio (INO): What's in the Cards this Earnings Season?,2017-03-06 16:16:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OPBwHIeYKBs/inovio-ino-whats-in-the-cards-this-earnings-season-cm756569,Inovio Pharmaceuticals Inc INO is expected to report fourth quarter 2016 results this month The company incurred wider than expected loss in the last quarter In the last one year Inovio s shares have underperformed the Zacks classified Medical Biomed Genetics industry Specifically
BMRN,BMRN:UW,BBG000CZX7N1,Inovio (INO): What's in the Cards this Earnings Season?,2017-03-06 14:28:02 +0000,http://finance.yahoo.com/news/inovio-ino-whats-cards-earnings-142802531.html,Inovio (INO): What's in the Cards this Earnings Season?
BMRN,BMRN:UW,BBG000CZX7N1,Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?,2017-03-06 13:46:01 +0000,http://finance.yahoo.com/news/celldex-therapeutics-cldx-q4-earnings-134601473.html?.tsrc=rss,"Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close."
BMRN,BMRN:UW,BBG000CZX7N1,BIOMARIN PHARMACEUTICAL INC Financials,2017-03-02 18:04:14 +0000,http://finance.yahoo.com/q/is?s=bmrn,BIOMARIN PHARMACEUTICAL INC Financials
BMRN,BMRN:UW,BBG000CZX7N1,Analysts Expect BBH Will Reach $134,2017-03-02 14:13:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b81KryS4paA/analysts-expect-bbh-will-reach-134-cm755271,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BMRN,BMRN:UW,BBG000CZX7N1,Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?,2017-03-02 01:12:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xVea_hJVif8/aerie-pharmaceuticals-aeri-q4-earnings-what-to-expect-cm755162,Aerie Pharmaceuticals Inc AERI is expected to report fourth quarter 2016 results on Mar 7 Last quarter the company recorded a negative earnings surprise of 15 71 In fact Aerie s performance over the last four quarters has been disappointing The company reported a wider than expected
BMRN,BMRN:UW,BBG000CZX7N1,Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?,2017-03-01 22:42:10 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-aeri-q4-earnings-224210249.html,Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?
BMRN,BMRN:UW,BBG000CZX7N1,"Biotechs Leap On Trump's Calls For Innovation, Speedy FDA Approval",2017-03-01 22:29:45 +0000,http://www.investors.com/news/technology/biotechs-leap-on-trumps-calls-for-innovation-speedy-fda-approval/,"Biotechs Leap On Trump's Calls For Innovation, Speedy FDA Approval"
BMRN,BMRN:UW,BBG000CZX7N1,"Biotechs Leap On Trump's Calls For Innovation, Speedy FDA Approval",2017-03-01 22:29:45 +0000,http://finance.yahoo.com/r/d7237cf2-18fc-3ff7-adc2-30c9772887e0/biotechs-leap-on-trumps-calls-for-innovation-speedy-fda-approval?yptr=yahoo&.tsrc=rss,President Trump's late Tuesday address to Congress prodded biotech stocks to rocket Wednesday on his apparent support for drug innovation.
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals",2017-03-01 14:15:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7159NqQxPQk/biotech-stock-roundup-kite-soars-on-car-t-data-exel-in-immuno-oncology-deals-cm754656,Key updates in the biotech sector included earnings results from several companies like BioMarin BMRN and Sarepta while Kite KITE saw its shares soaring on positive data on its lead pipeline candidate Recap of the Week s Most Important Stories Kite Shoots up on CAR T Data
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals",2017-03-01 12:24:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-kite-soars-122412088.html?.tsrc=rss,Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals",2017-03-01 12:24:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-kite-soars-122412088.html,"Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals"
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017",2017-02-28 16:36:37 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-bmrn-us-earnings-analysis-2016-by-the-numbers-february-28-2017/,"BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017"
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017",2017-02-28 16:36:37 +0000,http://finance.yahoo.com/r/179753c7-e8ba-3dc2-bf0f-ce6779fba23e/biomarin-pharmaceutical-inc-bmrn-us-earnings-analysis-2016-by-the-numbers-february-28-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis BioMarin Pharmaceutical, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of BioMarin Pharmaceutical, Inc. – Ultragenyx Pharmaceutical, Inc., Shire PLC Sponsored ADR, Esperion Therapeutics, Inc., Sanofi Sponsored ADR and Alexion Pharmaceuticals, Inc. (RARE-US, SHPG-US, ESPR-US, SNY-US and ALXN-US) that ... Read more    
<b>(Read more...)</b>"
BMRN,BMRN:UW,BBG000CZX7N1,"Market Close Report: NASDAQ Composite index closes at 5,861.90 up 16.59 points",2017-02-27 21:48:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B1Snhh1AHn4/market-close-report-nasdaq-composite-index-closes-at-586190-up-1659-points-cm753833,Monday s session closes with the NASDAQ Composite Index at 5 861 90 The total shares traded for the NASDAQ was over 2 07 billion Monday s session closes with the NASDAQ Composite Index at 5 861 90 The total shares traded for the NASDAQ was over 2 07 billion Advancers stocks led declining by 1
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 27, 2017",2017-02-27 14:52:55 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-bmrn-us-earnings-analysis-q4-2016-by-the-numbers-february-27-2017/,"BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 27, 2017"
BMRN,BMRN:UW,BBG000CZX7N1,Blog Coverage Cempra Announced Positive Results from the Phase-III Study for the Treatment of Acute Bacterial Skin and Skin Structure Infections,2017-02-27 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-cempra-announced-positive-131500667.html?.tsrc=rss,"Upcoming AWS Coverage on BioMarin Pharmaceutical Post-Earnings Results LONDON, UK / ACCESSWIRE / February 27, 2017 / Active Wall St. blog coverage looks at the headline from Chapel Hill, North Carolina-based ..."
BMRN,BMRN:UW,BBG000CZX7N1,Blog Coverage Cempra Announced Positive Results from the Phase-III Study for the Treatment of Acute Bacterial Skin and Skin Structure Infections,2017-02-27 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-cempra-announced-positive-131500667.html,"[Accesswire] - Upcoming AWS Coverage on BioMarin Pharmaceutical Post-Earnings Results LONDON, UK / ACCESSWIRE / February 27, 2017 / Active Wall St. blog coverage looks at the headline from Chapel Hill, North Carolina-based ..."
BMRN,BMRN:UW,BBG000CZX7N1,"BIOMARIN PHARMACEUTICAL INC Files SEC form 10-K, Annual Report",2017-02-27 11:12:15 +0000,http://biz.yahoo.com/e/170227/bmrn10-k.html,"BIOMARIN PHARMACEUTICAL INC Files SEC form 10-K, Annual Report"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster,2017-02-25 17:50:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bs095hOcvM4/biomarin-pharmaceutical-inc-logs-a-combined-blockbuster-cm753214,BioMarin Pharmaceutical NASDAQ BMRN logged over 1 billion in revenue the traditional level for a blockbuster for the first time in 2016 Of course that s combined sales of its four drugs but it s still a mighty accomplishment that many drugmakers never reach
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster,2017-02-25 16:42:52 +0000,http://finance.yahoo.com/r/32b2e31c-575b-3d60-a47c-529cf2b80876/biomarin-pharmaceutical-inc-logs-a-combined-blockb.aspx?yptr=yahoo&.tsrc=rss,It only took four drugs to do it.
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster,2017-02-25 16:42:52 +0000,http://www.fool.com/investing/2017/02/25/biomarin-pharmaceutical-inc-logs-a-combined-blockb.aspx,BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin 'Attractive' M&A Target Despite Growing Losses: RBC,2017-02-24 21:18:38 +0000,http://finance.yahoo.com/r/f4cbdab4-4c9b-3635-8f37-26f6989a78fc/biomarin-attractive-ma-target-despite-third-year-of-losses-rbc?yptr=yahoo&.tsrc=rss,"Late Thursday, BioMarin reported 2016 losses that grew for at least a third year — prompting the stock to plunge Friday."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin 'Attractive' M&A Target Despite Growing Losses: RBC,2017-02-24 21:18:38 +0000,http://www.investors.com/news/technology/biomarin-attractive-ma-target-despite-third-year-of-losses-rbc/,BioMarin 'Attractive' M&A Target Despite Growing Losses: RBC
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical Breaks Below 200-Day Moving Average - Notable for BMRN,2017-02-24 17:51:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/65ckRCLZFJE/biomarin-pharmaceutical-breaks-below-200-day-moving-average-notable-for-bmrn-cm752880,In trading on Friday shares of BioMarin Pharmaceutical Inc Symbol BMRN crossed below their 200 day moving average of 88 52 changing hands as low as 86 89 per share BioMarin Pharmaceutical Inc shares are currently trading off about 2 6 on the day The chart below shows the one
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat,2017-02-24 16:53:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FR48qT6gNNM/biomarin-bmrn-q4-loss-narrower-than-expected-sales-beat-cm752785,BioMarin Pharmaceutical Inc BMRN reported a loss of 37 cents per share in the fourth quarter of 2016 including stock based compensation expense narrower than the year ago loss of 57 cents as well as the Zacks Consensus Estimate of a loss of 39 cents per share Total revenue came in at
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat,2017-02-24 14:41:02 +0000,http://finance.yahoo.com/news/biomarin-bmrn-q4-loss-narrower-144102166.html?.tsrc=rss,BioMarin Pharmaceutical Inc. (BMRN) reported a loss of 37 cents per share in the fourth quarter of 2016.
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat,2017-02-24 14:41:02 +0000,http://finance.yahoo.com/news/biomarin-bmrn-q4-loss-narrower-144102166.html,BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat
BMRN,BMRN:UW,BBG000CZX7N1,Edited Transcript of BMRN earnings conference call or presentation 23-Feb-17 9:30pm GMT,2017-02-24 08:52:19 +0000,http://finance.yahoo.com/news/edited-transcript-bmrn-earnings-conference-085219625.html,Edited Transcript of BMRN earnings conference call or presentation 23-Feb-17 9:30pm GMT
BMRN,BMRN:UW,BBG000CZX7N1,Edited Transcript of BMRN earnings conference call or presentation 23-Feb-17 9:30pm GMT,2017-02-24 08:52:19 +0000,http://finance.yahoo.com/news/edited-transcript-bmrn-earnings-conference-085219625.html?.tsrc=rss,Q4 2016 Biomarin Pharmaceutical Inc Earnings Call
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin reports 4Q loss,2017-02-23 21:32:53 +0000,http://finance.yahoo.com/news/biomarin-reports-4q-loss-213253873.html?.tsrc=rss,"On a per-share basis, the San Rafael, California-based company said it had a loss of 53 cents. Losses, adjusted for one-time gains and costs, came to 16 cents per share. The results surpassed Wall Street ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin reports 4Q loss,2017-02-23 21:32:53 +0000,http://sg.finance.yahoo.com/news/biomarin-reports-4q-loss-213253702.html,BioMarin reports 4Q loss
BMRN,BMRN:UW,BBG000CZX7N1,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a",2017-02-23 21:17:41 +0000,http://biz.yahoo.com/e/170223/bmrn8-k.html,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a"
BMRN,BMRN:UW,BBG000CZX7N1,"4:08 pm BioMarin Pharm misses by $0.08, beats on revs; guides FY17 revs below consensus",2017-02-23 21:08:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#bmrn,"4:08 pm BioMarin Pharm misses by $0.08, beats on revs; guides FY17 revs below consensus"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results,2017-02-23 21:01:00 +0000,http://finance.yahoo.com/news/biomarin-announces-fourth-quarter-full-210100082.html,"[PR Newswire] - SAN RAFAEL, Calif., Feb. 23, 2017 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2016 ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results,2017-02-23 21:01:00 +0000,http://finance.yahoo.com/news/biomarin-announces-fourth-quarter-full-210100082.html?.tsrc=rss,"SAN RAFAEL, Calif., Feb. 23, 2017 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2016 ..."
BMRN,BMRN:UW,BBG000CZX7N1,"After-Hours Earnings Report for February 23, 2017 :  BIDU, HPE, INTU, BMRN, PBA, GPS, MELI, LNT, SPLK, JWN, WPC, LYV",2017-02-23 20:05:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0dBPLp3TQzM/after-hours-earnings-report-for-february-23-2017-bidu-hpe-intu-bmrn-pba-gps-meli-lnt-splk-jwn-wpc-lyv-cm752288,The following companies are expected to report earnings after hours on 02 23 2017 Visit our Earnings Calendar for a full list of expected earnings releases Baidu Inc BIDU is reporting for the quarter ending December 31 2016 The internet services company
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharmaceutical Q4 16 Earnings Conference Call At 4:30 PM ET,2017-02-23 14:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7kr7_BxvPvs/biomarin-pharmaceutical-q4-16-earnings-conference-call-at-430-pm-et-20170223-01470,Biomarin Pharmaceutical Q4 16 Earnings Conference Call At 4:30 PM ET
BMRN,BMRN:UW,BBG000CZX7N1,Q4 2016 Biomarin Pharmaceutical Inc Earnings Release - Time Not Supplied,2017-02-23 12:07:03 +0000,http://biz.yahoo.com/research/earncal/20170223.html?t=bmrn,Q4 2016 Biomarin Pharmaceutical Inc Earnings Release - Time Not Supplied
BMRN,BMRN:UW,BBG000CZX7N1,3 Biotech Stocks You May Be Overlooking,2017-02-22 21:51:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iIwcdIcBEH8/3-biotech-stocks-you-may-be-overlooking-cm751612,With hundreds of biotech stocks on the market who can keep up with them all Probably no one What happens as a result is that usually only the biggest biotechs or the small biotechs getting bought by the biggest biotechs get a lot of coverage 160 But sometimes those aren t the
BMRN,BMRN:UW,BBG000CZX7N1,3 Biotech Stocks You May Be Overlooking,2017-02-22 20:53:12 +0000,http://finance.yahoo.com/r/af0001fc-f4c7-3398-9655-2860ca058a67/3-biotech-stocks-you-may-be-overlooking.aspx?yptr=yahoo&.tsrc=rss,"Why investors should keep their eyes on Akebia Therapeutics, BioMarin Pharmaceutical, and Idera Pharmaceuticals."
BMRN,BMRN:UW,BBG000CZX7N1,3 Biotech Stocks You May Be Overlooking,2017-02-22 20:53:12 +0000,http://www.fool.com/investing/2017/02/22/3-biotech-stocks-you-may-be-overlooking.aspx,3 Biotech Stocks You May Be Overlooking
BMRN,BMRN:UW,BBG000CZX7N1,"Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More",2017-02-22 15:12:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KcgF6FkWn34/drug-stocks-q4-earnings-slated-for-feb-23-bmrn-icpt-more-cm751080,The fourth quarter earnings season is drawing to a close with results from 411 S amp P 500 members or 82 2 of the index s total membership already out as of Feb 22 2017 according to the latest Earnings Preview report Total earnings for these 411 index members were up 8 from the year
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising",2017-02-22 14:11:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lvmQma1GC9s/biotech-stock-roundup-alexion-reports-4q-results-celgene-ms-drug-looks-promising-cm751060,Key updates in the biotech sector include a mixed quarter from Alexion ALXN and promising data on Celgene s CELG investigational multiple sclerosis MS treatment Recap of the Week s Most Important Stories Mixed Results from Alexion Alexion s fourth quarter results were mixed
BMRN,BMRN:UW,BBG000CZX7N1,"Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More",2017-02-22 13:29:01 +0000,http://finance.yahoo.com/news/drug-stocks-q4-earnings-slated-132901558.html,"Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More"
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising",2017-02-22 11:43:11 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-alexion-reports-114311834.html,"Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising"
BMRN,BMRN:UW,BBG000CZX7N1,JANA Partners Made Massive New Pharma Investments in Q4,2017-02-21 19:07:00 +0000,http://www.investopedia.com/news/jana-partners-made-massive-new-pharma-investments-q4-aet-bmy/?partner=YahooSA,JANA Partners Made Massive New Pharma Investments in Q4
BMRN,BMRN:UW,BBG000CZX7N1,Blog Coverage Celgene's Multiple Sclerosis Drug Reported Positive Phase-III Results,2017-02-21 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-celgenes-multiple-sclerosis-131500877.html,"[Accesswire] - Upcoming AWS Coverage on BioMarin Pharmaceutical Post-Earnings Results LONDON, UK / ACCESSWIRE / February 21, 2017 / Active Wall St. blog coverage looks at the headline from Celgene Corp. (NASDAQ: CELG ..."
BMRN,BMRN:UW,BBG000CZX7N1,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc.",2017-02-20 14:57:38 +0000,http://www.fool.com/investing/2017/02/20/better-buy-alnylam-pharmaceuticals-inc-vs-biomarin.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc."
BMRN,BMRN:UW,BBG000CZX7N1,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc.",2017-02-20 14:54:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gius2nIhMP8/better-buy-alnylam-pharmaceuticals-inc-vs-biomarin-pharmaceutical-inc-cm750192,Late last year Alnylam Pharmaceuticals Inc NASDAQ ALNY took a big hit when the company scuttled an important development program because of safety concerns Meanwhile plenty of clinical stage programs at Biomarin Pharmaceutical Inc NASDAQ BMRN have been chugging
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?,2017-02-17 14:58:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qTP1yu0rxU4/biomarin-bmrn-q4-earnings-will-it-post-a-beat-again-cm749441,We expect BioMarin Pharmaceutical Inc BMRN to beat expectations when it reports fourth quarter and full year 2016 results on Feb 23 after the market closes BioMarin had delivered a positive earnings surprise of 66 67 in the last quarter BioMarin s shares are up 9 2 so far this
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?,2017-02-17 13:09:01 +0000,http://finance.yahoo.com/news/biomarin-bmrn-q4-earnings-post-130901189.html,BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharma To Participate In Leerink Partners Global Conference At 1:00 PM,2017-02-16 12:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k_j4Jj-WtFY/biomarin-pharma-to-participate-in-leerink-partners-global-conference-at-100-pm-20170216-01163,Biomarin Pharma To Participate In Leerink Partners Global Conference At 1:00 PM
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces 11 Presentations at 13th Annual WORLDSymposium™ 2017,2017-02-15 13:30:00 +0000,http://finance.yahoo.com/news/biomarin-announces-11-presentations-13th-133000675.html,"[PR Newswire] - SAN RAFAEL, Calif., Feb. 15, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in four oral and seven poster presentations at the 13 th ..."
BMRN,BMRN:UW,BBG000CZX7N1,Can Wright Medical (WMGI) Surprise Investors in Q4 Earnings?,2017-02-14 17:20:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P0Mi8y2Rb08/can-wright-medical-wmgi-surprise-investors-in-q4-earnings-cm747724,Global medical device company Wright Medical Group N V WMGI is scheduled to release fourth quarter 2016 results on Feb 21 Wright Medical has an impressive track record of beating estimates in all the four trailing quarters In the last reported quarter it recorded a positive
BMRN,BMRN:UW,BBG000CZX7N1,LabCorp (LH) Q4 Earnings: What's in the Cards for the Stock?,2017-02-14 15:22:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4tSPezpiqGY/labcorp-lh-q4-earnings-whats-in-the-cards-for-the-stock-cm747550,Laboratory Corp of America Holdings LH or LabCorp is expected to report fourth quarter 2016 results before the market opens on Feb 16 Last quarter the company reported a negative earnings surprise of 1 75 with an average beat of 0 42 for the trailing four quarters Let s see how
BMRN,BMRN:UW,BBG000CZX7N1,What's in Store for ImmunoGen (IMGN) this Earnings Season?,2017-02-13 16:22:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/klYpW97IM3A/whats-in-store-for-immunogen-imgn-this-earnings-season-cm747000,ImmunoGen Inc IMGN is scheduled to report results for the three months ended Dec 31 2016 on Feb 17 before the opening bell ImmunoGen s track record has been disappointing with the company missing expectations in each of the last four reported quarters Overall the company has posted
BMRN,BMRN:UW,BBG000CZX7N1,Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?,2017-02-11 00:17:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eAgKcVoxXHE/will-zoetis-zts-disappoint-estimates-this-earnings-season-cm746604,Zoetis Inc ZTS is scheduled to report fourth quarter and full year 2016 results on Feb 16 before the market opens The company has consistently beaten earnings expectations In fact Zoetis earnings surpassed expectations in each of the last four quarters with an average positive surprise
BMRN,BMRN:UW,BBG000CZX7N1,Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?,2017-02-10 16:21:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BW3UORxZllk/perrigo-company-prgo-q4-earnings-disappointment-in-store-cm746254,Perrigo Company plc PRGO is expected to report fourth quarter 2016 results this month Perrigo has a mixed track record as the company beat expectations in two of the last four quarters and missed the same in the other two Overall the company has an average negative earnings surprise of 1
BMRN,BMRN:UW,BBG000CZX7N1,Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?,2017-02-10 16:21:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d0Mb7ThaZ-A/agios-pharmaceuticals-agio-q4-earnings-whats-in-store-cm746246,Agios Pharmaceuticals Inc AGIO is scheduled to report fourth quarter and full year 2016 results on Feb 16 Agios shares gained 10 3 so far this year while the Zacks classified Medical Products industry witnessed an increase of 5 3 Agios performance has been far
BMRN,BMRN:UW,BBG000CZX7N1,Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?,2017-02-10 14:29:02 +0000,http://finance.yahoo.com/news/agios-pharmaceuticals-agio-q4-earnings-142902997.html,Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
BMRN,BMRN:UW,BBG000CZX7N1,Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?,2017-02-10 14:28:02 +0000,http://finance.yahoo.com/news/perrigo-company-prgo-q4-earnings-142802893.html,Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?
BMRN,BMRN:UW,BBG000CZX7N1,Teva (TEVA) Q4 Earnings: What's in Store for the Stock?,2017-02-08 15:21:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0HOHTC-kiDs/teva-teva-q4-earnings-whats-in-store-for-the-stock-cm744860,Teva Pharmaceutical Industries Ltd TEVA will be reporting fourth quarter 2016 and full year earnings on Feb 13 before the market opens Last quarter the company delivered in line earnings This generic drug maker s shares have lost 11 3 so far this year while the Zacks classified
BMRN,BMRN:UW,BBG000CZX7N1,Gilead Sciences & Bristol Myers: Two Wrongs Make a Right?,2017-02-08 15:17:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/02/08/gilead-sciences-bristol-myers-two-wrongs-make-a-right/?mod=yahoobarrons&ru=yahoo,Gilead Sciences & Bristol Myers: Two Wrongs Make a Right?
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin to Attend Three Investor Conferences in 1Q17,2017-02-08 13:30:00 +0000,http://finance.yahoo.com/news/biomarin-attend-three-investor-conferences-133000450.html,"[PR Newswire] - SAN RAFAEL, Calif., Feb. 8, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will participate in the ..."
BMRN,BMRN:UW,BBG000CZX7N1,5 Great Biotech Stocks to Buy Now,2017-02-07 22:16:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jLjhvST47po/5-great-biotech-stocks-to-buy-now-cm744505,Through the second half of 2015 biotech stocks were the preferred choice of investors seeking aggressive growth options Even as the S amp P 500 gained around 50 from 2013 up to that point the likes of the iShares Nasdaq Biotechnology Index and the SPDR S amp P Biotech nearly tripled in
BMRN,BMRN:UW,BBG000CZX7N1,Your Guide To 2017's Emerging Pharmaceuticals Catalysts,2017-02-07 19:39:19 +0000,http://finance.yahoo.com/news/guide-2017s-emerging-pharmaceuticals-catalysts-193919266.html,Your Guide To 2017's Emerging Pharmaceuticals Catalysts
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin sues to stop generic version of its $90K-a-year drug,2017-02-07 18:24:13 +0000,http://www.bizjournals.com/sanfrancisco/news/2017/02/06/biomarin-bmrn-dr-reddys-laboratories-rdy-kuvan-pku.html?ana=yahoo,BioMarin sues to stop generic version of its $90K-a-year drug
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on Thursday, February 23 at 4:30pm ET",2017-02-07 13:30:00 +0000,http://finance.yahoo.com/news/biomarin-host-fourth-quarter-full-133000452.html,"[PR Newswire] - SAN RAFAEL, Calif., Feb. 7, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin's Hemophilia Candidate Included in PRIME Initiative,2017-02-02 17:36:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wi5nY45v7MA/biomarins-hemophilia-candidate-included-in-prime-initiative-cm742340,BioMarin Pharmaceutical Inc BMRN announced thatBMN 270 being evaluated for the treatment for severe hemophilia A has been granted access to Priority Medicines PRIME a regulatory initiative by the European Medicines Agency EMA For a candidate to be accepted under PRIME it has
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin's Hemophilia Candidate Included in PRIME Initiative,2017-02-02 15:14:03 +0000,http://finance.yahoo.com/news/biomarins-hemophilia-candidate-included-prime-151403521.html,BioMarin's Hemophilia Candidate Included in PRIME Initiative
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Receives Access to Priority Medicines (PRIME) Regulatory Support from EMA for BMN 270 Gene Therapy in Hemophilia A,2017-02-01 21:15:00 +0000,http://finance.yahoo.com/news/biomarin-receives-access-priority-medicines-211500566.html,"[PR Newswire] - SAN RAFAEL, Calif., Feb. 1, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) regulatory initiative for the company's investigational gene therapy treatment for severe hemophilia A, BMN 270. To be accepted for PRIME, an investigational therapy has to show its potential to benefit patients with unmet medical needs based on early clinical data. PRIME is a scheme to strengthen support to medicines that target an unmet medical need."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical (BMRN) Shares Cross Above 200 DMA,2017-02-01 18:32:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DukPw3PEXPA/biomarin-pharmaceutical-bmrn-shares-cross-above-200-dma-cm741705,In trading on Wednesday shares of BioMarin Pharmaceutical Inc Symbol BMRN crossed above their 200 day moving average of 88 32 changing hands as high as 89 15 per share BioMarin Pharmaceutical Inc shares are currently trading up about 0 3 on the day The chart below shows the one
BMRN,BMRN:UW,BBG000CZX7N1,4 Top Biotech Stocks With Big Upcoming Catalysts,2017-01-31 15:15:10 +0000,http://finance.yahoo.com/news/4-top-biotech-stocks-big-151510658.html,4 Top Biotech Stocks With Big Upcoming Catalysts
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : January 30, 2017",2017-01-30 12:24:37 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bullish-manner-bmrn-us-january-30-2017/,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : January 30, 2017"
BMRN,BMRN:UW,BBG000CZX7N1,Is BioMarin (BMRN) Well Poised for Growth in 2017?,2017-01-26 17:34:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5eLgf7DCyGg/is-biomarin-bmrn-well-poised-for-growth-in-2017-cm738794,We issued an updated research report on BioMarin Pharmaceutical Inc BMRN on Jan 25 BioMarin should continue to see growth in both its orphan disease drugs Vimizim and Kuvan in 2017 Vimizim sales continue to be driven by robust patient growth and penetration in additional markets
BMRN,BMRN:UW,BBG000CZX7N1,Is BioMarin (BMRN) Well Poised for Growth in 2017?,2017-01-26 15:04:03 +0000,http://finance.yahoo.com/news/biomarin-bmrn-well-poised-growth-150403580.html,Is BioMarin (BMRN) Well Poised for Growth in 2017?
BMRN,BMRN:UW,BBG000CZX7N1,Look Under The Hood: PXMG Has 10% Upside,2017-01-24 15:32:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v3OWFU83PkA/look-under-the-hood-pxmg-has-10-upside-cm737246,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
BMRN,BMRN:UW,BBG000CZX7N1,"We’re in the year of the biotech buyout, and here are five prime targets",2017-01-23 20:21:48 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=017E3E92-E0DC-11E6-A68E-C10141C44E92&siteid=yhoof2,"We’re in the year of the biotech buyout, and here are five prime targets"
BMRN,BMRN:UW,BBG000CZX7N1,Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential,2017-01-19 13:40:50 +0000,http://finance.yahoo.com/news/baird-4-red-hot-biotechs-134050054.html,Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : January 18, 2017",2017-01-18 14:53:32 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-bmrn-us-january-18-2017/,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : January 18, 2017"
BMRN,BMRN:UW,BBG000CZX7N1,"Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears",2017-01-10 15:33:00 +0000,https://www.thestreet.com/story/13948568/1/sarepta-opens-up-about-duchenne-drug-launch-allays-investors-worst-fears.html?puc=yahoo&cm_ven=YAHOO,"Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears"
BMRN,BMRN:UW,BBG000CZX7N1,Top Stocks to Buy Now That the 21st Century Cures Act Has Passed,2017-01-10 14:39:05 +0000,http://www.fool.com/investing/2017/01/09/top-stocks-to-buy-now-that-the-21st-century-cures.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Top Stocks to Buy Now That the 21st Century Cures Act Has Passed
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical Breaks Above 200-Day Moving Average - Bullish for BMRN,2017-01-09 18:49:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rnJ7CwdW86w/biomarin-pharmaceutical-breaks-above-200-day-moving-average-bullish-for-bmrn-cm731198,In trading on Monday shares of BioMarin Pharmaceutical Inc Symbol BMRN crossed above their 200 day moving average of 88 15 changing hands as high as 92 20 per share BioMarin Pharmaceutical Inc shares are currently trading up about 2 2 on the day The chart below shows the one
BMRN,BMRN:UW,BBG000CZX7N1,Top Stocks to Buy Now That the 21st Century Cures Act Has Passed,2017-01-09 15:52:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kMQaWvon3ZM/top-stocks-to-buy-now-that-the-21st-century-cures-act-has-passed-cm731004,Now that Washington has signed off on the 21st Century Cures Act deregulation streamlining and billions of additional research dollars could cause healthcare stocks to pop Do you own the stocks most likely to benefit In this clip from The Motley Fool s Industry
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin CEO: Positive results for hemophilia treatment,2017-01-09 13:38:00 +0000,http://finance.yahoo.com/video/biomarin-ceo-positive-results-hemophilia-133800757.html,BioMarin CEO: Positive results for hemophilia treatment
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharmaceutical To Present At J.P. Morgan Conference; Webcast At 11:30AM,2017-01-09 10:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V73hNDrcT1M/biomarin-pharmaceutical-to-present-at-jp-morgan-conference-webcast-at-1130am-20170109-00692,Biomarin Pharmaceutical To Present At J.P. Morgan Conference; Webcast At 11:30AM
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharma cites positive results for hemophilia treatment,2017-01-09 02:19:18 +0000,http://finance.yahoo.com/news/biomarin-pharma-cites-positive-results-021918341.html,BioMarin Pharma cites positive results for hemophilia treatment
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin to Provide Update to Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A at 35th Annual J.P. Morgan Healthcare Conference,2017-01-09 00:45:00 +0000,http://finance.yahoo.com/news/biomarin-proof-concept-data-bmn-004500614.html,"[PR Newswire] - SAN RAFAEL, Calif., Jan. 8, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today an update to its positive interim results of an open-label Phase 1/2 study of BMN 270, an investigational ..."
BMRN,BMRN:UW,BBG000CZX7N1,Could Sanofi Acquire BioMarin In Wake Of Amgen LDL Brouhaha?,2017-01-06 21:22:41 +0000,http://www.investors.com/news/technology/could-sanofi-acquire-biomarin-in-wake-of-amgen-ldl-brouhaha/,Could Sanofi Acquire BioMarin In Wake Of Amgen LDL Brouhaha?
BMRN,BMRN:UW,BBG000CZX7N1,Biotech Investing: 3 Bold Predictions for 2017,2017-01-06 15:55:41 +0000,http://www.fool.com/investing/2017/01/06/biotech-investing-3-bold-predictions-for-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Biotech Investing: 3 Bold Predictions for 2017
BMRN,BMRN:UW,BBG000CZX7N1,Biotech Investing: 3 Bold Predictions for 2017,2017-01-06 14:40:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/75sL-Uy4MWA/biotech-investing-3-bold-predictions-for-2017-cm730229,Making bold predictions actually isn t too hard to do Having them come true is another story altogether Nevertheless a new year is now upon us and I can t resist the urge to make a few bold predictions about the world of biotech investing in 2017 A handful of biotechs showed up in
BMRN,BMRN:UW,BBG000CZX7N1,Blog Coverage Affimed Join Hands with MD Anderson Cancer Center for Clinical Immuno-Oncology Development Collaboration,2017-01-05 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-affimed-join-hands-131500393.html,"[Accesswire] - Upcoming AWS Coverage on BioMarin Pharmaceutical LONDON, UK / ACCESSWIRE / January 5, 2017 / Active Wall St. blog coverage looks at the headline from Affimed N.V. (NASDAQ: AFMD ) as the Company and The ..."
BMRN,BMRN:UW,BBG000CZX7N1,"The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen",2017-01-04 16:42:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4dVoICHOy0E/the-zacks-analyst-blog-highlights-sucampo-pharmaceuticals-dr-reddys-laboratories-biomarin-pharmaceutical-and-repligen-cm729418,For Immediate Release Chicago IL January 04 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BMRN,BMRN:UW,BBG000CZX7N1,"The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen",2017-01-04 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-sucampo-143002818.html,"The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen"
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : January 4, 2017",2017-01-04 13:09:21 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bullish-manner-bmrn-us-january-4-2017/,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : January 4, 2017"
BMRN,BMRN:UW,BBG000CZX7N1,3 Overlooked Drug Stocks to Watch Out for in 2017,2017-01-03 15:01:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mAFvUeim7xQ/3-overlooked-drug-stocks-to-watch-out-for-in-2017-cm728634,2016 was a rough year for the medical sector especially biotech stocks with the NASDAQ Biotechnology index declining 19 1 during the year while the NYSE ARCA Pharmaceutical Index was down 9 7 The pharma biotech sector faced several headwinds last year including slow product launches fewer
BMRN,BMRN:UW,BBG000CZX7N1,3 Overlooked Drug Stocks to Watch Out for in 2017,2017-01-03 13:32:01 +0000,http://finance.yahoo.com/news/3-overlooked-drug-stocks-watch-133201454.html,3 Overlooked Drug Stocks to Watch Out for in 2017
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin to Present at 35th Annual J.P. Morgan Healthcare Conference in San Francisco,2017-01-03 13:00:00 +0000,http://finance.yahoo.com/news/biomarin-present-35th-annual-j-130000899.html,"[PR Newswire] - SAN RAFAEL, Calif., Jan. 3, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will participate in the ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Raised to Buy: Should You Add the Stock?,2016-12-29 16:57:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wdEK022OWF4/biomarin-bmrn-raised-to-buy-should-you-add-the-stock-cm727417,On Dec 28 Zacks Investment Research upgraded BioMarin Pharmaceutical Inc BMRN by one notch to a Zacks Rank 2 Buy Why the Upgrade BioMarin s shares have gained 3 8 since the company reported stellar results for the third quarter of 2016 on Oct 27 Moreover its year to date
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Raised to Buy: Should You Add the Stock?,2016-12-29 15:11:03 +0000,http://finance.yahoo.com/news/biomarin-bmrn-raised-buy-add-151103603.html,BioMarin (BMRN) Raised to Buy: Should You Add the Stock?
BMRN,BMRN:UW,BBG000CZX7N1,3 Precision Medicine Stocks to Buy in January,2016-12-27 20:07:34 +0000,http://www.fool.com/investing/2016/12/27/3-precision-medicine-stocks-to-buy-in-january.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Precision Medicine Stocks to Buy in January
BMRN,BMRN:UW,BBG000CZX7N1,Time for biotech to boom ... or bust?,2016-12-27 19:45:00 +0000,http://finance.yahoo.com/video/time-biotech-boom-bust-194500895.html,Time for biotech to boom ... or bust?
BMRN,BMRN:UW,BBG000CZX7N1,3 Precision Medicine Stocks to Buy in January,2016-12-27 13:57:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Egsu_sEbeRo/3-precision-medicine-stocks-to-buy-in-january-cm726145,Precision medicine The term might sound futuristic but the future has arrived The National Institutes of Health defines precision medicine as an emerging approach for disease treatment and prevention that takes into account individual variability in genes environment and
BMRN,BMRN:UW,BBG000CZX7N1,RBC Likes Large Cap Biotech Leaders for 2017,2016-12-22 13:25:48 +0000,http://247wallst.com/healthcare-business/2016/12/22/rbc-likes-large-cap-biotech-leaders-for-2017/,RBC Likes Large Cap Biotech Leaders for 2017
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. – Value Analysis (NASDAQ:BMRN) : December 21, 2016",2016-12-21 14:35:54 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-value-analysis-nasdaqbmrn-december-21-2016/,"BioMarin Pharmaceutical, Inc. – Value Analysis (NASDAQ:BMRN) : December 21, 2016"
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : December 20, 2016",2016-12-20 12:40:11 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-bmrn-us-december-20-2016/,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : December 20, 2016"
BMRN,BMRN:UW,BBG000CZX7N1,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pr",2016-12-19 21:16:38 +0000,http://biz.yahoo.com/e/161219/bmrn8-k.html,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pr"
BMRN,BMRN:UW,BBG000CZX7N1,3 Growth Stocks You Should Avoid in 2017,2016-12-15 17:58:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eoRuxQP5R04/3-growth-stocks-you-should-avoid-in-2017-cm722065,Image source Getty Images There s no sugar coating it Growth stocks have been the shining stars over value stocks since the Great Recession ended Although a Bank of America Merrill Lynch study found that value stocks have outperformed growth stocks over the past 90 years with
BMRN,BMRN:UW,BBG000CZX7N1,3 Growth Stocks You Should Avoid in 2017,2016-12-15 16:02:07 +0000,http://www.fool.com/investing/2016/12/15/3-growth-stocks-you-should-avoid-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Growth Stocks You Should Avoid in 2017
BMRN,BMRN:UW,BBG000CZX7N1,Will Insurers Pay For Sarepta's DMD Drug?,2016-12-14 19:13:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/14/will-insurers-pay-for-sareptas-dmd-drug/?mod=yahoobarrons&ru=yahoo,Will Insurers Pay For Sarepta's DMD Drug?
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia,2016-12-12 13:29:00 +0000,http://finance.yahoo.com/news/biomarin-enrolls-first-participant-phase-132900693.html,"[GlobeNewswire] - SAN RAFAEL, Calif., Dec. 12, 2016-- BioMarin Pharmaceutical Inc. announced today that the company has initiated a global Phase 3 study for vosoritide, an analog of C-type Natriuretic Peptide, in children ..."
BMRN,BMRN:UW,BBG000CZX7N1,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E",2016-12-09 21:16:36 +0000,http://biz.yahoo.com/e/161209/bmrn8-k.html,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E"
BMRN,BMRN:UW,BBG000CZX7N1,[$$] Would Gilead Buy BioMarin?,2016-12-08 20:06:00 +0000,http://www.barrons.com/articles/would-gilead-buy-biomarin-1481227564?mod=yahoobarrons&ru=yahoo,[$$] Would Gilead Buy BioMarin?
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharma To Present At Citi Healthcare Conference; Webcast At 8:45 AM ET,2016-12-08 07:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f3wriGVKcuI/biomarin-pharma-to-present-at-citi-healthcare-conference-webcast-at-845-am-et-20161208-00278,Biomarin Pharma To Present At Citi Healthcare Conference; Webcast At 8:45 AM ET
BMRN,BMRN:UW,BBG000CZX7N1,Do Hedge Funds Love Agilent Technologies Inc (A)?,2016-12-07 12:33:58 +0000,http://www.insidermonkey.com/blog/do-hedge-funds-love-agilent-technologies-inc-a-499777/,Do Hedge Funds Love Agilent Technologies Inc (A)?
BMRN,BMRN:UW,BBG000CZX7N1,Hedge Funds Are Buying BioMarin Pharmaceutical Inc. (BMRN),2016-12-06 15:38:17 +0000,http://www.insidermonkey.com/blog/hedge-funds-are-buying-biomarin-pharmaceutical-inc-bmrn-499608/,Hedge Funds Are Buying BioMarin Pharmaceutical Inc. (BMRN)
BMRN,BMRN:UW,BBG000CZX7N1,7 of the Most Shocking Biotech Pipeline Blowups of 2016,2016-12-04 18:04:17 +0000,http://www.fool.com/investing/2016/12/04/7-of-the-most-shocking-biotech-pipeline-blowups-of.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,7 of the Most Shocking Biotech Pipeline Blowups of 2016
BMRN,BMRN:UW,BBG000CZX7N1,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina",2016-12-02 21:17:01 +0000,http://biz.yahoo.com/e/161202/bmrn8-k.html,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Surging Beneath the Surface,2016-11-29 16:58:00 +0000,http://realmoney.thestreet.com/articles/11/29/2016/biomarin-surging-beneath-surface?puc=yahoo&cm_ven=YAHOO,BioMarin Surging Beneath the Surface
BMRN,BMRN:UW,BBG000CZX7N1,"Nasdaq 100 Movers: BMRN, NFLX",2016-11-29 16:54:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Orhc7QXLPGc/nasdaq-100-movers-bmrn-nflx-cm715113,In early trading on Tuesday shares of Netflix NFLX topped the list of the day s best performing components of the Nasdaq 100 index trading up 1 9 Year to date Netflix registers a 4 2 gain And the worst performing Nasdaq 100 component thus far on the day is BioMarin
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $12.1 million of Shares,2016-11-24 00:15:03 +0000,http://finance.yahoo.com/news/biomarin-pharmaceutical-inc-bmrn-ceo-001503148.html,Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $12.1 million of Shares
BMRN,BMRN:UW,BBG000CZX7N1,"Market Close Report: NASDAQ Composite index closes at 5,380.68 down -5.67 points",2016-11-23 21:49:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Teh7U4JYR1A/market-close-report-nasdaq-composite-index-closes-at-538068-down-567-points-cm713552,Wednesday s session closes with the NASDAQ Composite Index at 5 380 68 The total shares traded for the NASDAQ was over 1 69 billion Wednesday s session closes with the NASDAQ Composite Index at 5 380 68 The total shares traded for the NASDAQ was over 1 69 billion Advancers stocks led
BMRN,BMRN:UW,BBG000CZX7N1,5 Biotech Stocks George Soros Is Buying,2016-11-23 15:29:28 +0000,http://www.fool.com/investing/2016/11/22/5-biotech-stocks-george-soros-is-buying.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Biotech Stocks George Soros Is Buying
BMRN,BMRN:UW,BBG000CZX7N1,5 Biotech Stocks George Soros Is Buying,2016-11-22 23:19:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ttlUPyNBqXQ/5-biotech-stocks-george-soros-is-buying-cm713020,George Soros namesake fund known as Soros Fund Management has continued to show interest in the beaten down biotech space this year even as most of its hedge fund peers have run for cover due to the political headwinds emanating from the U S presidential election
BMRN,BMRN:UW,BBG000CZX7N1,"ETFs with exposure to BioMarin Pharmaceutical, Inc. : November 22, 2016",2016-11-22 17:11:34 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-biomarin-pharmaceutical-inc-november-22-2016/,"ETFs with exposure to BioMarin Pharmaceutical, Inc. : November 22, 2016"
BMRN,BMRN:UW,BBG000CZX7N1,Analysts Anticipate QLD Will Reach $94,2016-11-21 15:51:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kInzqH19X-8/analysts-anticipate-qld-will-reach-94-cm711891,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
BMRN,BMRN:UW,BBG000CZX7N1,Stock Exchange: Is Post-Election Technical Analysis Useful?,2016-11-21 12:51:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ipnQdDzV6nE/stock-exchange-is-post-election-technical-analysis-useful-cm707598,By Jeff Miller ByJeff Miller A truly disruptive event generates surprisingly large moves sectors stocks and sometimes the overall market Methods that work well in normal times may break down under this stress Traders and investors must ask A truly disruptive event generates
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : November 21, 2016",2016-11-21 12:20:37 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-bmrn-us-november-21-2016/,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : November 21, 2016"
BMRN,BMRN:UW,BBG000CZX7N1,Weighing The Week Ahead: Is It Finally Time For Clarity?,2016-11-18 10:50:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vOBJDnwqDfY/weighing-the-week-ahead-is-it-finally-time-for-clarity-cm704555,By Jeff Miller ByJeff Miller We have a light week for data but plenty of other big news Earnings season continues There will be plenty of FedSpeak and most importantly the results of the U S elections I see everyone to be asking Will the election results
BMRN,BMRN:UW,BBG000CZX7N1,"10 biotech companies ripe for a buyout, courtesy of Donald Trump",2016-11-17 14:28:16 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=9AEFC198-ACC7-11E6-A769-02A54265C928&siteid=yhoof2,"10 biotech companies ripe for a buyout, courtesy of Donald Trump"
BMRN,BMRN:UW,BBG000CZX7N1,Merck KGaA's (MKGAF) Q3 Earnings and Sales Increase Y/Y,2016-11-16 15:52:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hC9f8PRERmc/merck-kgaas-mkgaf-q3-earnings-and-sales-increase-yy-cm710000,Merck KGaA MKGAF reported third quarter 2016 earnings of 1 20 per American Depositary Share higher than the year ago tally of 90 cents Net sales in the reported quarter came in at 4 1 billion 3 7 billion up 19 7 primarily due to portfolio changes following the Sigma
BMRN,BMRN:UW,BBG000CZX7N1,Merck KGaA's (MKGAF) Q3 Earnings and Sales Increase Y/Y,2016-11-16 13:48:01 +0000,http://finance.yahoo.com/news/merck-kgaas-mkgaf-q3-earnings-134801463.html,Merck KGaA's (MKGAF) Q3 Earnings and Sales Increase Y/Y
BMRN,BMRN:UW,BBG000CZX7N1,Soros 13F Points to More Than Just Emerging Markets,2016-11-15 21:18:00 +0000,http://www.investopedia.com/news/soros-13f-points-more-just-emerging-markets-abx-bmrn/?partner=YahooSA,Soros 13F Points to More Than Just Emerging Markets
BMRN,BMRN:UW,BBG000CZX7N1,Why BioMarin (BMRN) Could Be Positioned for a Surge,2016-11-15 17:28:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/29dClzMCp84/why-biomarin-bmrn-could-be-positioned-for-a-surge-cm709488,BioMarin Pharmaceutical Inc BMRN an American biotechnology company could be an interesting play for investors That is because not only does the stock have decent short term momentum but it is seeing solid activity on the earnings estimate revision front as well These positive
BMRN,BMRN:UW,BBG000CZX7N1,"Nasdaq 100 Movers: BMRN, JD",2016-11-15 16:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4K3n1qwsPf4/nasdaq-100-movers-bmrn-jd-cm709373,In early trading on Tuesday shares of JD com JD topped the list of the day s best performing components of the Nasdaq 100 index trading up 9 2 Year to date JD com has lost about 19 8 of its value And the worst performing Nasdaq 100 component thus far on the day is
BMRN,BMRN:UW,BBG000CZX7N1,Why BioMarin (BMRN) Could Be Positioned for a Surge,2016-11-15 15:21:03 +0000,http://finance.yahoo.com/news/why-biomarin-bmrn-could-positioned-152103278.html,Why BioMarin (BMRN) Could Be Positioned for a Surge
BMRN,BMRN:UW,BBG000CZX7N1,"Merck KgaA Lifts FY16 Earnings View As Q3 Results Climb, Stock Up",2016-11-15 04:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hEgwY2TgUnU/merck-kgaa-lifts-fy16-earnings-view-as-q3-results-climb-stock-up-20161115-00118,"Merck KgaA Lifts FY16 Earnings View As Q3 Results Climb, Stock Up"
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : November 11, 2016",2016-11-11 12:16:16 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bullish-manner-bmrn-us-november-11-2016/,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : November 11, 2016"
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $––.6 million of Shares,2016-11-11 01:12:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mPhMNJ4WBv0/biomarin-pharmaceutical-inc-bmrn-ceo-jean-jacques-bienaime-sold-6-million-of-shares-cm707534,CEO of Biomarin Pharmaceutical Inc BMRN Jean Jacques Bienaime sold 4 shares of BMRN on 8 6 at an average price of 8 67 a share The total sale was 6 million Biomarin Pharmaceutical Inc develops and commercializes pharmaceuticals for serious diseases and
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $11.6 million of Shares,2016-11-10 03:15:05 +0000,http://finance.yahoo.com/news/biomarin-pharmaceutical-inc-bmrn-ceo-031505939.html,Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $11.6 million of Shares
BMRN,BMRN:UW,BBG000CZX7N1,Why These Biotechs Are Soaring Today,2016-11-09 22:54:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZJGGZxGdoIE/why-these-biotechs-are-soaring-today-cm706827,Image source Getty Images What happened Juno Therapeutics NASDAQ JUNO Vertex Pharmaceuticals NASDAQ VRTX BioMarin Pharmaceutical NASDAQ BMRN and Celgene NASDAQ CELG were all up at least 10 as of 2 58 p m after Donald Trump won the U
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Rises On 'Life-Changing' Hemophilia Drug, Trump Victory",2016-11-09 21:49:49 +0000,http://www.investors.com/news/technology/biomarin-gets-lift-on-life-changing-hep-a-drug-trump-victory/,"BioMarin Rises On 'Life-Changing' Hemophilia Drug, Trump Victory"
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech, Drug Stocks Fly On Clinton Loss, But 'Trump Uncertainty'",2016-11-09 21:33:40 +0000,http://www.investors.com/research/ibd-industry-themes/biotechs-drugs-fly-on-clinton-defeat-but-trump-uncertainty-lingers/,"Biotech, Drug Stocks Fly On Clinton Loss, But 'Trump Uncertainty'"
BMRN,BMRN:UW,BBG000CZX7N1,Why These Biotechs Are Soaring Today,2016-11-09 21:10:59 +0000,http://www.fool.com/investing/2016/11/09/why-these-biotechs-are-soaring-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why These Biotechs Are Soaring Today
BMRN,BMRN:UW,BBG000CZX7N1,BMRN Crosses Above Key Moving Average Level,2016-11-09 19:54:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fC8RXMtLdhY/bmrn-crosses-above-key-moving-average-level-cm706687,In trading on Wednesday shares of BioMarin Pharmaceutical Inc Symbol BMRN crossed above their 200 day moving average of 86 57 changing hands as high as 98 34 per share BioMarin Pharmaceutical Inc shares are currently trading up about 10 3 on the day The chart below shows the one
BMRN,BMRN:UW,BBG000CZX7N1,"Nasdaq 100 Movers: TRIP, BMRN",2016-11-09 16:54:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bQjtiq-lFrk/nasdaq-100-movers-trip-bmrn-cm706472,In early trading on Wednesday shares of BioMarin Pharmaceutical BMRN topped the list of the day s best performing components of the Nasdaq 100 index trading up 9 6 Year to date BioMarin Pharmaceutical has lost about 12 7 of its value And the worst performing Nasdaq 100
BMRN,BMRN:UW,BBG000CZX7N1,"Palo Alto Investors’s Bets on ABIOMED, Inc. (ABMD), United Therapeutics Corporation (UTHR) and Other Stocks Lift Its Q3 Returns",2016-11-08 22:35:56 +0000,http://www.insidermonkey.com/blog/palo-alto-investorss-bets-on-abiomed-inc-abmd-united-therapeutics-corporation-uthr-and-other-stocks-lift-its-q3-returns-485345/,"Palo Alto Investors’s Bets on ABIOMED, Inc. (ABMD), United Therapeutics Corporation (UTHR) and Other Stocks Lift Its Q3 Returns"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin's Stock Tumbled in October. Is It Now a Buy?,2016-11-08 22:22:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tfmN4BWTID4/biomarins-stock-tumbled-in-october-is-it-now-a-buy-cm705976,Image source Getty Images What happened Shares of the orphan drug specialist BioMarin Pharmaceutical NASDAQ BMRN fell by more than 16 in October 160 according to data from S amp P Global Market Intelligence BMRN data by
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin's Stock Tumbled in October. Is It Now a Buy?,2016-11-08 20:12:04 +0000,http://www.fool.com/investing/2016/11/08/biomarins-stock-tumbles-in-october-is-it-now-a-buy.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,BioMarin's Stock Tumbled in October. Is It Now a Buy?
BMRN,BMRN:UW,BBG000CZX7N1,Piper Jaffray Thinks It Might Be A Good Time For BioMarin To Sell Itself,2016-11-07 15:19:28 +0000,http://finance.yahoo.com/news/piper-jaffray-thinks-might-good-151928554.html,Piper Jaffray Thinks It Might Be A Good Time For BioMarin To Sell Itself
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharmaceutical To Participate In Credit Suisse Conference At 12:00 PM,2016-11-07 11:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-ICsBMr7cnM/biomarin-pharmaceutical-to-participate-in-credit-suisse-conference-at-1200-pm-20161107-00897,Biomarin Pharmaceutical To Participate In Credit Suisse Conference At 12:00 PM
BMRN,BMRN:UW,BBG000CZX7N1,"Nasdaq 100 Movers: SYMC, ALXN",2016-11-04 16:23:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K8YQYw8hd5M/nasdaq-100-movers-symc-alxn-cm704149,In early trading on Friday shares of Alexion Pharmaceuticals ALXN topped the list of the day s best performing components of the Nasdaq 100 index trading up 10 2 Year to date Alexion Pharmaceuticals has lost about 26 3 of its value And the worst performing Nasdaq 100
BMRN,BMRN:UW,BBG000CZX7N1,"BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report",2016-11-03 13:05:04 +0000,http://biz.yahoo.com/e/161103/bmrn10-q.html,"BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin to Attend Three Upcoming Investor Conferences,2016-11-03 12:48:17 +0000,http://www.publicnow.com/view/D0A1E55377FD7A7F7A8EEC1A338DA4074417A2EF,"[at noodls] - November 3, 2016 Credit Suisse 25th Annual Healthcare Conference on November 7 in Scottsdale, Arizona Jefferies 2016 London Healthcare Conference on November 16 in London Citi 2016 Global Healthcare Conference ..."
BMRN,BMRN:UW,BBG000CZX7N1,Strensiq: A Potential Driver for Alexion,2016-11-02 14:05:12 +0000,http://marketrealist.com/2016/10/strensiq-a-potential-driver-for-alexion/?utm_source=yahoo&utm_medium=feed,Strensiq: A Potential Driver for Alexion
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $9.8 million of Shares,2016-11-02 00:14:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9Qhvavkz4YU/biomarin-pharmaceutical-inc-bmrn-ceo-jean-jacques-bienaime-sold-98-million-of-shares-cm702120,CEO of Biomarin Pharmaceutical Inc BMRN Jean Jacques Bienaime sold shares of BMRN on 8 6 at an average price of 8 a share The total sale was 9 8 million Biomarin Pharmaceutical Inc develops and commercializes pharmaceuticals for serious diseases and
BMRN,BMRN:UW,BBG000CZX7N1,"ETF’s with exposure to BioMarin Pharmaceutical, Inc. : November 1, 2016",2016-11-01 15:52:11 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-biomarin-pharmaceutical-inc-november-1-2016/,"ETF’s with exposure to BioMarin Pharmaceutical, Inc. : November 1, 2016"
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $9.8 million of Shares,2016-11-01 03:15:01 +0000,http://finance.yahoo.com/news/biomarin-pharmaceutical-inc-bmrn-ceo-031501828.html,Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $9.8 million of Shares
BMRN,BMRN:UW,BBG000CZX7N1,Analyst Recommendations for BioMarin after Its 3Q16 Earnings,2016-10-31 22:04:05 +0000,http://marketrealist.com/2016/10/analyst-recommendations-for-biomarin-after-its-3q16-earnings-2/?utm_source=yahoo&utm_medium=feed,Analyst Recommendations for BioMarin after Its 3Q16 Earnings
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical Inc.: Sales Up, Losses Down, Waiting on Pipeline",2016-10-31 20:15:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G1qtr5xGWN0/biomarin-pharmaceutical-inc-sales-up-losses-down-waiting-on-pipeline-cm701335,Image source Getty Images BioMarin Pharmaceutical NASDAQ BMRN reported third quarter earnings on Thursday and updated investors on its pipeline BioMarin Pharmaceutical results The raw numbers Metric Q3 2016
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin’s Product-Specific Performance in 3Q16,2016-10-31 20:04:25 +0000,http://marketrealist.com/2016/10/biomarins-product-specific-performance-in-3q16/?utm_source=yahoo&utm_medium=feed,BioMarin’s Product-Specific Performance in 3Q16
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical Inc.: Sales Up, Losses Down, Waiting on Pipeline",2016-10-31 19:04:47 +0000,http://www.fool.com/investing/2016/10/31/biomarin-pharmaceutical-inc-sales-up-losses-down-w.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"BioMarin Pharmaceutical Inc.: Sales Up, Losses Down, Waiting on Pipeline"
BMRN,BMRN:UW,BBG000CZX7N1,"Novo Nordisk (NVO) Tops Q3 Earnings, Revenues Up Y/Y",2016-10-31 18:15:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IeBZPeLf2wc/novo-nordisk-nvo-tops-q3-earnings-revenues-up-yy-cm701243,Novo Nordisk A S NVO reported third quarter 2016 earnings of 58 cents per American Depository Receipt ADR above the Zacks Consensus Estimate of 56 cents and up from the year ago figure of 49 cents Quarterly revenues were also up 3 4 year over year to 4 1 billion Reported
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin’s Disappointing 3Q16 Earnings,2016-10-31 18:12:24 +0000,http://marketrealist.com/2016/10/biomarins-disappointing-3q16-earnings/?utm_source=yahoo&utm_medium=feed,BioMarin’s Disappointing 3Q16 Earnings
BMRN,BMRN:UW,BBG000CZX7N1,ImmunoGen (IMGN) Reports Wider-than-Expected Loss,2016-10-31 16:19:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WcFiUFlb2F8/immunogen-imgn-reports-wider-than-expected-loss-cm701083,ImmunoGen Inc IMGN reported a loss of 46 cents per share excluding restructuring charge in the three months ended Sep 30 wider than both the Zacks Consensus Estimate of a loss of 38 cents and the year ago loss of 39 cents We note that ImmunoGen is transitioning to a fiscal year ending
BMRN,BMRN:UW,BBG000CZX7N1,"Novo Nordisk (NVO) Tops Q3 Earnings, Revenues Up Y/Y",2016-10-31 15:38:03 +0000,http://finance.yahoo.com/news/novo-nordisk-nvo-tops-q3-153803073.html,"Novo Nordisk (NVO) Tops Q3 Earnings, Revenues Up Y/Y"
BMRN,BMRN:UW,BBG000CZX7N1,ImmunoGen (IMGN) Reports Wider-than-Expected Loss,2016-10-31 14:16:02 +0000,http://finance.yahoo.com/news/immunogen-imgn-reports-wider-expected-141602741.html,ImmunoGen (IMGN) Reports Wider-than-Expected Loss
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q3, 2016 By the Numbers : October 31, 2016",2016-10-31 14:11:45 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-bmrn-us-earnings-analysis-q3-2016-by-the-numbers-october-31-2016/,"BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q3, 2016 By the Numbers : October 31, 2016"
BMRN,BMRN:UW,BBG000CZX7N1,No. 1 Biotech Amgen Dives As Rebates Chip Away At 2017 Sales View,2016-10-28 20:21:33 +0000,http://www.investors.com/research/ibd-industry-themes/no-1-biotech-amgen-dives-as-rebates-chip-away-at-2017-sales-view/,No. 1 Biotech Amgen Dives As Rebates Chip Away At 2017 Sales View
BMRN,BMRN:UW,BBG000CZX7N1,Seattle Genetics (SGEN) Loss Narrower than Expected in Q3,2016-10-28 19:32:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r2WQSJA7A8E/seattle-genetics-sgen-loss-narrower-than-expected-in-q3-cm700470,Seattle Genetics Inc SGEN reported a loss of 23 cents per share narrower than the Zacks Consensus Estimate of a loss of 29 cents but wider than the year ago loss of 21 cents Revenues came in at 106 3 million up 26 5 year over year primarily on the back of strong sales of
BMRN,BMRN:UW,BBG000CZX7N1,"AbbVie (ABBV) Q3 Earnings in Line, Revenues Lag Estimates",2016-10-28 17:33:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0rQZXDRYDiE/abbvie-abbv-q3-earnings-in-line-revenues-lag-estimates-cm700410,AbbVie Inc ABBV reported third quarter 2016 earnings of 1 21 per share in line with the Zacks Consensus Estimate but up 7 1 from the year ago quarter FindTheCompany Graphiq Revenues increased 8 2 to 6 43 billion in the third quarter but missed the Zacks
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin (BMRN) Q3 Loss Narrows Y/Y, Pipeline in Focus",2016-10-28 16:35:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/74q6bQBXFaY/biomarin-bmrn-q3-loss-narrows-yy-pipeline-in-focus-cm700295,BioMarin Pharmaceutical Inc BMRN reported a loss of 18 cents per share in the third quarter of 2016 including stock based compensation expense narrower than the year ago loss of 44 cents The Zacks Consensus Estimate was of a loss of 39 cents per share Total revenue came in at
BMRN,BMRN:UW,BBG000CZX7N1,Agenus (AGEN) Reports Wider-than-Expected Loss in Q3,2016-10-28 15:35:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J2YfD1aMdOk/agenus-agen-reports-wider-than-expected-loss-in-q3-cm700168,Agenus Inc AGEN reported third quarter 2016 loss of 47 cents per share including non cash expenses wider than the Zacks Consensus Estimate of a loss of 32 cents as well as the loss of 16 cents in the prior year quarter Lower revenues and higher costs hurt earnings in the
BMRN,BMRN:UW,BBG000CZX7N1,"United Therapeutics (UTHR) Beats Q3 Earnings, Sales Miss",2016-10-28 15:35:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jF0NKpmW6hc/united-therapeutics-uthr-beats-q3-earnings-sales-miss-cm700153,United Therapeutics Corporation UTHR reported adjusted earnings of 3 63 per share including after tax impact of stock based compensation expense for third quarter 2016 which beat the Zacks Consensus Estimate of 3 47 by 4 61 Revenues for the reported quarter increased 5 6 year over year
BMRN,BMRN:UW,BBG000CZX7N1,"AbbVie (ABBV) Q3 Earnings in Line, Revenues Lag Estimates",2016-10-28 15:23:03 +0000,http://finance.yahoo.com/news/abbvie-abbv-q3-earnings-line-152303035.html,"AbbVie (ABBV) Q3 Earnings in Line, Revenues Lag Estimates"
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3,2016-10-28 14:33:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I91QFyOccf0/sarepta-therapeutics-srpt-incurs-narrower-yy-loss-in-q3-cm700177,Sarepta Therapeutics Inc SRPT posted a loss of 1 15 per share in the third quarter of 2016 narrower than the year ago loss of 1 25 The Zacks Consensus Estimate reported a loss of 1 35 per share No revenue was recorded by the company in the reported quarter as was the case a year
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin (BMRN) Q3 Loss Narrows Y/Y, Pipeline in Focus",2016-10-28 14:21:02 +0000,http://finance.yahoo.com/news/biomarin-bmrn-q3-loss-narrows-142102834.html,"BioMarin (BMRN) Q3 Loss Narrows Y/Y, Pipeline in Focus"
BMRN,BMRN:UW,BBG000CZX7N1,"McKesson (MCK) Misses on Q2 Earnings & Sales, Cuts View",2016-10-28 13:44:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2SMUsErOyl8/mckesson-mck-misses-on-q2-earnings-sales-cuts-view-cm700128,McKesson Corporation MCK reported second quarter fiscal 2017 ended Sep 30 2016 earnings of 2 94 per share missing the Zacks Consensus Estimate of 3 05 and declining from the year ago figure of 3 17 FindTheCompany Graphiq Revenues on the other hand improved 2 5 to
BMRN,BMRN:UW,BBG000CZX7N1,"Acorda (ACOR) Reports Wider Q3 Loss, Revenues Down Y/Y",2016-10-28 13:43:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q7IIsXF_F7A/acorda-acor-reports-wider-q3-loss-revenues-down-yy-cm700121,Acorda Therapeutics Inc ACOR reported a loss of 28 cents per share in the third quarter of 2016 including the impact of stock based compensation expense and other non recurring items which was wider than the Zacks Consensus Estimate of a loss of 26 cents However including the impact
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3,2016-10-28 13:35:01 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-srpt-incurs-narrower-133501322.html,Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3
BMRN,BMRN:UW,BBG000CZX7N1,"Acorda (ACOR) Reports Wider Q3 Loss, Revenues Down Y/Y",2016-10-28 12:25:12 +0000,http://finance.yahoo.com/news/acorda-acor-reports-wider-q3-122512916.html,"Acorda (ACOR) Reports Wider Q3 Loss, Revenues Down Y/Y"
BMRN,BMRN:UW,BBG000CZX7N1,"McKesson (MCK) Misses on Q2 Earnings & Sales, Cuts View",2016-10-28 12:24:12 +0000,http://finance.yahoo.com/news/mckesson-mck-misses-q2-earnings-122412874.html,"McKesson (MCK) Misses on Q2 Earnings & Sales, Cuts View"
BMRN,BMRN:UW,BBG000CZX7N1,"Alexion (ALXN) Q3 Earnings Lag, Revenues Tops; Lifts View",2016-10-27 21:43:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3wXufHWsTJ0/alexion-alxn-q3-earnings-lag-revenues-tops-lifts-view-cm699808,Alexion Pharmaceuticals Inc s ALXN third quarter 2016 earnings including stock based compensation expense of 1 03 cents per share missed the Zacks Consensus Estimate of 1 04 Revenues on the other hand soared 20 1 year over year to 799 million The impact of currency headwind
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin reports 3Q loss,2016-10-27 21:06:05 +0000,http://sg.finance.yahoo.com/news/biomarin-reports-3q-loss-210605551.html,BioMarin reports 3Q loss
BMRN,BMRN:UW,BBG000CZX7N1,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a",2016-10-27 20:17:29 +0000,http://biz.yahoo.com/e/161027/bmrn8-k.html,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces Third Quarter 2016 Financial Results,2016-10-27 20:16:09 +0000,http://www.publicnow.com/view/ED27346A2E28B2813BD566C1F16D817E0BEEEAE5,"[at noodls] - October 27, 2016 - Third Quarter 2016 Total BioMarin Revenues Increase 34% Year over Year to $280 million Vimizim Net Product Revenues Increase 25% Year over Year to $81 million in the Third Quarter 2016 ..."
BMRN,BMRN:UW,BBG000CZX7N1,"Alexion (ALXN) Q3 Earnings Lag, Revenues Tops; Lifts View",2016-10-27 19:44:07 +0000,http://finance.yahoo.com/news/alexion-alxn-q3-earnings-lag-194407907.html,"Alexion (ALXN) Q3 Earnings Lag, Revenues Tops; Lifts View"
BMRN,BMRN:UW,BBG000CZX7N1,"Bristol-Myers (BMY) Beats on Q3 Earnings, Ups 2016 View",2016-10-27 17:44:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-eBxuF7vS0k/bristol-myers-bmy-beats-on-q3-earnings-ups-2016-view-cm699608,Bristol Myers Squibb Company s BMY third quarter 2016 earnings of 77 cents per share beat the Zacks Consensus Estimate of 65 cents and surged 97 from the year ago period FindTheCompany Graphiq Total revenue of 4 92 billion was also above the Zacks Consensus Estimate
BMRN,BMRN:UW,BBG000CZX7N1,"Glaxo (GSK) Beats Q3 Earnings Estimates, Keeps 2016 View",2016-10-27 17:42:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MSHBkLyUhYo/glaxo-gsk-beats-q3-earnings-estimates-keeps-2016-view-cm699551,GlaxoSmithKline plc GSK reported third quarter 2016 core earnings of 85 cents per American Depositary Share ADS beating the Zacks Consensus Estimate of 77 cents Core earnings were also up 12 year over year at constant exchange rates CER Quarterly revenues were up 8 at CER to 7
BMRN,BMRN:UW,BBG000CZX7N1,"Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook",2016-10-27 17:42:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NShLezeq-80/celgene-celg-beats-on-q3-earnings-raises-16-outlook-cm699542,Celgene Corporation CELG reported third quarter 2016 earnings of 1 39 per share including share based compensation expense and tax adjustments beating the Zacks Consensus Estimate of 1 31 and surging almost 28 from the year ago period Excluding share based compensation expense Celgene
BMRN,BMRN:UW,BBG000CZX7N1,The Medicines Co. (MDCO) Q3 Loss Narrower than Expected,2016-10-27 16:46:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hoa1kLrNVSw/the-medicines-co-mdco-q3-loss-narrower-than-expected-cm699494,The Medicines Company MDCO reported a loss of 75 cents per share including the impact of share based compensation expenses in the third quarter of 2016 significantly narrower than both the Zacks Consensus Estimate of a loss of 1 38 and the year ago loss of 94 cents Meanwhile
BMRN,BMRN:UW,BBG000CZX7N1,"Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook",2016-10-27 15:45:03 +0000,http://finance.yahoo.com/news/celgene-celg-beats-q3-earnings-154503140.html,"Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook"
BMRN,BMRN:UW,BBG000CZX7N1,"Glaxo (GSK) Beats Q3 Earnings Estimates, Keeps 2016 View",2016-10-27 15:42:03 +0000,http://finance.yahoo.com/news/glaxo-gsk-beats-q3-earnings-154203289.html,"Glaxo (GSK) Beats Q3 Earnings Estimates, Keeps 2016 View"
BMRN,BMRN:UW,BBG000CZX7N1,"Bristol-Myers (BMY) Beats on Q3 Earnings, Ups 2016 View",2016-10-27 15:22:03 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-beats-q3-152203873.html,"Bristol-Myers (BMY) Beats on Q3 Earnings, Ups 2016 View"
BMRN,BMRN:UW,BBG000CZX7N1,"Bayer (BAYRY) Beats on Q3 Earnings, Lifts 2016 Guidance",2016-10-27 14:45:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S9hgtkNstI8/bayer-bayry-beats-on-q3-earnings-lifts-2016-guidance-cm699409,Bayer AG s BAYRY third quarter 2016 core earnings increased 2 4 year over year to 1 73 per share approximately 1 93 Reported earnings were able to beat the Zacks Consensus Estimate of 1 80 Total sales in the third quarter improved 2 3 to 11 3 billion approximately 13 billion on
BMRN,BMRN:UW,BBG000CZX7N1,The Medicines Co. (MDCO) Q3 Loss Narrower than Expected,2016-10-27 14:33:02 +0000,http://finance.yahoo.com/news/medicines-co-mdco-q3-loss-143302841.html,The Medicines Co. (MDCO) Q3 Loss Narrower than Expected
BMRN,BMRN:UW,BBG000CZX7N1,ProQR Therapeutics (PRQR) Worth a Look: Stock Up 9.8%,2016-10-27 13:43:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y_fTw1q8pu4/proqr-therapeutics-prqr-worth-a-look-stock-up-98-cm699254,ProQR Therapeutics N V PRQR was a big mover last session as the company saw its shares rise nearly 10 on the day The move came on solid volume too with far more shares changing hands than in a normal session This reverses the recent trend for the company as the stock is now down nearly
BMRN,BMRN:UW,BBG000CZX7N1,ProQR Therapeutics (PRQR) Worth a Look: Stock Up 9.8%,2016-10-27 12:45:12 +0000,http://finance.yahoo.com/news/proqr-therapeutics-prqr-worth-look-124512661.html,ProQR Therapeutics (PRQR) Worth a Look: Stock Up 9.8%
BMRN,BMRN:UW,BBG000CZX7N1,Q3 2016 Biomarin Pharmaceutical Inc Earnings Release - Time Not Supplied,2016-10-27 11:07:08 +0000,http://biz.yahoo.com/research/earncal/20161027.html?t=bmrn,Q3 2016 Biomarin Pharmaceutical Inc Earnings Release - Time Not Supplied
BMRN,BMRN:UW,BBG000CZX7N1,10 Most Successful Innovative Companies in The World in 2016,2016-10-26 18:50:57 +0000,http://www.insidermonkey.com/blog/10-most-successful-innovative-companies-in-the-world-in-2016-482431/,10 Most Successful Innovative Companies in The World in 2016
BMRN,BMRN:UW,BBG000CZX7N1,Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q2,2016-10-26 15:53:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GHhuVeh21MY/dr-reddys-rdy-earnings-revenues-decline-yy-in-q2-cm698533,Dr Reddy s Laboratories Ltd RDY reported second quarter fiscal 2017 earnings per American Depositary Share ADS of 27 cents down 57 1 year over year Moreover quarterly revenues declined 10 year over year to 539 million primarily due to lower contribution from all its
BMRN,BMRN:UW,BBG000CZX7N1,"Express Scripts (ESRX) Q3 Earnings in Line, Revenues Lag",2016-10-26 14:53:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HLdl7KafoLY/express-scripts-esrx-q3-earnings-in-line-revenues-lag-cm698574,Pharmacy benefit manager Express Scripts Holding Company ESRX posted third quarter 2016 earnings per share excluding special items of 1 74 in line with the Zacks Consensus Estimate Reported earnings were up 20 from the year ago period FindTheCompany Graphiq On a
BMRN,BMRN:UW,BBG000CZX7N1,"Vertex's (VRTX) Q3 Loss Wider than Expected, Sales Miss",2016-10-26 13:50:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ynaMS2__G10/vertexs-vrtx-q3-loss-wider-than-expected-sales-miss-cm698458,Vertex Pharmaceuticals Inc VRTX reported third quarter 2016 loss of 8 cents per share including the impact of stock based compensation expense wider than the Zacks Consensus Estimate of a loss of 6 cents However the loss was narrower than a loss of 40 cents reported in the year ago
BMRN,BMRN:UW,BBG000CZX7N1,"Express Scripts (ESRX) Q3 Earnings in Line, Revenues Lag",2016-10-26 13:17:01 +0000,http://finance.yahoo.com/news/express-scripts-esrx-q3-earnings-131701657.html,"Express Scripts (ESRX) Q3 Earnings in Line, Revenues Lag"
BMRN,BMRN:UW,BBG000CZX7N1,Ligand Partner Melinta Therapeutics Submits NDA for Baxdela,2016-10-25 22:24:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HNlZ2OxTG5Q/ligand-partner-melinta-therapeutics-submits-nda-for-baxdela-cm698250,Ligand Pharmaceuticals Incorporated LGND said its partner Melinta Therapeutics a private pharma company has submitted New Drug Applications NDAs to the FDA for its pipeline candidate Baxdela delafloxacin to treat serious bacterial infections Ligand Pharma and Melinta Therapeutics
BMRN,BMRN:UW,BBG000CZX7N1,Ligand Partner Melinta Therapeutics Submits NDA for Baxdela,2016-10-25 20:32:08 +0000,http://finance.yahoo.com/news/ligand-partner-melinta-therapeutics-submits-203208669.html,Ligand Partner Melinta Therapeutics Submits NDA for Baxdela
BMRN,BMRN:UW,BBG000CZX7N1,"Lilly (LLY) Misses on Q3 Earnings, Sales; Animal Health Hurts",2016-10-25 16:28:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fLETdGBg3aA/lilly-lly-misses-on-q3-earnings-sales-animal-health-hurts-cm697939,Eli Lilly and Company s LLY third quarter results were below expectations with both earnings and sales missing the Zacks Consensus Estimate The company revised certain elements of its 2016 outlook Shares declined 1 in pre market trading Earnings Miss Third quarter 2016
BMRN,BMRN:UW,BBG000CZX7N1,"Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View",2016-10-25 16:28:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UIXvyQoplXI/merck-mrk-beats-on-q3-earnings-revenues-lifts-view-cm697925,Merck amp Co Inc MRK reported third quarter 2016 earnings of 1 07 per share comfortably surpassing the Zacks Consensus Estimate of 98 cents and increasing approximately 12 from the year ago period FindTheCompany Graphiq Again revenues for the quarter were up 5
BMRN,BMRN:UW,BBG000CZX7N1,Inovio Stock Down on FDA Hold on VGX-3100 Phase III Study,2016-10-25 14:25:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/idUNRrGc11A/inovio-stock-down-on-fda-hold-on-vgx-3100-phase-iii-study-cm697806,Inovio Pharmaceuticals Inc s INO shares plunged 16 4 after the company announced that the FDA has placed a clinical hold on the proposed phase III program on its lead pipeline candidate VGX 3100 We note that a clinical hold is a notification issued by the FDA to a sponsor of the
BMRN,BMRN:UW,BBG000CZX7N1,"Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View",2016-10-25 14:04:02 +0000,http://finance.yahoo.com/news/merck-mrk-beats-q3-earnings-140402772.html,"Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View"
BMRN,BMRN:UW,BBG000CZX7N1,Bristol-Myers's (BMY) Opdivo Under Priority Review by FDA,2016-10-24 16:27:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tEbTnB-ytRA/bristol-myerss-bmy-opdivo-under-priority-review-by-fda-cm697211,Bristol Myers Squibb Company BMY announced that its supplemental biologics license application sBLA for immuno oncology drug Opdivo has been accepted for priority review by the FDA The company is looking to expand Opdivo s label to include the treatment of locally advanced unresectable
BMRN,BMRN:UW,BBG000CZX7N1,Merck Gets FDA Approval for Investigational Drug Zinplava,2016-10-24 13:35:01 +0000,http://finance.yahoo.com/news/merck-gets-fda-approval-investigational-133501578.html,Merck Gets FDA Approval for Investigational Drug Zinplava
BMRN,BMRN:UW,BBG000CZX7N1,Top Health Care Earnings Coming Next Week,2016-10-23 14:35:30 +0000,http://247wallst.com/healthcare-business/2016/10/23/top-health-care-earnings-coming-next-week/,Top Health Care Earnings Coming Next Week
BMRN,BMRN:UW,BBG000CZX7N1,"Commit To Buy BioMarin Pharmaceutical At $65, Earn 8.6% Using Options",2016-10-21 17:25:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7uKcrS8Fjfw/commit-to-buy-biomarin-pharmaceutical-at-65-earn-86-using-options-cm696659,Investors considering a purchase of BioMarin Pharmaceutical Inc Symbol BMRN stock but tentative about paying the going market price of 83 08 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular
BMRN,BMRN:UW,BBG000CZX7N1,"Roche (RHHBY) Misses Q3 Sales Estimates, 2016 View Intact",2016-10-21 14:02:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o-0m2t6pu3I/roche-rhhby-misses-q3-sales-estimates-2016-view-intact-cm696461,Roche Holding AG RHHBY reported sales of 12 79 billion CHF12 48 billion in the third quarter of 2016 compared to CHF11 94 billion 12 38 billion in the year ago comparable period The reported figure however missed the Zacks Consensus Estimate of 12 88 billion by a whisker
BMRN,BMRN:UW,BBG000CZX7N1,How The Parts Add Up: QUS Targets $69,2016-10-21 14:01:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7seZAO5YvHg/how-the-parts-add-up-qus-targets-69-cm696429,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BMRN,BMRN:UW,BBG000CZX7N1,Alkermes Depression Candidate Positive in Phase III Study,2016-10-21 13:25:01 +0000,http://finance.yahoo.com/news/alkermes-depression-candidate-positive-phase-132501229.html,Alkermes Depression Candidate Positive in Phase III Study
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Could Reap $1.1 Billion In 2025 On 'Dwarfism' Drug: Analyst,2016-10-20 20:48:38 +0000,http://www.investors.com/news/technology/biomarin-could-reap-1-1-billion-in-2025-on-dwarfism-drug-analyst/,BioMarin Could Reap $1.1 Billion In 2025 On 'Dwarfism' Drug: Analyst
BMRN,BMRN:UW,BBG000CZX7N1,Alexion Graft-Versus-Host Disease Drug Wins Orphan Status,2016-10-20 17:27:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b4VrFi1OLFQ/alexion-graft-versus-host-disease-drug-wins-orphan-status-cm696084,Alexion Pharmaceuticals Inc ALXN announced that the FDA has granted orphan drug designation ODD to its pipeline candidate ALXN1007 for the treatment of acute graft versus host disease GVHD The FDA through its Office of Orphan Products Development grants this status to candidates
BMRN,BMRN:UW,BBG000CZX7N1,A Look At The Science Behind BioMarin Pharmaceutical Inc. (BMRN)’s Next Pivotal Candidate,2016-10-20 15:46:38 +0000,http://www.insidermonkey.com/blog/a-look-at-the-science-behind-biomarin-pharmaceutical-inc-bmrns-next-pivotal-candidate-482378/,A Look At The Science Behind BioMarin Pharmaceutical Inc. (BMRN)’s Next Pivotal Candidate
BMRN,BMRN:UW,BBG000CZX7N1,What's in Store for BioMarin (BMRN) This Earnings Season?,2016-10-20 15:28:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/holgreg2CpE/whats-in-store-for-biomarin-bmrn-this-earnings-season-cm695926,BioMarin Pharmaceutical Inc BMRN is scheduled to report third quarter 2016 results on Oct 27 after the market closes In the last reported quarter the company had posted a positive surprise of 78 00 Let s see how things are shaping up for this announcement Factors Influencing
BMRN,BMRN:UW,BBG000CZX7N1,What's in Store for BioMarin (BMRN) This Earnings Season?,2016-10-20 13:56:01 +0000,http://finance.yahoo.com/news/whats-store-biomarin-bmrn-earnings-135601378.html,What's in Store for BioMarin (BMRN) This Earnings Season?
BMRN,BMRN:UW,BBG000CZX7N1,Eli Lilly Lartruvo Gets FDA Approval for Soft Tissue Sarcoma,2016-10-20 13:51:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3CwzFCuosCg/eli-lilly-lartruvo-gets-fda-approval-for-soft-tissue-sarcoma-cm695769,Eli Lilly and Company LLY announced that the FDA has granted accelerated approval to its pipeline candidate Lartruvo olaratumab injection 10 mg mL in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma STS not amenable to curative
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting,2016-10-19 21:01:00 +0000,http://finance.yahoo.com/news/biomarin-presents-vosoritide-data-achondroplasia-210100615.html,"[GlobeNewswire] - Highest Dose Shows Approximately 50% Increase in Mean Annualized Growth Velocity, Comparable with 15 µg/kg/day dose. Consistent Safety Profile at High Dose. Findings Support 15 µg/kg/day in Phase 3, Randomized ..."
BMRN,BMRN:UW,BBG000CZX7N1,How Much Return Could Alexion Offer over the Next 12 months?,2016-10-19 19:55:01 +0000,http://marketrealist.com/2016/10/how-much-return-could-alexion-offer-over-the-next-12-months/?utm_source=yahoo&utm_medium=feed,How Much Return Could Alexion Offer over the Next 12 months?
BMRN,BMRN:UW,BBG000CZX7N1,AstraZeneca's Hyperkalemia Drug NDA Resubmission Accepted,2016-10-19 15:49:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/28CHthdi4rA/astrazenecas-hyperkalemia-drug-nda-resubmission-accepted-cm695337,AstraZeneca plc AZN announced that the FDA has accepted for review its complete re submission of the new drug application NDA for ZS 9 sodium zirconium cyclosilicate The company is looking to get ZS 9 approved for the treatment of hyperkalemia high potassium level in the blood
BMRN,BMRN:UW,BBG000CZX7N1,Precious Metal Outlook,2016-10-19 15:47:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CSIc-G8OY2o/precious-metal-outlook-cm694958,A stronger dollar sent gold prices falling on Friday The looming of a potential interest rate hike in December has weighed on precious metals Gold prices fell to 5 6 a troy ounce down over 6 to end the session Upbeat economic reports out of the United States on Wednesday led to
BMRN,BMRN:UW,BBG000CZX7N1,AstraZeneca's Hyperkalemia Drug NDA Resubmission Accepted,2016-10-19 13:56:01 +0000,http://finance.yahoo.com/news/astrazenecas-hyperkalemia-drug-nda-resubmission-135601402.html,AstraZeneca's Hyperkalemia Drug NDA Resubmission Accepted
BMRN,BMRN:UW,BBG000CZX7N1,The Medicines Co. Reports Positive Phase II Data on PCSK9si,2016-10-19 12:30:12 +0000,http://finance.yahoo.com/news/medicines-co-reports-positive-phase-123012474.html,The Medicines Co. Reports Positive Phase II Data on PCSK9si
BMRN,BMRN:UW,BBG000CZX7N1,3 Top Stocks for Your Roth IRA,2016-10-19 12:23:14 +0000,http://www.fool.com/investing/2016/10/19/3-top-stocks-for-your-roth-ira.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Top Stocks for Your Roth IRA
BMRN,BMRN:UW,BBG000CZX7N1,David Rolfe Comments on TreeHouse Foods,2016-10-18 22:47:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L5gTaso-y0o/david-rolfe-comments-on-treehouse-foods-cm694810,We initiated positions in TreeHouse Foods Inc NYSE THS during the third quarter TreeHouse is the largest private label food manufacturer and distributor in North America An aphorism in the private label industry is that a grocer is only as good as their private label As such
BMRN,BMRN:UW,BBG000CZX7N1,Vertex Not the Only Pharmaceutical to See Its Share Price Fall,2016-10-18 17:04:14 +0000,http://marketrealist.com/2016/10/vertex-not-the-only-pharmaceutical-to-see-its-share-price-fall/?utm_source=yahoo&utm_medium=feed,Vertex Not the Only Pharmaceutical to See Its Share Price Fall
BMRN,BMRN:UW,BBG000CZX7N1,J&J (JNJ) Outshines in Q3 Earnings on Strong Pharma Sales,2016-10-18 15:50:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ir8EQZrt_0A/jj-jnj-outshines-in-q3-earnings-on-strong-pharma-sales-cm694705,Johnson amp Johnson JNJ reported another strong quarter with both earnings and sales beating expectations Moreover the company raised the lower end of its earnings outlook for the year The healthcare giant s third quarter 2016 earnings came in at 1 68 per share beating the Zacks
BMRN,BMRN:UW,BBG000CZX7N1,J&J (JNJ) Outshines in Q3 Earnings on Strong Pharma Sales,2016-10-18 14:05:02 +0000,http://finance.yahoo.com/news/j-j-jnj-outshines-q3-140502774.html,J&J (JNJ) Outshines in Q3 Earnings on Strong Pharma Sales
BMRN,BMRN:UW,BBG000CZX7N1,Teva Trisenox Wins CHMP Nod for Expanded Use in Leukemia,2016-10-18 13:23:01 +0000,http://finance.yahoo.com/news/teva-trisenox-wins-chmp-nod-132301590.html,Teva Trisenox Wins CHMP Nod for Expanded Use in Leukemia
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $5.6 million of Shares,2016-10-18 03:15:01 +0000,http://finance.yahoo.com/news/biomarin-pharmaceutical-inc-bmrn-ceo-031501928.html,Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $5.6 million of Shares
BMRN,BMRN:UW,BBG000CZX7N1,Tetraphase Begins Phase III Dosing of Antibiotic Candidate,2016-10-17 15:42:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZgvIc9PgEhc/tetraphase-begins-phase-iii-dosing-of-antibiotic-candidate-cm694100,Tetraphase Pharmaceuticals TTPH announced that it has begun dosing in the phase III IGNITE4 study on its lead antibiotic candidate eravacycline IGNITE4 is evaluating the efficacy and safety of twice daily intravenous IV eravacycline compared to meropenem for the treatment of
BMRN,BMRN:UW,BBG000CZX7N1,Allergan's Belkyra Gets Swedish Approval for Double Chin,2016-10-17 14:44:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kJi3sB9iMvo/allergans-belkyra-gets-swedish-approval-for-double-chin-cm694040,Allergan plc AGN announced that its prescription medicine Belkyra deoxycholic acid has been granted marketing approval in Sweden for the treatment of moderate to severe fullness under the chin in adults commonly referred to as double chin Belkyra was added to Allergan s portfolio
BMRN,BMRN:UW,BBG000CZX7N1,Allergan's Belkyra Gets Swedish Approval for Double Chin,2016-10-17 12:57:12 +0000,http://finance.yahoo.com/news/allergans-belkyra-gets-swedish-approval-125712395.html,Allergan's Belkyra Gets Swedish Approval for Double Chin
BMRN,BMRN:UW,BBG000CZX7N1,Bristol-Myers Wins CHMP Nod for Opdivo Label Expansion,2016-10-17 12:44:12 +0000,http://finance.yahoo.com/news/bristol-myers-wins-chmp-nod-124412636.html,Bristol-Myers Wins CHMP Nod for Opdivo Label Expansion
BMRN,BMRN:UW,BBG000CZX7N1,PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal,2016-10-17 12:32:00 +0000,https://www.thestreet.com/story/13855101/1/ptc-therapeutics-getting-cold-shoulder-from-regulators-on-duchenne-drug-appeal.html?puc=yahoo&cm_ven=YAHOO,PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Issues Encouraging Update on Hemophilia A Drug,2016-10-14 14:23:02 +0000,http://finance.yahoo.com/news/biomarin-issues-encouraging-hemophilia-drug-142302451.html,BioMarin Issues Encouraging Update on Hemophilia A Drug
BMRN,BMRN:UW,BBG000CZX7N1,Sunesis Submits Response to Questions on Leukemia Drug,2016-10-14 14:03:02 +0000,http://finance.yahoo.com/news/sunesis-submits-response-questions-leukemia-140302689.html,Sunesis Submits Response to Questions on Leukemia Drug
BMRN,BMRN:UW,BBG000CZX7N1,"OncoGenex Cancer Drug Fails in Phase III Study, Stock Down",2016-10-14 13:59:01 +0000,http://finance.yahoo.com/news/oncogenex-cancer-drug-fails-phase-135901809.html,"OncoGenex Cancer Drug Fails in Phase III Study, Stock Down"
BMRN,BMRN:UW,BBG000CZX7N1,UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A,2016-10-13 20:20:04 +0000,http://www.publicnow.com/view/88C96B4A9FBFF6C9849FB58B868D7A234A539552,"[at noodls] - October 13, 2016 Phase 1/2 Study Expected to Resume by End of 2016 Requirement for Prophylactic Corticosteroids Removed SAN RAFAEL, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. ..."
BMRN,BMRN:UW,BBG000CZX7N1,BMRN Crosses Below Key Moving Average Level,2016-10-13 19:42:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HYrrNSP4RUI/bmrn-crosses-below-key-moving-average-level-cm693116,In trading on Thursday shares of BioMarin Pharmaceutical Inc Symbol BMRN crossed below their 200 day moving average of 87 62 changing hands as low as 86 00 per share BioMarin Pharmaceutical Inc shares are currently trading down about 1 on the day The chart below shows the one
BMRN,BMRN:UW,BBG000CZX7N1,Supernus (SUPN) Reports Encouraging Data from ADHD Study,2016-10-13 18:25:06 +0000,http://finance.yahoo.com/news/supernus-supn-reports-encouraging-data-182506855.html,Supernus (SUPN) Reports Encouraging Data from ADHD Study
BMRN,BMRN:UW,BBG000CZX7N1,AMAG Issues Encouraging Updates on Makena & Feraheme,2016-10-13 15:43:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6Lp6BDxnNfY/amag-issues-encouraging-updates-on-makena-feraheme-cm692801,AMAG Pharmaceuticals Inc AMAG announced the achievement of key milestones with respect to its next generation development programs on Makena and Feraheme The company announced that it has initiated a randomized open label parallel definitive pharmacokinetic and the comparative pain
BMRN,BMRN:UW,BBG000CZX7N1,"Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics",2016-10-13 15:39:00 +0000,https://www.thestreet.com/story/13852472/1/pardon-me-but-i-have-a-few-things-to-say-seattle-genetics-biomarin-sarepta-tg-therapeutics.html?puc=yahoo&cm_ven=YAHOO,"Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics"
BMRN,BMRN:UW,BBG000CZX7N1,What Makes Vertex Pharmaceuticals (VRTX) a Strong Sell?,2016-10-13 14:16:02 +0000,http://finance.yahoo.com/news/makes-vertex-pharmaceuticals-vrtx-strong-141602998.html,What Makes Vertex Pharmaceuticals (VRTX) a Strong Sell?
BMRN,BMRN:UW,BBG000CZX7N1,AMAG Issues Encouraging Updates on Makena & Feraheme,2016-10-13 13:59:01 +0000,http://finance.yahoo.com/news/amag-issues-encouraging-updates-makena-135901072.html,AMAG Issues Encouraging Updates on Makena & Feraheme
BMRN,BMRN:UW,BBG000CZX7N1,"Market Close Report: NASDAQ Composite index closes at 5,239.02 down -7.77 points",2016-10-12 20:48:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KfYLVexERgk/market-close-report-nasdaq-composite-index-closes-at-523902-down-777-points-cm692601,Wednesday s session closes with the NASDAQ Composite Index at 5 239 02 The total shares traded for the NASDAQ was over 1 55 billion Declining stocks led advancers by 1 09 to 1 ratio There were 1351 advancers and 1475 decliners for the day On the NASDAQ Stock Exchange 18 stocks reached a 52
BMRN,BMRN:UW,BBG000CZX7N1,3 Biotechs Most Likely to Be Acquired,2016-10-12 11:28:03 +0000,http://www.fool.com/investing/2016/10/11/3-biotechs-most-likely-to-be-acquired.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotechs Most Likely to Be Acquired
BMRN,BMRN:UW,BBG000CZX7N1,3 Biotechs Most Likely to Be Acquired,2016-10-11 18:19:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tEgLZ4W6cao/3-biotechs-most-likely-to-be-acquired-cm691966,Image source Getty Images Mergers and acquisitions are a way of life in the biotech world Several big buyouts have taken place this year and it s only a matter of time before the industry is abuzz over the next one But which biotech stocks are most likely to be
BMRN,BMRN:UW,BBG000CZX7N1,Alexion Presents New Long-Term Phase III Data on Kanuma,2016-10-11 15:21:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RBoWQ9DXcKI/alexion-presents-new-long-term-phase-iii-data-on-kanuma-cm691774,Alexion Pharmaceuticals Inc ALXN announced that new long term data from an ongoing open label extension of the pivotal phase III ARISE study on Kanuma in children and adults suffering from lysosomal acid lipase deficiency LAL D were presented at the World Congress of
BMRN,BMRN:UW,BBG000CZX7N1,Catabasis Presents Data from DMD study on Edasalonexent,2016-10-11 15:21:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CgJmOAeHPw4/catabasis-presents-data-from-dmd-study-on-edasalonexent-cm691773,Catabasis Pharmaceuticals Inc CATB announced that it has presented results from the part A of the MoveDMD study phase I II on edasalonexent at the congress of the World Muscle Society Edasalonexent a molecule that inhibits a protein called NF kB is being developed for the treatment
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET",2016-10-11 12:30:00 +0000,http://finance.yahoo.com/news/biomarin-host-third-quarter-2016-123000555.html,"[GlobeNewswire] - SAN RAFAEL, Calif., Oct. 11, 2016-- BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on ..."
BMRN,BMRN:UW,BBG000CZX7N1,3 biotech breakouts,2016-10-10 21:42:00 +0000,http://finance.yahoo.com/video/3-biotech-breakouts-214200206.html,3 biotech breakouts
BMRN,BMRN:UW,BBG000CZX7N1,New Strong Buy Stocks for October 6th,2016-10-06 15:48:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/atjqRWyBcUY/new-strong-buy-stocks-for-october-6th-cm689889,Here are 5 stocks added to the Zacks Rank 1 Strong Buy List today Activision Blizzard Inc ATVI This developer and seller of interactive software products and content has seen the Zacks Consensus Estimate for its current year earnings increasing 0 5 over the last 60 days
BMRN,BMRN:UW,BBG000CZX7N1,New Strong Buy Stocks for October 6th,2016-10-06 12:52:12 +0000,http://finance.yahoo.com/news/strong-buy-stocks-october-6th-125212637.html,[Zacks] - New Strong Buy Stocks for October 6th
BMRN,BMRN:UW,BBG000CZX7N1,"Why Sarepta's Licensing Deal Makes This Drug Maker An ""Even More Attractive M&A Candidate""",2016-10-04 15:34:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/04/why-sareptas-licensing-deal-makes-this-drug-maker-an-even-more-attractive-ma-candidate/?mod=yahoobarrons&ru=yahoo,"Why Sarepta's Licensing Deal Makes This Drug Maker An ""Even More Attractive M&A Candidate"""
BMRN,BMRN:UW,BBG000CZX7N1,Is Sarepta Therapeutics Still a Risky Bet?,2016-10-02 15:43:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ItrrUrl8ZXU/is-sarepta-therapeutics-still-a-risky-bet-cm687528,IMAGE SOURCE GETTY IMAGES Snag a much needed Food and Drug Administration approval Check Increase the company s market cap by over 120 in a matter of days Check Sarepta Therapeutics NASDAQ SRPT managed to do both thanks to a stunning regulatory win for Duchenne
BMRN,BMRN:UW,BBG000CZX7N1,Is Sarepta Therapeutics Still a Risky Bet?,2016-10-02 13:57:16 +0000,http://www.fool.com/investing/2016/10/02/is-sarepta-therapeutics-still-a-risky-bet.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Sarepta Therapeutics Still a Risky Bet?
BMRN,BMRN:UW,BBG000CZX7N1,What Do Analysts Say about Regeneron’s Upside Potential?,2016-09-30 14:05:05 +0000,http://marketrealist.com/2016/09/what-do-analysts-say-about-regenerons-upside-potential/?utm_source=yahoo&utm_medium=feed,What Do Analysts Say about Regeneron’s Upside Potential?
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : September 30, 2016",2016-09-30 12:30:32 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-bmrn-us-september-30-2016/,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : September 30, 2016"
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta's Costly Muscular Dystrophy Drug Flirts With Big Pharma M&A,2016-09-28 20:21:03 +0000,http://www.investors.com/news/technology/sareptas-costly-muscular-dystrophy-drug-flirts-with-big-pharma-ma/,Sarepta's Costly Muscular Dystrophy Drug Flirts With Big Pharma M&A
BMRN,BMRN:UW,BBG000CZX7N1,Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc,2016-09-28 18:22:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S_91qTkPFRY/better-buy-biomarin-pharmaceuticals-inc-vs-sarepta-therapeutics-inc-cm686133,Image source Getty Investing in the biotech industry is risky business The majority of companies from the sector operate at a loss for years on end in the hope that they will eventually create a blockbuster drug That formula that works great when everything goes according to plan
BMRN,BMRN:UW,BBG000CZX7N1,Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc,2016-09-28 16:21:00 +0000,http://www.fool.com/investing/2016/09/28/better-buy-biomarin-pharmaceuticals-inc-vs-sarepta.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc
BMRN,BMRN:UW,BBG000CZX7N1,What’s the Upward Return Potential for BioMarin?,2016-09-28 14:04:58 +0000,http://marketrealist.com/2016/09/whats-the-upward-return-potential-for-biomarin/?utm_source=yahoo&utm_medium=feed,What’s the Upward Return Potential for BioMarin?
BMRN,BMRN:UW,BBG000CZX7N1,What’s the Word on Street for Vertex?,2016-09-28 14:04:36 +0000,http://marketrealist.com/2016/09/whats-the-word-on-street-for-vertex/?utm_source=yahoo&utm_medium=feed,What’s the Word on Street for Vertex?
BMRN,BMRN:UW,BBG000CZX7N1,"Sarepta: 'Yes, We're Aware Our Price Target is $50 Higher Than the Current Price'",2016-09-28 14:04:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/28/sarepta-yes-were-aware-our-price-target-is-50-higher-than-the-current-price/?mod=yahoobarrons&ru=yahoo,"Sarepta: 'Yes, We're Aware Our Price Target is $50 Higher Than the Current Price'"
BMRN,BMRN:UW,BBG000CZX7N1,A Look at BioMarin’s Early Stage Pipeline,2016-09-28 12:05:33 +0000,http://marketrealist.com/2016/09/a-look-at-biomarins-early-stage-pipeline/?utm_source=yahoo&utm_medium=feed,A Look at BioMarin’s Early Stage Pipeline
BMRN,BMRN:UW,BBG000CZX7N1,How Promising is BioMarin’s Late-Stage Pipeline?,2016-09-27 21:04:07 +0000,http://marketrealist.com/2016/09/how-promising-is-biomarins-late-stage-pipeline/?utm_source=yahoo&utm_medium=feed,How Promising is BioMarin’s Late-Stage Pipeline?
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin to Cross $1 Billion Revenue in 2016,2016-09-27 20:05:02 +0000,http://marketrealist.com/2016/09/biomarin-to-cross-1-billion-revenue-in-2016/?utm_source=yahoo&utm_medium=feed,BioMarin to Cross $1 Billion Revenue in 2016
BMRN,BMRN:UW,BBG000CZX7N1,What Are BioMarin’s Valuation Drivers?,2016-09-27 17:48:10 +0000,http://marketrealist.com/2016/09/what-are-biomarins-valuation-drivers/?utm_source=yahoo&utm_medium=feed,What Are BioMarin’s Valuation Drivers?
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Takes Aim at Rival Sarepta (BMRN, SRPT)",2016-09-26 16:43:00 +0000,http://www.investopedia.com/news/biomarin-takes-aim-rival-sarepta-bmrn-srpt/?partner=YahooSA,"BioMarin Takes Aim at Rival Sarepta (BMRN, SRPT)"
BMRN,BMRN:UW,BBG000CZX7N1,"Nasdaq 100 Movers: ALXN, BMRN",2016-09-23 16:22:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mUMPezSm8nU/nasdaq-100-movers-alxn-bmrn-cm683814,In early trading on Friday shares of BioMarin Pharmaceutical BMRN topped the list of the day s best performing components of the Nasdaq 100 index trading up 1 7 Year to date BioMarin Pharmaceutical has lost about 5 4 of its value And the worst performing Nasdaq 100 component
BMRN,BMRN:UW,BBG000CZX7N1,"Nasdaq 100 Movers: BMRN, BBBY",2016-09-22 16:22:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fT84dDUtiW8/nasdaq-100-movers-bmrn-bbby-cm683221,In early trading on Thursday shares of Bed Bath amp Beyond topped the list of the day s best performing components of the Nasdaq 100 index trading up 3 5 Year to date Bed Bath amp Beyond has lost about 7 6 of its value And the worst performing Nasdaq 100 component thus far on
BMRN,BMRN:UW,BBG000CZX7N1,Blue Jay Capital Betting On Big Returns From These Healthcare Stocks,2016-09-22 14:52:13 +0000,http://www.insidermonkey.com/blog/blue-jay-capital-betting-on-big-returns-from-these-healthcare-stocks-475956/,Blue Jay Capital Betting On Big Returns From These Healthcare Stocks
BMRN,BMRN:UW,BBG000CZX7N1,"BMRN To Seek Review Of PTAB Ruling, CERC Awaits Phase 2 Data In Nov, OCRX Abuzz",2016-09-22 00:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kl_-7N_Yiuk/bmrn-to-seek-review-of-ptab-ruling-cerc-awaits-phase-2-data-in-nov-ocrx-abuzz-20160922-00007,"BMRN To Seek Review Of PTAB Ruling, CERC Awaits Phase 2 Data In Nov, OCRX Abuzz"
BMRN,BMRN:UW,BBG000CZX7N1,"Sarepta (SRPT) Stock Lower, BioMarin to Appeal Patent Ruling",2016-09-21 18:56:00 +0000,https://www.thestreet.com/story/13747880/1/sarepta-srpt-stock-lower-biomarin-to-appeal-patent-ruling.html?puc=yahoo&cm_ven=YAHOO,"Sarepta (SRPT) Stock Lower, BioMarin to Appeal Patent Ruling"
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta to Sell Up to $225 Million of Stock,2016-09-21 18:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hLtJ-7DErmo/sarepta-to-sell-up-to-225-million-of-stock-20160921-01016,Sarepta to Sell Up to $225 Million of Stock
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta Therapeutics: BioMarin Still Wants a Piece of the Action,2016-09-21 17:34:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/21/sarepta-therapeutics-biomarin-still-wants-a-piece-of-the-action/?mod=yahoobarrons&ru=yahoo,Sarepta Therapeutics: BioMarin Still Wants a Piece of the Action
BMRN,BMRN:UW,BBG000CZX7N1,Patent Trial And Appeal Board Hands Sarepta Another Big Win,2016-09-21 15:50:39 +0000,http://finance.yahoo.com/news/patent-trial-appeal-board-hands-155039798.html,Patent Trial And Appeal Board Hands Sarepta Another Big Win
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics,2016-09-21 13:11:04 +0000,http://www.publicnow.com/view/64418BE782BC9DE70CAE546F4635ACE0D2786872,"[at noodls] - September 21, 2016 BioMarin to Seek Review of Ruling in Composition of Matter Patent Interference (No. 106,008) Patent Trial and Appeal Board Ruled in BioMarin's Favor on Method of Use (MOU) Patent Interference ..."
BMRN,BMRN:UW,BBG000CZX7N1,"MSTX Crashes On EPIC Data, MIRN Ditches MRX34, More Good News From SRPT",2016-09-21 02:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AYXMV9I-zTU/mstx-crashes-on-epic-data-mirn-ditches-mrx34-more-good-news-from-srpt-20160921-00036,"MSTX Crashes On EPIC Data, MIRN Ditches MRX34, More Good News From SRPT"
BMRN,BMRN:UW,BBG000CZX7N1,[$$] Sarepta Soars 100% in a Week Yet Remains a Buy,2016-09-20 19:12:00 +0000,http://www.barrons.com/articles/sarepta-soars-100-in-a-week-yet-remains-a-buy-1474398772?mod=yahoobarrons&ru=yahoo,[$$] Sarepta Soars 100% in a Week Yet Remains a Buy
BMRN,BMRN:UW,BBG000CZX7N1,Does Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy?,2016-09-20 18:17:07 +0000,http://www.fool.com/investing/2016/09/20/does-sarepta-therapeuticss-fda-win-make-shares-a-b.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Does Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy?
BMRN,BMRN:UW,BBG000CZX7N1,Does Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy?,2016-09-20 17:22:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CVUJmQzjO2s/does-sarepta-therapeutics-incs-fda-win-make-shares-a-buy-cm682141,Image source Getty Images It s been a long 160 and winding road for investors in Sarepta Therapeutics NASDAQ SRPT but shareholders who stuck with the company through thick and thin finally have been rewarded for their patience In a move that stunned the markets the Food
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug,2016-09-20 16:25:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ftq01yLcFy4/sarepta-stock-nearly-doubles-on-fda-approval-for-dmd-drug-cm682077,Shares of Sarepta Therapeutics Inc SRPT shot up 73 9 on Monday after the company announced that it has received accelerated approval for its Duchenne muscular dystrophy DMD drug Exondys 51 eteplirsen in the U S Sarepta s shares hit a new 52 week high of 56 18 on Monday
BMRN,BMRN:UW,BBG000CZX7N1,"Why Sarepta Approval is Good News for BioMarin, Alexion",2016-09-20 15:32:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/20/why-sarepta-approval-is-good-news-for-biomarin-alexion/?mod=yahoobarrons&ru=yahoo,"Why Sarepta Approval is Good News for BioMarin, Alexion"
BMRN,BMRN:UW,BBG000CZX7N1,Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition,2016-09-20 10:55:00 +0000,https://www.thestreet.com/story/13745109/1/biotech-stock-mailbag-sarepta-therapeutics-approval-edition.html?puc=yahoo&cm_ven=YAHOO,Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $13.1 million of Shares,2016-09-20 03:15:01 +0000,http://finance.yahoo.com/news/biomarin-pharmaceutical-inc-bmrn-ceo-031501007.html,Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $13.1 million of Shares
BMRN,BMRN:UW,BBG000CZX7N1,"ARLZ Gets FDA Nod, ACRX Scores Hat Trick, OTIC On Watch, No Relief For NVAX",2016-09-16 02:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_-b5Ef8NgOE/arlz-gets-fda-nod-acrx-scores-hat-trick-otic-on-watch-no-relief-for-nvax-20160916-00036,"ARLZ Gets FDA Nod, ACRX Scores Hat Trick, OTIC On Watch, No Relief For NVAX"
BMRN,BMRN:UW,BBG000CZX7N1,"Sarepta Therapeutics: Wait, I Thought Turmoil at the FDA Was Good News?",2016-09-15 15:49:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/15/sarepta-therapeutics-wait-i-thought-turmoil-at-the-fda-was-good-news/?mod=yahoobarrons&ru=yahoo,"Sarepta Therapeutics: Wait, I Thought Turmoil at the FDA Was Good News?"
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. – Value Analysis (NASDAQ:BMRN) : September 15, 2016",2016-09-15 15:19:24 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-value-analysis-nasdaqbmrn-september-15-2016/,"BioMarin Pharmaceutical, Inc. – Value Analysis (NASDAQ:BMRN) : September 15, 2016"
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease",2016-09-15 12:48:01 +0000,http://www.publicnow.com/view/15C457168805E67A0B0C1475A4E7E3445569D002,"[at noodls] - September 15, 2016 CHMP Opinion and EU Decision Expected Q3 2017 SAN RAFAEL, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the European Medicines ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Reports EMA Validation Of Brineura MAA For Treatment Of CLN2 Disease,2016-09-15 08:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nkg4ca83iTc/biomarin-reports-ema-validation-of-brineura-maa-for-treatment-of-cln2-disease-20160915-00466,BioMarin Reports EMA Validation Of Brineura MAA For Treatment Of CLN2 Disease
BMRN,BMRN:UW,BBG000CZX7N1,SunTrust On Sarepta Therapeutics: FDA Likely To Deny Approval For Eteplirsen,2016-09-14 19:27:53 +0000,http://finance.yahoo.com/news/suntrust-sarepta-therapeutics-fda-likely-192753383.html,SunTrust On Sarepta Therapeutics: FDA Likely To Deny Approval For Eteplirsen
BMRN,BMRN:UW,BBG000CZX7N1,[$$] Sarepta Rally Has Legs as FDA Critic Leaves Agency,2016-09-14 17:59:00 +0000,http://www.barrons.com/articles/sarepta-rally-has-legs-as-fda-critic-leaves-agency-1473874326?mod=yahoobarrons&ru=yahoo,[$$] Sarepta Rally Has Legs as FDA Critic Leaves Agency
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : September 14, 2016",2016-09-14 12:50:09 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-bmrn-us-september-14-2016/,"BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : September 14, 2016"
BMRN,BMRN:UW,BBG000CZX7N1,These 5 Biotech Stocks Are Ready for a Volatility Break,2016-09-14 10:17:00 +0000,https://www.thestreet.com/story/13727901/1/these-5-biotech-stocks-are-ready-for-a-volatility-break.html?puc=yahoo&cm_ven=YAHOO,These 5 Biotech Stocks Are Ready for a Volatility Break
BMRN,BMRN:UW,BBG000CZX7N1,Low Valuation Ratios Lead to Strong Portfolio Returns,2016-09-13 20:48:34 +0000,http://finance.yahoo.com/news/low-valuation-ratios-lead-strong-204834828.html,Low Valuation Ratios Lead to Strong Portfolio Returns
BMRN,BMRN:UW,BBG000CZX7N1,"2 Biotech Stocks that Turned $8,000 into over $250,000",2016-09-12 15:34:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1NmDSjtia4Y/2-biotech-stocks-that-turned-8000-into-over-250000-cm677955,Image source Getty Images Investing in small biotech stocks is terribly risky but once in a while a few stocks produce astounding gains An 8 000 investment in AxoGen NASDAQ AXGN 160 10 years ago for example would be worth about 258 400 today The biggest long
BMRN,BMRN:UW,BBG000CZX7N1,"Notable ETF Outflow Detected - PBE, INCY, BMRN, REGN",2016-09-08 16:18:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T6_o810aC6k/notable-etf-outflow-detected-pbe-incy-bmrn-regn-cm676274,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the PowerShares Dynamic Biotechnology amp Genome Portfolio Symbol PBE where we have detected an approximate 35 1 million dollar outflow that s a 12 0
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces Two Oral and 16 Poster Presentations at Society for the Study of Inborn Errors of Metabolism 2016 Annual Meeting,2016-09-08 08:49:02 +0000,http://www.publicnow.com/view/1A212A796FD3B1045C9D701ACFD55333522911F4,"[at noodls] - September 8, 2016 Oral Presentations Include Updated Long-Term Data from Extension Study of Brineura™ (Cerliponase Alfa) in Children with CLN2 Disease, and Long-Term Safety and Efficacy Data of Pegvaliase ..."
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharmaceutical To Participate In Robert W. Baird Conference At 9:40 AM,2016-09-08 08:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FsEEiKkoDDI/biomarin-pharmaceutical-to-participate-in-robert-w-baird-conference-at-940-am-20160908-00493,Biomarin Pharmaceutical To Participate In Robert W. Baird Conference At 9:40 AM
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin's (BMRN) Brineura Review Period Extended by FDA,2016-09-07 17:18:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yG2wX5Rm2T4/biomarins-bmrn-brineura-review-period-extended-by-fda-cm675724,BioMarin Pharmaceutical Inc BMRN announced that the FDA has extended the review period of its biologics license application BLA for Brineura cerliponase alfa by three months The company is looking to get Brineura approved for the treatment of children with CLN2 disease a form of
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical Inc. (BMRN)’s Setback Isn’t Really A Setback,2016-09-07 15:26:26 +0000,http://www.insidermonkey.com/blog/biomarin-pharmaceutical-inc-bmrns-setback-isnt-really-a-setback-472816/,BioMarin Pharmaceutical Inc. (BMRN)’s Setback Isn’t Really A Setback
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled",2016-09-07 15:21:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oik0MnvC884/biotech-stock-roundup-colucid-soars-on-migraine-data-dynavax-drug-fda-panel-meeting-cancelled-cm675560,It was a relatively slow week for the biotech sector though companies like CoLucid CLCD and Dynavax DVAX came out with important pipeline updates Recap of the Week s Most Important Stories CoLucid Hits 52 Week High on Positive Migraine Data CoLucid s shares shot up 123 6
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin's (BMRN) Brineura Review Period Extended by FDA,2016-09-07 14:58:02 +0000,http://finance.yahoo.com/news/biomarins-bmrn-brineura-review-period-145802573.html,BioMarin's (BMRN) Brineura Review Period Extended by FDA
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled",2016-09-07 13:30:01 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-colucid-soars-133001542.html,"Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled"
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharma. To Present At Citi's Biotech Conference; Webcast At 1:00 PM ET,2016-09-07 12:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tNiQZ6x-HIM/biomarin-pharma-to-present-at-citis-biotech-conference-webcast-at-100-pm-et-20160907-00931,Biomarin Pharma. To Present At Citi's Biotech Conference; Webcast At 1:00 PM ET
BMRN,BMRN:UW,BBG000CZX7N1,"CERC Data Due Dec., SAMURAI Brings Cheer To CLCD, TNXP Slumps As Study Fails",2016-09-07 02:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GVbsP55jeVQ/cerc-data-due-dec-samurai-brings-cheer-to-clcd-tnxp-slumps-as-study-fails-20160907-00032,"CERC Data Due Dec., SAMURAI Brings Cheer To CLCD, TNXP Slumps As Study Fails"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Updates On Brineura Program For Treatment Of CLN2 Disease,2016-09-06 23:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_LrRZqIk4W8/biomarin-updates-on-brineura-program-for-treatment-of-cln2-disease-20160906-01412,BioMarin Updates On Brineura Program For Treatment Of CLN2 Disease
BMRN,BMRN:UW,BBG000CZX7N1,"After-hours buzz: CMG, PLAY, AMD & more",2016-09-06 21:30:51 +0000,http://www.cnbc.com/id/103918126?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103918126,"After-hours buzz: CMG, PLAY, AMD & more"
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Announces Update to Brineura™ (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten Disease",2016-09-06 20:19:01 +0000,http://www.publicnow.com/view/65175C2A7D387AB805D9ED38FFF607E6DC3C35BA,"[at noodls] - September 6, 2016 Additional Data Submitted to BLA following FDA Request, PDUFA Action Date Extended to April 27, 2017 Additional 8 Months of Treatment (81-Week Data) Show Maintenance of Efficacy, Consistent ..."
BMRN,BMRN:UW,BBG000CZX7N1,Biotech Stocks: Look At Those Takeover Premiums!,2016-09-01 17:53:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/01/biotech-stocks-look-at-those-takeover-premiums/?mod=yahoobarrons&ru=yahoo,Biotech Stocks: Look At Those Takeover Premiums!
BMRN,BMRN:UW,BBG000CZX7N1,Biotech: In Unfamiliar Territory?,2016-08-31 14:24:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/31/biotech-in-unfamiliar-territory/?mod=yahoobarrons&ru=yahoo,Biotech: In Unfamiliar Territory?
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin to Attend Upcoming Investor Conferences,2016-08-31 13:03:01 +0000,http://www.publicnow.com/view/898E30CEFAEC430EEB4A613FD00F2D8D1ED48CC7,"[at noodls] - August 31, 2016 Citi's 11th Annual Biotech Conference September 7 in Boston Robert W. Baird & Co. 2016 Global Healthcare Conference September 8 in New York Leerink Partners Roundtable Series: Rare Disease ..."
BMRN,BMRN:UW,BBG000CZX7N1,3 Biotech Stocks Could Be the Next Big Takeover Targets,2016-08-31 12:20:37 +0000,http://247wallst.com/healthcare-business/2016/08/31/3-biotech-stocks-could-be-the-next-big-takeover-targets/,3 Biotech Stocks Could Be the Next Big Takeover Targets
BMRN,BMRN:UW,BBG000CZX7N1,What Do Analysts Think about BioMarin’s Return Potential?,2016-08-26 15:06:30 +0000,http://marketrealist.com/2016/08/analysts-think-biomarins-return-potential/?utm_source=yahoo&utm_medium=feed,What Do Analysts Think about BioMarin’s Return Potential?
BMRN,BMRN:UW,BBG000CZX7N1,What Should We Expect from BioMarin’s Kuvan in 2016?,2016-08-26 14:05:05 +0000,http://marketrealist.com/2016/08/expect-biomarins-kuvan-2016/?utm_source=yahoo&utm_medium=feed,What Should We Expect from BioMarin’s Kuvan in 2016?
BMRN,BMRN:UW,BBG000CZX7N1,How Much Did BioMarin’s Lead Drug Vimizim Earn in 1H16?,2016-08-26 12:04:55 +0000,http://marketrealist.com/2016/08/much-biomarins-lead-drug-vimizim-earn-1h16/?utm_source=yahoo&utm_medium=feed,How Much Did BioMarin’s Lead Drug Vimizim Earn in 1H16?
BMRN,BMRN:UW,BBG000CZX7N1,What’s BioMarin’s Expected Revenue Growth in 2016 and 2017?,2016-08-25 17:04:05 +0000,http://marketrealist.com/2016/08/whats-biomarins-expected-revenue-growth-2016-2017/?utm_source=yahoo&utm_medium=feed,What’s BioMarin’s Expected Revenue Growth in 2016 and 2017?
BMRN,BMRN:UW,BBG000CZX7N1,Why Roche Might Be Interested in BioMarin,2016-08-25 16:04:30 +0000,http://marketrealist.com/2016/08/roche-might-interested-biomarin/?utm_source=yahoo&utm_medium=feed,Why Roche Might Be Interested in BioMarin
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin’s Valuation on a Price-to-Sales Basis: Does It Matter?,2016-08-25 14:00:31 +0000,http://marketrealist.com/2016/08/biomarins-valuation-price-sales-basis-matter/?utm_source=yahoo&utm_medium=feed,BioMarin’s Valuation on a Price-to-Sales Basis: Does It Matter?
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stocks: Oops, She Did It Again",2016-08-25 13:38:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/25/biotech-stocks-oops-she-did-it-again/?mod=yahoobarrons&ru=yahoo,"Biotech Stocks: Oops, She Did It Again"
BMRN,BMRN:UW,BBG000CZX7N1,[$$] Smaller Biotech Buyout Targets After Medivation,2016-08-24 15:17:00 +0000,http://www.barrons.com/articles/smaller-biotech-buyout-targets-after-medivation-1472051871?mod=yahoobarrons&ru=yahoo,[$$] Smaller Biotech Buyout Targets After Medivation
BMRN,BMRN:UW,BBG000CZX7N1,Forbes Ranks BioMarin 10th Most Innovative Company in the World,2016-08-24 13:54:14 +0000,http://finance.yahoo.com/news/forbes-ranks-biomarin-10th-most-135414506.html,"[GlobeNewswire] - SAN RAFAEL, Calif., Aug. 24, 2016-- BioMarin Pharmaceutical Inc. announced today that it has been ranked 10th on Forbes magazine's 2016 list of the ""World's Most Innovative Companies."" This is ..."
BMRN,BMRN:UW,BBG000CZX7N1,"4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss",2016-08-23 13:44:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/23/4-biotech-buyout-targets-for-gilead-sanofi-after-medivation-miss/?mod=yahoobarrons&ru=yahoo,"4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss"
BMRN,BMRN:UW,BBG000CZX7N1,The $150 million winner — and the losers — in Pfizer's $14 billion takeout of Medivation,2016-08-23 03:05:11 +0000,http://www.bizjournals.com/sanfrancisco/blog/biotech/2016/08/medivation-pfizer-mdvn-pfe-winners-losers.html?ana=yahoo,The $150 million winner — and the losers — in Pfizer's $14 billion takeout of Medivation
BMRN,BMRN:UW,BBG000CZX7N1,"Why Syngenta, Valeant Pharmaceuticals, and BioMarin Pharmaceutical Jumped Today",2016-08-22 23:44:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pRGymE6JKDE/why-syngenta-valeant-pharmaceuticals-and-biomarin-pharmaceutical-jumped-today-cm668741,"Image source  Syngenta.  Monday was a generally quiet day for the stock market, and the Dow and S&P 500 both posted very slight declines of around a tenth of a percent each. In"
BMRN,BMRN:UW,BBG000CZX7N1,"Why Syngenta, Valeant Pharmaceuticals, and BioMarin Pharmaceutical Jumped Today",2016-08-22 21:57:00 +0000,http://www.fool.com/investing/2016/08/22/why-syngenta-valeant-pharmaceuticals-and-biomari-2.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Syngenta, Valeant Pharmaceuticals, and BioMarin Pharmaceutical Jumped Today"
BMRN,BMRN:UW,BBG000CZX7N1,Biotech's next big deal?,2016-08-22 21:25:00 +0000,http://finance.yahoo.com/video/biotechs-next-big-deal-212500006.html,Biotech's next big deal?
BMRN,BMRN:UW,BBG000CZX7N1,Betting on BioMarin,2016-08-22 18:43:40 +0000,http://www.bloomberg.com/gadfly/articles/2016-08-22/for-sanofi-biomarin-comes-up-short-as-medivation-substitute?cmpid=yhoo.headline,Betting on BioMarin
BMRN,BMRN:UW,BBG000CZX7N1,Biotechs Rise on Bet Medivation Losers Will Look to Next Deal,2016-08-22 17:14:52 +0000,http://finance.yahoo.com/news/biotechs-rise-bet-medivation-losers-171452706.html,Biotechs Rise on Bet Medivation Losers Will Look to Next Deal
BMRN,BMRN:UW,BBG000CZX7N1,Biotech stocks rally as investors bet on the next big tie-up,2016-08-22 15:57:44 +0000,http://www.cnbc.com/id/103884606?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103884606,Biotech stocks rally as investors bet on the next big tie-up
BMRN,BMRN:UW,BBG000CZX7N1,"Nasdaq 100 Movers: VIAB, INCY",2016-08-22 15:43:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VKjnAsmpBQM/nasdaq-100-movers-viab-incy-cm668408,"In early trading on Monday, shares of Incyte topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.9%. Year to date, Incyte has lost"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Stock Surges on Takeover Speculation,2016-08-22 15:16:00 +0000,https://www.thestreet.com/story/13681449/1/biomarin-bmrn-stock-surges-on-takeover-speculation.html?puc=yahoo&cm_ven=YAHOO,BioMarin (BMRN) Stock Surges on Takeover Speculation
BMRN,BMRN:UW,BBG000CZX7N1,Break Up Gilead Sciences? Not So Fast,2016-08-19 14:05:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/19/break-up-gilead-sciences-not-so-fast/?mod=yahoobarrons&ru=yahoo,Break Up Gilead Sciences? Not So Fast
BMRN,BMRN:UW,BBG000CZX7N1,What Are the Opportunities for Horizon in 2016?,2016-08-18 15:10:16 +0000,http://marketrealist.com/2016/08/what-are-the-opportunities-for-horizon-in-2016/?utm_source=yahoo&utm_medium=feed,What Are the Opportunities for Horizon in 2016?
BMRN,BMRN:UW,BBG000CZX7N1,We Did The Math PTH Can Go To $54,2016-08-17 21:56:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oztct2XJWoM/we-did-the-math-pth-can-go-to-54-cm666376,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
BMRN,BMRN:UW,BBG000CZX7N1,Why You Shouldn't Bet Against BioMarin Pharmaceutical (BMRN) Stock,2016-08-16 22:36:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JahBYJ4wubw/why-you-shouldnt-bet-against-biomarin-pharmaceutical-bmrn-stock-cm665991,"One stock that might be an intriguing choice for investors right now is BioMarin Pharmaceutical Inc.BMRN . This is because this security in the Medical Generic Drugs space is seeing solid earnings estimate revision activity, and is in great"
BMRN,BMRN:UW,BBG000CZX7N1,Why You Shouldn't Bet Against BioMarin Pharmaceutical (BMRN) Stock,2016-08-16 14:20:02 +0000,http://finance.yahoo.com/news/why-shouldnt-bet-against-biomarin-142002954.html,Why You Shouldn't Bet Against BioMarin Pharmaceutical (BMRN) Stock
BMRN,BMRN:UW,BBG000CZX7N1,7 Battered Biotech Stocks to Buy,2016-08-15 13:35:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gy9ryP6mR8o/7-battered-biotech-stocks-to-buy-cm665200,"Sometimes bad news is good news. A pummeling of biotechnology stocks over the past year means that gutsy investors can get in on a formerly high flying sector at discounted prices. From its peak in July 2015,"
BMRN,BMRN:UW,BBG000CZX7N1,"The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen",2016-08-13 05:37:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-3EbIvzc6kQ/the-zacks-analyst-blog-highlights-regeneron-biomarin-abbvie-amgen-and-biogen-cm664678,"For Immediate Release Chicago, IL August 12, 2016 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks"
BMRN,BMRN:UW,BBG000CZX7N1,"The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen",2016-08-12 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-regeneron-133001795.html,"The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen"
BMRN,BMRN:UW,BBG000CZX7N1,How to Play a Nasdaq Breakout,2016-08-12 12:53:00 +0000,http://finance.yahoo.com/video/play-nasdaq-breakout-125300808.html,How to Play a Nasdaq Breakout
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat",2016-08-11 23:49:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D0r-_VK3Z-I/biotech-stock-roundup-earnings-in-focus-abbvie-takes-steps-to-block-humira-copycat-cm664385,"Several small and mid sized as well as big biotech companies like Regeneron REGN and BioMarin BMRN reported second quarter results last week. Meanwhile, among other major updates, AbbVie ABBV filed a patent infringement lawsuit against Amgen AMGN ."
BMRN,BMRN:UW,BBG000CZX7N1,"Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat",2016-08-11 21:30:09 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-earnings-focus-213009456.html,"Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat"
BMRN,BMRN:UW,BBG000CZX7N1,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S",2016-08-11 21:02:06 +0000,http://biz.yahoo.com/e/160811/bmrn8-k.html,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S"
BMRN,BMRN:UW,BBG000CZX7N1,"Solid BioMarin Pharmaceutical Inc. Earnings, More to Come",2016-08-10 21:52:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gRGHLvGJnEI/solid-biomarin-pharmaceutical-inc-earnings-more-to-come-cm663704,"Image source  Getty Images.  BioMarin Pharmaceuticals (NASDAQ  BMRN) reported second quarter earnings last week. While the biotech's current drugs are still growing at a nice pace, it's BioMarin's pipeline, including two drugs"
BMRN,BMRN:UW,BBG000CZX7N1,"Solid BioMarin Pharmaceutical Inc. Earnings, More to Come",2016-08-10 20:00:00 +0000,http://www.fool.com/investing/2016/08/10/solid-biomarin-pharmaceutical-inc-earnings-more-to.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Solid BioMarin Pharmaceutical Inc. Earnings, More to Come"
BMRN,BMRN:UW,BBG000CZX7N1,"Why Wayfair Inc (W), BioMarin Pharmaceutical Inc. (BMRN) and Norwegian Cruise Line Holdings Ltd (NCLH) Are 3 of Today’s Worst Stocks",2016-08-10 03:52:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9AHSI7gxPg4/why-wayfair-inc-w-biomarin-pharmaceutical-inc-bmrn-and-norwegian-cruise-line-holdings-ltd-nclh-are-3-of-todays-worst-stocks-cm662962,"It was another wishy washy day for stocks, with traders still hungry for some sort of news catalyst that will get them off the fence."
BMRN,BMRN:UW,BBG000CZX7N1,"Health Care Sector Update for 08/09/2016: IPXL,HIIQ,BMRN",2016-08-09 20:09:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XmRvIpwZ9Vk/health-care-sector-update-for-08092016-ipxlhiiqbmrn-cm662833,"Top Health Care Stocks JNJ 0.24% PFE +0.57% MRK +0.09% ABT 0.55% AMGN 0.21% Health care stocks rose during Tuesday trade, with the NYSE Health Care Index jumping out to a 0.4% gain while shares of health care companies"
BMRN,BMRN:UW,BBG000CZX7N1,"ETF’s with exposure to BioMarin Pharmaceutical, Inc. : August 9, 2016",2016-08-09 17:21:26 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-biomarin-pharmaceutical-inc-august-9-2016/,"ETF’s with exposure to BioMarin Pharmaceutical, Inc. : August 9, 2016"
BMRN,BMRN:UW,BBG000CZX7N1,"Health Care Sector Update for 08/09/2016: NVRO,HIIQ,BMRN",2016-08-09 17:08:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xZfZ_6KlWos/health-care-sector-update-for-08092016-nvrohiiqbmrn-cm662653,"Top Health Care Stocks JNJ 0.09% PFE +0.63% MRK +0.09% ABT 0.11% AMGN +0.03% Health care stocks were climbing during Tuesday trade, with the NYSE Health Care Index jumping out to a 0.4% gain and shares of health care"
BMRN,BMRN:UW,BBG000CZX7N1,"Nasdaq 100 Movers: NCLH, MCHP",2016-08-09 15:32:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aQsXzcs0eBU/nasdaq-100-movers-nclh-mchp-cm662497,"In early trading on Tuesday, shares of Microchip Technology ( MCHP ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 7.1%. Year to date, Microchip Technology registers a 30.4% gain. And"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces Pricing of Public Offering of Common Stock,2016-08-09 13:40:02 +0000,http://www.publicnow.com/view/23F5C54341BB23B9B6E9E478D2BC6609B2D5D19D,"[at noodls] - August 9, 2016 SAN RAFAEL, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing of an underwritten public offering of 7,500,000 shares of its ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin (BMRN) Stock Tumbles in After-Hours Trading on Public Offering,2016-08-08 20:52:00 +0000,https://www.thestreet.com/story/13668643/1/biomarin-bmrn-stock-tumbles-in-after-hours-trading-on-public-offering.html?puc=yahoo&cm_ven=YAHOO,BioMarin (BMRN) Stock Tumbles in After-Hours Trading on Public Offering
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces Public Offering of Common Stock,2016-08-08 20:49:12 +0000,http://www.publicnow.com/view/26BBEE6F6206CBB047BCB8F76AD7189542DD0CE5,"[at noodls] - August 8, 2016 SAN RAFAEL, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 7,500,000 shares ..."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016",2016-08-08 15:26:12 +0000,http://www.capitalcube.com/blog/index.php/biomarin-pharmaceutical-inc-bmrn-us-earnings-analysis-q2-2016-by-the-numbers-august-8-2016/,"BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016"
BMRN,BMRN:UW,BBG000CZX7N1,"BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report",2016-08-08 13:33:11 +0000,http://biz.yahoo.com/e/160808/bmrn10-q.html,"BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report"
BMRN,BMRN:UW,BBG000CZX7N1,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Financial Statements and Exhibits",2016-08-08 13:31:59 +0000,http://biz.yahoo.com/e/160808/bmrn8-k_a.html,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Financial Statements and Exhibits"
BMRN,BMRN:UW,BBG000CZX7N1,Why BioMarin Pharmaceutical Inc. Stock Rose 22.2% in July,2016-08-07 04:15:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZTGbwyFSJPs/why-biomarin-pharmaceutical-inc-stock-rose-222-in-july-cm661463,"Image source  Getty Images.  What  Shares of BioMarin Pharmaceutical Inc. (NASDAQ  BMRN) , a biopharmaceutical company focused on diseases with unmet need, gained 22.2% in July, according to data from S&P"
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin (BMRN) Posts Narrower Q2 Loss, Sales View Upped",2016-08-05 19:25:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/35bgjL9Sozs/biomarin-bmrn-posts-narrower-q2-loss-sales-view-upped-cm661280,"BioMarin Pharmaceutical Inc.BMRN reported a loss of 11 cents per share in the second quarter of 2016 (including stock based compensation expense), substantially narrower than the Zacks Consensus Estimate of a loss of 50 cents. The reported figure was"
BMRN,BMRN:UW,BBG000CZX7N1,"Merck KGaA (MKGAF) Q2 Earnings Fall, Guides Up on Sales",2016-08-05 15:38:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BFQxeTe97_8/merck-kgaa-mkgaf-q2-earnings-fall-guides-up-on-sales-cm661140,"Merck KGaAMKGAF reported second quarter 2016 earnings of 80 cents per American Depositary Share, lower than the year ago tally of 90 cents. Meanwhile, net sales in the reported quarter came in at $4.3 billion (€3.8 billion), up 20.7%."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin (BMRN) Posts Narrower Q2 Loss, Sales View Upped",2016-08-05 15:34:03 +0000,http://finance.yahoo.com/news/biomarin-bmrn-posts-narrower-q2-153403625.html,"BioMarin (BMRN) Posts Narrower Q2 Loss, Sales View Upped"
BMRN,BMRN:UW,BBG000CZX7N1,Edited Transcript of BMRN earnings conference call or presentation 4-Aug-16 8:30pm GMT,2016-08-05 01:49:34 +0000,http://finance.yahoo.com/news/edited-transcript-bmrn-earnings-conference-014934860.html,Edited Transcript of BMRN earnings conference call or presentation 4-Aug-16 8:30pm GMT
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin reports 2Q loss,2016-08-04 20:47:43 +0000,http://sg.finance.yahoo.com/news/biomarin-reports-2q-loss-204743925.html,BioMarin reports 2Q loss
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces Second Quarter 2016 Financial Results,2016-08-04 20:22:09 +0000,http://www.publicnow.com/view/21B26815FCEF8A12513BEB908D0F002E8CDB8E3A,"[at noodls] - August 4, 2016 - Second Quarter 2016 Total BioMarin Revenue Increases 20.0% Y/Y to $300.1 million Vimizim Net Product Revenue Increases 98.1% Y/Y and Contributes $106.8 million in the Second Quarter 2016; ..."
BMRN,BMRN:UW,BBG000CZX7N1,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a",2016-08-04 20:18:02 +0000,http://biz.yahoo.com/e/160804/bmrn8-k.html,"BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a"
BMRN,BMRN:UW,BBG000CZX7N1,"Earnings Reaction History: BioMarin Pharmaceutical, 50.0% Follow-Through Indicator, 3.1% Sensitive",2016-08-04 18:55:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G3Aw_dh0uJY/earnings-reaction-history-biomarin-pharmaceutical-500-follow-through-indicator-31-sensitive-cm660665,"Expected Earnings Release 08 04 2016, After hours Avg. Extended Hours Dollar Volume $7,880,733 BioMarin Pharmaceutical ( BMRN ) is due to issue its quarterly earnings report in the upcoming extended hours session. Given its history, traders can expect"
BMRN,BMRN:UW,BBG000CZX7N1,"After-Hours Earnings Report for August 4, 2016 :  KHC, PCLN, ATVI, ED, LNKD, BMRN, MHK, FLT, SYMC, MSI, FRT, LBTYA",2016-08-04 18:54:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IavBxegbAF0/after-hours-earnings-report-for-august-4-2016-khc-pcln-atvi-ed-lnkd-bmrn-mhk-flt-symc-msi-frt-lbtya-cm660615,The following companies are expected to report earnings after hours on 08 04 2016. Visit our Earnings Calendar for a full list of expected earnings releases.  The Kraft Heinz Company ( KHC ) is reporting for
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharmaceutical Q2 16 Earnings Conference Call At 4:30 PM ET,2016-08-04 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HgPg8P_IoMg/biomarin-pharmaceutical-q2-16-earnings-conference-call-at-430-pm-et-20160804-01131,Biomarin Pharmaceutical Q2 16 Earnings Conference Call At 4:30 PM ET
BMRN,BMRN:UW,BBG000CZX7N1,Merrill Lynch Says the Time to Put Money Into Biotech Is Now,2016-08-04 14:40:14 +0000,http://247wallst.com/healthcare-business/2016/08/04/merrill-lynch-says-the-time-to-put-money-into-biotech-is-now/,Merrill Lynch Says the Time to Put Money Into Biotech Is Now
BMRN,BMRN:UW,BBG000CZX7N1,Q2 2016 Biomarin Pharmaceutical Inc Earnings Release - Time Not Supplied,2016-08-04 11:07:02 +0000,http://biz.yahoo.com/research/earncal/20160804.html?t=bmrn,Q2 2016 Biomarin Pharmaceutical Inc Earnings Release - Time Not Supplied
BMRN,BMRN:UW,BBG000CZX7N1,Will AVEO (AVEO) Pull a Surprise This Earnings Season?,2016-08-03 23:54:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vl_2DmConHg/will-aveo-aveo-pull-a-surprise-this-earnings-season-cm660041,"AVEO Pharmaceuticals, Inc.AVEO is expected to report second quarter 2016 results on Aug 8. AVEO has an impressive track record over the last four reported quarters. While the company has beaten estimates on three occasions, it met expectations in"
BMRN,BMRN:UW,BBG000CZX7N1,5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More,2016-08-03 15:59:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PYcNWphP2W0/5-drug-stocks-to-watch-for-earnings-on-aug-4-bmrn-more-cm659656,"With Q2 earnings season drawing to a close, we have seen about 317 S&P 500 members (representing 73.5% of the index's total market capitalization) announce quarterly results as of Jul 29. Reported results show a 3.3% year over year"
BMRN,BMRN:UW,BBG000CZX7N1,5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More,2016-08-03 13:36:01 +0000,http://finance.yahoo.com/news/5-drug-stocks-watch-earnings-133601603.html,5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin’s Key Order-Driven Drugs: Vimizim and Naglazyme,2016-08-03 13:05:39 +0000,http://marketrealist.com/2016/07/biomarins-key-order-driven-drugs-vimizim-naglazyme/?utm_source=yahoo&utm_medium=feed,BioMarin’s Key Order-Driven Drugs: Vimizim and Naglazyme
BMRN,BMRN:UW,BBG000CZX7N1,"FDA Accepts BLA for BioMarin's Cerliponase Alfa for CLN2 Disease, Form of Batten Disease",2016-07-27 22:28:02 +0000,http://www.publicnow.com/view/894AD8AFEDF73B67EA50D81C9023E052BB5196F5,"[at noodls] - July 27, 2016 Potential First Treatment for Fatal, Rare, Brain Disease in Children FDA Grants Priority Review Status and Breakthrough Therapy Designation PDUFA Action Date is January 27, 2017 MAA Submitted ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Provides Positive Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress,2016-07-27 18:48:06 +0000,http://www.publicnow.com/view/A4D88A8C12706A4AAE421276BA2BFA6F72CA5A59,"[at noodls] - July 27, 2016 6 of 7 High Dose Patients Show Factor VIII levels above 50%, 7th patient above 10% No Clinically Relevant Sustained Rises in ALT Phase 2b Study to Begin Mid-2017 for Potential Accelerated ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pulls Back Off Best Levels But Holding On To Strong Gain,2016-07-07 13:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nBEXyjINDoI/biomarin-pulls-back-off-best-levels-but-holding-on-to-strong-gain-20160707-00809,BioMarin Pulls Back Off Best Levels But Holding On To Strong Gain
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pulls Back Off Best Levels But Holding On To Strong Gain,2016-07-07 13:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4G3g-ztm5GY/biomarin-pulls-back-off-best-levels-but-holding-on-to-strong-gain-20160707-00808,BioMarin Pulls Back Off Best Levels But Holding On To Strong Gain
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical (BMRN) Is Rising On Reports Of Roche Interest,2016-07-07 10:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tISYthROLrE/biomarin-pharmaceutical-bmrn-is-rising-on-reports-of-roche-interest-20160707-00627,BioMarin Pharmaceutical (BMRN) Is Rising On Reports Of Roche Interest
BMRN,BMRN:UW,BBG000CZX7N1,Buyout target Medivation says cancer drug could be 'best in class',2016-07-07 01:14:20 +0000,http://uk.finance.yahoo.com/news/buyout-target-medivation-says-cancer-011420113.html,Buyout target Medivation says cancer drug could be 'best in class'
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Announces Acceptance of Late Breaking Abstract for BMN 270 at the World Federation of Hemophilia (WFH) 2016 World Congress July 27 in Orlando, FL",2016-06-20 20:49:03 +0000,http://www.publicnow.com/view/AD23EC6C17DA47874A080B78BB7798B7DB93317F,"[at noodls] - SAN RAFAEL, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the upcoming oral presentation summarizing a late breaking abstract accepted for the XXXII ..."
BMRN,BMRN:UW,BBG000CZX7N1,Biomarin Pharma. To Present At Goldman Sachs Conference; Webcast At 1:00 PM ET,2016-06-09 12:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nUB7KAKbfJY/biomarin-pharma-to-present-at-goldman-sachs-conference-webcast-at-100-pm-et-20160609-00666,Biomarin Pharma. To Present At Goldman Sachs Conference; Webcast At 1:00 PM ET
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa™ (drisapersen) in Europe,2016-06-01 16:55:04 +0000,http://www.publicnow.com/view/8C229A6E10C232FE6D1276478D739CEE809AA248,"[at noodls] - SAN RAFAEL, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has withdrawn its Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) ..."
BMRN,BMRN:UW,BBG000CZX7N1,U.S. Hot Stocks: Hot Stocks to Watch,2016-06-01 09:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hMFdGLDyYGk/us-hot-stocks-hot-stocks-to-watch-20160601-00674,U.S. Hot Stocks: Hot Stocks to Watch
BMRN,BMRN:UW,BBG000CZX7N1,"BMRN Pulls The Plug On DMD Drug, LXRX To Face FDA In Nov, TEVA Snubbed",2016-06-01 03:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nh43xCMKM2E/bmrn-pulls-the-plug-on-dmd-drug-lxrx-to-face-fda-in-nov-teva-snubbed-20160601-00087,"BMRN Pulls The Plug On DMD Drug, LXRX To Face FDA In Nov, TEVA Snubbed"
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta: FDA's Decision on Dystrophy Drug Delayed,2016-05-25 09:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8pDrybpEKY4/sarepta-fdas-decision-on-dystrophy-drug-delayed-20160525-01070,Sarepta: FDA's Decision on Dystrophy Drug Delayed
BMRN,BMRN:UW,BBG000CZX7N1,Sarepta: FDA''s Decision on Dystrophy Drug Delayed,2016-05-25 09:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Aztl6yCcft8/sarepta-fdas-decision-on-dystrophy-drug-delayed-20160525-00557,Sarepta: FDA''s Decision on Dystrophy Drug Delayed
BMRN,BMRN:UW,BBG000CZX7N1,D-Day For Sarepta As FDA Decision Looms,2016-05-24 23:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SVvSCxvu21A/dday-for-sarepta-as-fda-decision-looms-20160524-01246,D-Day For Sarepta As FDA Decision Looms
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin to Attend Upcoming Investor Conferences,2016-05-04 13:00:04 +0000,http://www.publicnow.com/view/904E6F16EA15717308477FDB16CB223954061D3B,"[at noodls] - - Bank of America Merrill Lynch 2016 Health Care Conference on May 11 in Las Vegas - Goldman Sachs 37 Annual Global Healthcare Conference on June 9 in Ranchos Palos Verdes, California SAN RAFAEL, Calif., ..."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Announces EMA Grants Accelerated Assessment for Cerliponase Alfa, Experimental Treatment for a Form of Batten Disease",2016-05-03 12:40:06 +0000,http://www.publicnow.com/view/9073A4E58A36F43B9CE82265D062177C6904928B,"[at noodls] - EU and U.S. Marketing Application Submissions Planned for Mid-Year 2016 Company Seeking Priority Review in the U.S. ... This is an abstract of the original noodl. To continue reading this document, click ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin reports 1Q loss,2016-04-28 20:53:53 +0000,http://sg.finance.yahoo.com/news/biomarin-reports-1q-loss-205353968.html,BioMarin reports 1Q loss
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Announces First Quarter 2016 Financial Results,2016-04-28 20:15:37 +0000,http://www.publicnow.com/view/F3806434A9F450D1B62CC33CC46AEC7367E46EED,[at noodls] - -First Quarter 2016 Total BioMarin Revenue Increases 16.7% Y/Y to $236.7 million -Vimizim Net Product Revenue Increases 43.5% Y/Y and Contributes $72.6 million in the First Quarter 2016; Vimizim Full-year ...
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN 250 for Treatment of MPS IIIB (Sanfilippo B Syndrome),2016-04-21 20:42:08 +0000,http://www.publicnow.com/view/3736C8C4A39DB29CC00605D51F01D978B3A7C050,"[at noodls] - SAN RAFAEL, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has enrolled the first patient in a Phase 1/2 trial for BMN 250, an investigational ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Provides Program Update on Vosoritide in Achondroplasia,2016-04-20 14:51:18 +0000,http://www.publicnow.com/view/31C49FB69B0C4AF647665E3593A6D37F5A09AC93,[at noodls] - New Data Shows Durable and Consistent Effects on Mean Annualized Growth Velocity for up to 12 months with Increases of 46%-65% from Baseline Phase 3 Randomized Controlled Study Planned to Start at End ...
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program,2016-04-20 12:51:09 +0000,http://www.publicnow.com/view/B652719D2B329B061E4732767AF07B3994A42542,"[at noodls] - Two High Dose Patients Show Increasing Levels of Factor VIII Above 50% Five of Six High Dose Patients Show Factor VIII Levels Above 5% SAN RAFAEL, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing Bell,2016-04-18 14:32:07 +0000,http://www.publicnow.com/view/CD8A9893984D95E5BD94A1E8A8ED371F27AEDAE5,"[at noodls] - ADVISORY, April 18, 2016 (GLOBE NEWSWIRE) -- What: BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global biotechnology company that develops and commercializes innovative therapies for patients with serious ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on April 20th in New York,2016-04-18 12:52:16 +0000,http://www.publicnow.com/view/4DEA3B679DE2186A38BE7354AFF51F34307B904C,"[at noodls] - SAN RAFAEL, Calif., April 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will host an R&D Day from 8am (ET) to 12pm (ET) on Wednesday, April 20, 2016 in New York City. BioMarin ..."
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin to Host First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, April 28 at 4:30pm ET",2016-04-12 12:35:28 +0000,http://www.publicnow.com/view/8376915761B273A7A1E92EC85256162E54C605B1,"[at noodls] - SAN RAFAEL, Calif., April 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host ..."
BMRN,BMRN:UW,BBG000CZX7N1,US close: Stocks gain after FOMC meeting minutes,2016-04-07 08:50:00 +0000,http://uk.finance.yahoo.com/news/us-close-stocks-gain-fomc-085000098.html,US close: Stocks gain after FOMC meeting minutes
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin Receives European Orphan Drug Designation for BMN 270, First Investigational AAV-Factor VIII Gene Therapy for Patients with Hemophilia A",2016-03-24 12:38:28 +0000,http://www.publicnow.com/view/BFF6C358899C5E1C58EB6D5EFB485370C8CC06BA,"[at noodls] - SAN RAFAEL, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BMN 270, an investigational gene therapy for the treatment of hemophilia A, has been ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001),2016-03-21 10:16:17 +0000,http://www.publicnow.com/view/5BBD8E627EEB24596EF51861B266B6C8EB754FA2,"[at noodls] - In 8-week Placebo-Controlled Portion No Benefit in Inattention or Mood Scores Were Observed Approximately, 60% of Patients Maintained Phe Levels At or Below Medical Guidelines over Long-Term Extension ..."
BMRN,BMRN:UW,BBG000CZX7N1,US close: Wall Street finishes on mixed note,2016-02-29 08:40:00 +0000,http://uk.finance.yahoo.com/news/us-close-wall-street-finishes-084000203.html,US close: Wall Street finishes on mixed note
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin misses 4Q profit forecasts,2016-02-25 21:37:41 +0000,http://sg.finance.yahoo.com/news/biomarin-misses-4q-profit-forecasts-213741047.html,BioMarin misses 4Q profit forecasts
BMRN,BMRN:UW,BBG000CZX7N1,US close: Stocks slip as oil futures come under pressure,2016-02-19 08:18:00 +0000,http://uk.finance.yahoo.com/news/us-close-stocks-slip-oil-081800213.html,US close: Stocks slip as oil futures come under pressure
BMRN,BMRN:UW,BBG000CZX7N1,"BioMarin to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET",2016-01-28 13:52:20 +0000,http://www.publicnow.com/view/657F7FC79E46D27EEF2D7534423DF77139FB785D,"[at noodls] - SAN RAFAEL, Calif., Jan. 28, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host ..."
BMRN,BMRN:UW,BBG000CZX7N1,FDA Issues Complete Response Letter for KyndrisaTM for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping,2016-01-14 14:06:10 +0000,http://www.noodls.com/view/F7697010172A7821E8BBD90C0C1B05F3AAD495AC,"[at noodls] - SAN RAFAEL, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter to the ..."
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin reports 3Q loss,2015-10-29 20:46:01 +0000,http://sg.finance.yahoo.com/news/biomarin-reports-3q-loss-204601157.html,BioMarin reports 3Q loss
BMRN,BMRN:UW,BBG000CZX7N1,Nasdaq powers to new all-time high,2015-06-18 21:02:07 +0000,http://uk.finance.yahoo.com/news/nasdaq-powers-time-high-200931961.html,Nasdaq powers to new all-time high
BMRN,BMRN:UW,BBG000CZX7N1,Study for treatment for dwarfism send BioMarin stock skyward,2015-06-18 11:22:10 +0000,http://sg.finance.yahoo.com/news/study-treatment-dwarfism-send-biomarin-112210686.html,Study for treatment for dwarfism send BioMarin stock skyward
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin reports 4Q loss,2015-02-25 21:46:12 +0000,http://sg.finance.yahoo.com/news/biomarin-reports-4q-loss-214612697.html,BioMarin reports 4Q loss
BMRN,BMRN:UW,BBG000CZX7N1,US STOCKS-S&P 500 ticks up to record on central bank bets,2014-11-24 21:49:38 +0000,http://uk.finance.yahoo.com/news/us-stocks-p-500-ticks-214938585.html,US STOCKS-S&P 500 ticks up to record on central bank bets
BMRN,BMRN:UW,BBG000CZX7N1,"US STOCKS-Wall St up on central bank bets, deals support",2014-11-24 20:19:34 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-central-201934889.html,"US STOCKS-Wall St up on central bank bets, deals support"
BMRN,BMRN:UW,BBG000CZX7N1,"US STOCKS-Wall St hits new records, but telecom weighs on Dow",2014-11-24 17:34:04 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-hits-173404321.html,"US STOCKS-Wall St hits new records, but telecom weighs on Dow"
BMRN,BMRN:UW,BBG000CZX7N1,"US STOCKS-Wall St hits new records, boosted by cyclicals",2014-11-24 16:18:51 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-hits-161851504.html,"US STOCKS-Wall St hits new records, boosted by cyclicals"
BMRN,BMRN:UW,BBG000CZX7N1,"US STOCKS-Wall St surges to new records, boosted by cyclicals",2014-11-24 15:04:09 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-surges-150409846.html,"US STOCKS-Wall St surges to new records, boosted by cyclicals"
BMRN,BMRN:UW,BBG000CZX7N1,US STOCKS-Futures point to higher open on merger activity,2014-11-24 13:52:58 +0000,http://uk.finance.yahoo.com/news/us-stocks-futures-point-higher-135258843.html,US STOCKS-Futures point to higher open on merger activity
BMRN,BMRN:UW,BBG000CZX7N1,"US STOCKS-Futures rise, boosted by merger activity",2014-11-24 13:14:48 +0000,http://uk.finance.yahoo.com/news/us-stocks-futures-rise-boosted-131448731.html,"US STOCKS-Futures rise, boosted by merger activity"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin Pharma offers about $680M for Prosensa,2014-11-24 12:35:44 +0000,http://sg.finance.yahoo.com/news/biomarin-pharma-offers-680m-prosensa-123544926.html,BioMarin Pharma offers about $680M for Prosensa
BMRN,BMRN:UW,BBG000CZX7N1,"US STOCKS-Futures higher, building on recent gains",2014-11-24 12:14:27 +0000,http://uk.finance.yahoo.com/news/us-stocks-futures-higher-building-121427058.html,"US STOCKS-Futures higher, building on recent gains"
BMRN,BMRN:UW,BBG000CZX7N1,BioMarin beats 3Q profit forecasts,2014-10-23 20:57:49 +0000,http://sg.finance.yahoo.com/news/biomarin-beats-3q-profit-forecasts-205749817--finance.html,BioMarin beats 3Q profit forecasts
BMRN,BMRN:UW,BBG000CZX7N1,Roche's $8 billion InterMune buy not a signal for more big deals,2014-09-16 16:55:39 +0000,http://sg.finance.yahoo.com/news/roches-8-billion-intermune-buy-165539606.html,Roche's $8 billion InterMune buy not a signal for more big deals
BMRN,BMRN:UW,BBG000CZX7N1,"Early data suggest Sanofi, Regeneron drug may halve heart risk",2014-08-31 07:00:01 +0000,http://uk.finance.yahoo.com/news/early-data-suggest-sanofi-regeneron-070001896.html,"Early data suggest Sanofi, Regeneron drug may halve heart risk"
BMRN,BMRN:UW,BBG000CZX7N1,Roche to buy U.S. biotech firm InterMune for $8.3 billion,2014-08-25 08:50:20 +0000,http://sg.finance.yahoo.com/news/roche-buy-u-biotech-firm-085020080.html,Roche to buy U.S. biotech firm InterMune for $8.3 billion
BMRN,BMRN:UW,BBG000CZX7N1,Roche to buy U.S. biotech firm InterMune for $8.3 bln,2014-08-25 08:27:52 +0000,http://uk.finance.yahoo.com/news/roche-buy-u-biotech-firm-082752747.html,Roche to buy U.S. biotech firm InterMune for $8.3 bln
